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ABSTRACT
The high lipid content of the brain, coupled with its heavy oxygen dependence and
relatively weak antioxidant system, makes it highly susceptible to oxidative DNA damage
that contributes to neurodegeneration. This study assesses and compares the neurotoxic
effects of proton and photon radiation on mitochondrial function and DNA repair
capabilities of human astrocytes. Human astrocytes received either proton (0.5 Gy and 3
Gy), photon (0.5 Gy and 3 Gy), or sham-radiation treatment. The mRNA expression level
of the human base-excision repair protein, 8-deoxyguanosine DNA glycosylase 1
(hOGG1) was determined via RT-qPCR. Radiation-induced changes in mitochondrial
mass and oxidative activity were assessed using fluorescent imaging with MitoTracker™
Green FM and MitoTracker™ Orange CM-H2TMRos dyes, respectively. A significant
increase in mitochondrial mass and levels of reactive oxygen species was observed after
radiation treatment. This was accompanied by a decreased OGG1 mRNA expression.
These results are indicative of a radiation-induced dose-dependent decrease in
mitochondrial function, an increase in senescence and astrogliosis, and impairment of the
DNA repair capabilities in healthy glial cells. Photon irradiation was associated with a
more significant disruption in mitochondrial function and base-excision repair mechanisms
in vitro in comparison to the same dose of proton treatment.
This study further identifies specific ROS-responsive miRNAs that modulate the
expression and activity of the DNA repair proteins in human astrocytes, which could lead
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to the development of targeted therapeutic strategies for neurological diseases. Oxidative
DNA damage was established after treatment of human astrocytes with 10 µM sodium
dichromate for 16 hours. Comet assay analysis indicated a significant increase in oxidized
guanine lesions. PCR analysis confirmed that sodium dichromate reduced the mRNA
expression levels of hOGG1. Small RNAseq was performed on an Ion Torrent™ system
and the differentially expressed miRNAs were identified using Partek Flow® software.
The biologically significant miRNAs were selected using miRNet 2.0. Oxidative-stressinduced DNA damage was associated with a significant decrease in miRNA expression:
231 downregulated miRNAs and 2 upregulated miRNAs (p < 0.05; > 2-fold). In addition
to identifying multiple miRNA-mRNA pairs involved in DNA repair processes, this study
uncovered two novel miRNA-mRNA pairs interactions: miR-1248:OGG1 and miR-103aOGG1. Inhibition of miR-1248 and miR-103a via the transfection of their inhibitors
restored the increased expression levels of hOGG1. Therefore, targeting the identified
microRNAs could ameliorate the nuclear DNA damage caused by exposure to mutagens.
The miRNA candidates identified in this study could serve as potential biomarkers and
therapeutics for oxidative stress in the brain to reduce the incidence and improve the
treatment of cancer and neurodegenerative disorders.
In a parallel but closely related study, we report a direct, one-step exosome
sampling technology, for selective capture of CD63+ exosome subpopulations using an
immune-affinity protocol. The ExoPRIME microprobe provides a Precise Rapid
Inexpensive Mild (non-invasive) and Efficient (i.e. PRIME) alternative to the
conventional polymer precipitation-based methods by enriching a comparatively more
homogenous exosome population. The tool consists of an inert Serin™ stainless steelz
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microneedle (300 μm in diameter × 30 mm in height), pre-coated with a thin-film
polyelectrolyte layer that serves as a substrate for covalent bonding of biotin. An anti-CD63
steptavidin-conjugated antibody that selectively binds to the corresponding tetraspanin
embedded in the lipid bilayer of exosomes was immobilized to the outer surface of the
probe. The feasibility of the ExoPRIME technology was validated using two types of
biological samples: conditioned astrocyte medium (CAM) and astrocyte-derived exosome
suspension (EXO). The study investigated the impact of the temperature (4°C and 22°C)
and incubation duration (2h and 16h) on the capture efficiency of the ExoPRIME tool. A
fluorescence-based enzymatic assay for exosome quantification was used to assess the
probe’s exosomes capture efficiency and the reproducibility of the technology. The low
level of non-specific binding initially observed in non-functionalized microneedles was
drastically minimized by blocking the ExoPRIME probe with 0.1% BSA. The ExoPRIME
microprobe captured exponentially more exosomes than the non-functionalized
microneedle that indicates enrichment of CD63-expressing exosomes.
A major advantage provided by the ExoPRIME technology over existing platforms
is its applicability over a broad dynamic range of temperature and incubation parameters
without compromising the purity and viability of exosomal cargoes. The loading capacity
of the probe increased after incubation for 16 h at 40C in exosome suspension (24×106
exosomes per probe) while the efficiency decreased 10 folds after 2 h at 40C (24×105
exosomes per probe). The increase in temperature had an impact on the stability of the
reagents that contributed to a 2-fold efficiency reduction after incubation in exosome
suspension for 16 h at 220C (12×106 exosomes per probe). However, the 2-hour roomtemperature incubation (2 h at 220C) of the ExoPRIME probe yielded an increased capture
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efficiency (12×106 exosomes per probe) when compared to the 2 h at 4°C incubation
(24×105 exosomes per probe). These results suggest that lower temperatures with extended
incubation times constitute the most optimal parameters that ensure high probe loading
capacity.
Another advantage of the ExoPRIME microprobe is that it captures antigen-specific
subpopulation of exosomes directly from conditioned astrocyte medium (CAM),
eliminating the requirements for additional filtration and pre-concentration, and thereby
cutting down costs and handling time. Besides the relatively reduced number of enriched
exosomes, the CAM results are consistent with the trend obtained for EXO incubations, a
phenomenon that could be attributed to the presence of various extracellular proteins and
cellular debris, which could mask antibodies and compete physically with exosomes for
binding. The capabilities to integrate different incubation times, temperatures, and biofluid
type thus present exosome researchers with the flexibility to choose the combined
parameters that best suit their purpose, the desired factor in clinical and laboratory
applications.
The developed tool requires very low amounts of antibody, permits the use and reuse of minimal sample volumes (≤ 200 µL), can be multiplexed in arrays to diagnostically
profile multiple exosome classes and is amenable to integration into a lab-on-a-chip
platform to achieve parallel, high-throughput isolation in a [semi]-automated workstation.
Moreover, this platform could provide direct exosomal analysis of biological fluids since
it can elegantly interface with existing picomolar-range nucleic acid assays to provide a
clinical diagnostic tool at the point of care and facilitate fundamental studies in exosomes
functions.

APPROVAL FOR SCHOLARLY DISSEMINATION
The author grants to the Prescott Memorial Library of Louisiana Tech University
the right to reproduce, by appropriate methods, upon request, any or all portions of this
Dissertation. It is understood that “proper request” consists of the agreement, on the part
of the requesting party, that said reproduction is for his personal use and that subsequent
reproduction will not occur without written approval of the author of this Dissertation.
Further, any portions of the Dissertation used in books, papers, and other works must be
appropriately referenced to this Dissertation.
Finally, the author of this Dissertation reserves the right to publish freely, in the
literature, at any time, any or all portions of this Dissertation.

Author _____________________________

Date _____________________________

GS Form 14
(8/10)

DEDICATION
To:
My Beloved Mama, Obianuju C. Nwokwu (of Blessed Memory) – whose spirit
has been my staying power in my biomedical research adventures. Each time I was tempted
to quit the rigors of Science, I was spurred by the indelible vivid imagery of her courageous
struggle with cancer and by my bedside/graveside commitment to her to work towards a
cure to that tormentor of mankind. Nne m oma, uche m ka di ya!

To:
My beautiful and supportive wife, and best friend, Premina Obianuju
Chukwumaobim – who has made me a proud father! She has also been my backbone
through this doctoral journey and helped immensely with the formatting of this dissertation.

And to:
Our unborn baby, “Chemi” whose epochal arrival in the wake of notable events
and great fortunes is nothing short of the Divine – Omalubiauwa, Obianuju, Nnemabia.
May your birth herald times of refreshing for Ndigbo worldwide and usher in “the country
we deserve”.

viii

TABLE OF CONTENTS
ABSTRACT ....................................................................................................................... iii
APPROVAL FOR SCHOLARLY DISSEMINATION .................................................. vii
DEDICATION ................................................................................................................ viii
LIST OF FIGURES ........................................................................................................ xvi
LIST OF TABLES ........................................................................................................ xxii
ACKNOWLEDGEMENTS ......................................................................................... xxiii
CHAPTER 1 INTRODUCTION ........................................................................................ 1
1.1

Goals and Objectives .......................................................................................... 1

1.2

Significance ........................................................................................................ 1

1.3

Non-Coding RNAs ............................................................................................. 7

1.3.1

Types and Physiological Roles ................................................................... 7

1.3.2

MicroRNAs (miRNAs) ............................................................................. 10

1.3.2.1 miRNA Biogenesis ................................................................................... 11
1.3.2.2 miRNA Naming Convention .................................................................... 14
1.3.2.3 Biological (Epigenetic) Function of miRNAs .......................................... 15
1.3.2.4 RNA-Induced Silencing Complex (RISC) Assembly............................... 17
1.4

DNA Damage Response and Repair (DDR)..................................................... 18

1.4.1

Base Excision Repair (BER) Pathway/Mechanism .................................. 19

1.4.2

The Role of MicroRNAs in DDR Loop Regulation ..................................21

1.5
1.5.1

Methods and Techniques Employed in MicroRNA Target Analysis ............... 22
In silico Prediction of miRNA Targets ..................................................... 23
ix

x
1.5.2

Experimental Validation of miRNA-Target mRNA Interactions ............. 24

1.5.2.1 Chimeric Reporter Gene Assay ................................................................ 24
1.5.2.2 Immunoprecipitation Technique ............................................................... 24
1.5.3

Indirect Experimental Validation of miRNA-Target mRNA Interactions 25

1.5.3.1 Transcriptomics: miRNA and Target mRNA Inverse Transcription ........ 25
1.5.3.2 Gain of Function and Inhibition: Proteomics and Metabolomics
Analyses .................................................................................................... 26
1.6

Cellular Oxidative Stress .................................................................................. 28

1.6.1

8-OHdG as an Oxidative Stress Biomarker .............................................. 29

1.6.2

The Brain’s Susceptibility to Oxidative Stress ......................................... 30

1.6.2.1 Astrocyte as a CNS Model for Oxidative Stress ....................................... 30
1.6.3

Crosstalk Between ROS and MicroRNAs ................................................ 31

1.6.4

Chromium Toxicity................................................................................... 32

1.6.4.1 Sodium Dichromate .................................................................................. 34
1.6.5

Radiation Toxicity .................................................................................... 35

1.6.5.1 Radiation Therapy: Risks and Benefits..................................................... 36
1.7

Extracellular Vesicles (EVs) ............................................................................. 37

1.7.1

Exosomes: Biogenesis and Mechanisms of Action .................................. 37

1.7.2

Exosomal Cargoes .................................................................................... 39

1.7.3

Biomedical Applications of Exosomes ..................................................... 39

1.8
1.8.1

Purification of Extracellular Vesicles (EVs) .................................................... 41
The Need for Pure Exosome Populations ................................................. 41

xi
1.8.2
1.9

Existing Purification Methods: Advantages and Disadvantages .............. 42
Layer-by-Layer (LbL) Assembly...................................................................... 44

CHAPTER 2 IMPACT OF PHOTON AND PROTON IRRADIATION ON
MITOCHONDRIAL FUNCTION AND 8-OHDG BASE-EXCISION REPAIR
MECHANISM IN HUMAN ASTROCYTES ................................................................. 47
2.1

Motivation ........................................................................................................ 47

2.2

Specific Objectives .......................................................................................... 47

2.3

Materials and Methods...................................................................................... 48

2.3.1

Proton and Photon Irradiation of Cultured Astrocytes ............................. 48

2.3.2

Cell Viability Assays ................................................................................ 49

2.3.3

Determination of Mitochondrial Mass ...................................................... 50

2.3.4

Assessment of Oxidative Capacity of Mitochondria ................................ 51

2.3.5

Gene Expression Analysis ........................................................................ 52

2.3.6

Statistical Analysis .................................................................................... 52

2.4

Results ............................................................................................................... 53

2.4.1

Irradiation Induces Moderate Cellular Senescence and Apoptosis in
Human Astrocytes ..................................................................................... 53

2.4.2

Low-dose Irradiation is Associated with an Increase in Mitochonrial
Mass…………………………………………………………………….. 53

2.4.3

Mitochondrial Oxidative Activity Increases with Photon and Proton
Radiation ……………………………………………………………….. 55

2.4.4

Proton and Photon Irradiation Downregulates OGG1 Gene Expression .. 56

2.5

Discussion ......................................................................................................... 57

CHAPTER 3 IDENTIFICATION OF MIRNA-MRNA REGULATORY NETWORK
ASSOCIATED WITH OXIDATIVE DNA DAMAGE IN HUMAN ASTROCYTES .. 61
3.1

Knowledge Gap ............................................................................................... 61

3.2

Hypotheses and Specific Objectives ................................................................ 61

3.3

Materials and Methods ..................................................................................... 62

xii
3.3.1

Cell Culture .............................................................................................. 62

3.3.2

Sodium Dichromate Treatments ............................................................... 63

3.3.3

Cytomorphological Evaluation ................................................................. 63

3.3.4

Comet Assay ............................................................................................. 63

3.3.5

High-Throughput Small RNA Sequencing and Analysis ......................... 64

3.3.5.1 Library Preparation and Ion TorrentTM Sequencing ................................. 64
3.3.5.2 MicroRNA-Seq and QA/QC Analyses ..................................................... 65
3.3.5.3 Differential miRNA Analysis and Visualization ...................................... 65
3.3.5.4 miRNA Functional Enrichment Analysis ................................................. 66
3.4

Results ............................................................................................................... 66

3.4.1

Sodium Dichromate Induces Oxidative DNA Damage in Astrocytes ...... 66

3.4.2

Pre-Alignment QA/QC Charts .................................................................. 68

3.4.3

Small RNA Sequencing Identifies a Large Number of Differentially
Downregulated MicroRNAs ..................................................................... 71

3.4.4

Hierarchical Clustering Plots .................................................................... 72

3.4.5

Gene Ontology Analysis Identifies Biologically Significant miRNAs .... 74

3.4.5.1 miRNA-Gene/Pathway Analyses.............................................................. 74
3.4.5.2 miRNA-Disease Associations................................................................... 77
3.4.5.3 Protein-Protein Interaction (PPIs) ............................................................. 78
3.5

Discussion ......................................................................................................... 78

CHAPTER 4 MICRORNAS AND DNA REPAIR GENES: TARGET PREDICTION
AND VALIDATION ....................................................................................................... 83
4.1

Overview and Hypotheses ............................................................................... 83

4.2

Research Methodology ..................................................................................... 84

4.2.1

In Silico Prediction of OGG1-targeting MicroRNA Candidates .............. 84

4.2.2

Validation of miRNA-mRNA Interactions ............................................... 85

xiii
4.2.2.1 Reverse Transcription Quantitative PCR (RT-qPCR) .............................. 85
4.2.2.2 Capillary Western Analyses ...................................................................... 87
4.2.2.3 Exogenous miR-103a Expression: Co-immunoprecipitation with OGG1
mRNA ................................... ……………………………………………88
4.2.2.3.1 MirTrap System: Working Principle................................................. 88
4.2.2.3.2 MirTrap System Protocol .................................................................. 89
4.2.2.4 miR-1248 and miR-103a Inhibition: Assessment of miRNA:OGG1
Functional Relationship ........................................................................ 90
4.2.2.4.1 miRNA Inhibitor Transfection Protocol ........................................... 90
4.2.2.4.2 Relative Quantification of OGG1 mRNA via RT-qPCR .................. 91
4.3

Statistical Analysis ............................................................................................ 92

4.4

Experimental Outcomes .................................................................................... 92

4.4.1

Computationally Predicted miRNA/OGG1 mRNA Interactions .............. 92

4.4.2

RT-qPCR Confirms miR-335 and PARP-1 Interaction ............................ 93

4.4.3

Validation of Novel miRNA-Target mRNA Interactions ......................... 93

4.4.3.1 OGG1 is a Validated Target of miR-1248 ................................................ 94
4.4.3.2 miR-103a is a Possible Regulator of OGG1 ............................................. 95
4.4.4
4.5

Sodium Dichromate Exerts Dose-dependent Effect on OGG1
Expression ................................................................................................. 98
Discussion ......................................................................................................... 98

CHAPTER 5 EXOPRIME TECHNOLOGY: ‘SMART’ MICROPROBE IMBUED
WITH BIOSENSING ELEMENTS FOR SOLID-PHASE IMMUNOISOLATION
AND OMICS ANALYSIS OF SURFACE-MARKER-SPECIFIC EXOSOMAL
SUBPOPULATIONS .................................................................................................... 103
5.1

Rationale ........................................................................................................ 103

5.2

Aim and Hypothesis........................................................................................ 104

5.3

Experimental Workflow ................................................................................. 104

5.3.1

Functionalization of ExoPRIME Microprobe ......................................... 104

xiv
5.3.1.1 Preparation of Polyelectrolyte Solutions ................................................ 104
5.3.1.2 Thin Film Deposition via Layer-by-Layer (LbL) Assembly .................. 105
5.3.1.3 Anti-CD63 Antibody Immobilization ..................................................... 106
5.3.2

Evaluation of Probe Efficiency ............................................................... 107

5.3.2.1 Preparation of Conditioned Astrocyte Medium and Exosome
Suspension ............................................................................................. 107
5.3.2.2 Exosome Immunoisolation and Quantification ..................................... 108
5.3.3

OMICS Analysis of Exosomal Cargoes ................................................. 109

5.3.3.1 Extraction of RNA and Protein from ExoPRIME-captured Exosomes .. 109
5.3.3.2 MicroRNA Amplification of Enriched Exosomal RNA ......................... 110
5.4

Results ............................................................................................................. 111

5.4.1

Design and Fabrication of the ExoPRIME Microprobe ......................... 111

5.4.2

Evaluation of ExoPRIME’s Capture Efficiency ..................................... 111

5.4.3

Downstream Analysis of ExoPRIME-isolated Exosomes ...................... 114

5.4.3.1 MicroRNA and Protein Yields................................................................ 114
5.4.3.2 High Enrichment of Small RNAs (25 – 200 bp)..................................... 114
5.4.3.3 Assessment of ExoPRIME’s Diagnostic Utility ..................................... 116
5.5

Discussion ....................................................................................................... 117

CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS .................................. 120
6.1

Conclusions .................................................................................................... 120

6.1.1

Chapter 2 Conclusion ............................................................................. 120

6.1.2

Chapter 3 Conclusion .............................................................................. 121

6.1.3

Chapter 4 Conclusion .............................................................................. 122

6.1.4

Chapter 5 Conclusion .............................................................................. 123

6.2

Future Directions ............................................................................................ 124

APPENDIX C SMALL RNA-SEQ DATA ANALYSES [SEE COMPACT DISC] .... 126

xv
APPENDIX D VALIDATION OF PREDICTED MICRORNA TARGETS ............... 130
APPENDIX E CHARACTERIZATION OF THE EXOPRIME MICROPROBE ........ 137
BIBLIOGRAPHY ……………………………………………………………………...143

LIST OF FIGURES
Figure 1-1 Schematic of experimental workflow. Human astrocytes were treated with
0.5 Gy and 3 Gy proton and photon radiation. (A) Gene expression of
OGG1; and (B) mitochondrial mass and oxidative activity were assessed
16 h post-treatment [11] .................................................................................. 3
Figure 1-2 Schematic of experimental workflow that includes induction of oxidative
DNA damage using sodium dichromate treatment followed by small RNA
sequencing, computational analysis of differentially expressed targets, and
the restorative effect of miR-1248 and miR-103a inhibition on OGG1mediated DNA repair mechanism ................................................................... 5
Figure 1-3 A Prototype Design of a Benchtop [Semi-]automated ExoPRIME
Technology depicting Integration with Microfluidics and Bioanalytical
Platforms [36] .................................................................................................. 7
Figure 1-4 miRNA biogenesis. A.) The canonical pre-miRNA pathway produces premiRNAs through cleavage of pri-miRNA transcripts by the DroshaDGCR8 microprocessor complex. B.) The non-canonical pathway.
Mirtrons are spliced and debranched by the Ldbr enzyme, after which they
fold into pre-miRNA hairpins. Then, the pathways merge. The green box
indicates a miRNA gene; exons 1 and 2 are exons of the host gene encoding
intronic miRNA [56] ..................................................................................... 13
Figure 1-5 A schema portraying miRNA Biogenesis and its Functional Roles in the
context of the RNA-Induced Silencing Complex (RISC) [miRNA
(microRNA) Introduction (sigmaaldrich.com)] ............................................ 16
Figure 1-6 Transient interaction of RISC and miRNA/mRNA pair, resulting in
miRNA processing [Source: MirTrap Technology: Technical Notes,
Clontech 4.14 IN (633655). www.clontech.com] ......................................... 18
Figure 1-7 Oxidative DNA Damage Response and Repair in Cells. (A) Formation of
8-OHdG by oxidative stress. (B) Mechanism of ROS-induced G: C to A:
T DNA mutation and OGG1’s substrate-specific excision of the 8-OHdG
lesion [98] ...................................................................................................... 20

xvi

xvii
Figure 1-8 Proposed Scheme for miRNA target validation. Prediction methods and
validation techniques of both microRNAs and their targets are codependent [122] ............................................................................................. 23
Figure 1-9 Mechanisms conferring protein loss and toxic gain-of-function effects. The
diagram illustrates pathogenic mutations (repeat expansions, deletions,
point mutations) that may occur either in noncoding or coding regions of
the genome (left and right sides, respectively). (A) Protein loss-offunction. Haploinsufficiency can occur when the level of a particular
mRNA is down-regulated due to mutations in noncoding regions of genes
such as in promoters/introns, or if the promoter is subjected to
histone/DNA modifications (transcriptional repression), but also if
mutations in 5′ or 3′ untranslated regions (UTRs) decrease mRNA stability.
Protein loss-of-function can also occur when mutations in coding regions
alter directly the activity of the mutated protein (misfolding, alteration of
the active site). (B) Protein toxic gain-of-functions are caused by mutations
in coding regions that either promote abnormal interactions, increase the
interaction of the mutated protein with its natural binders and/or promote
misfolding/aggregation [Adopted from [130]] .............................................. 27
Figure 1-10 Schematic model showing mechanisms in which ROS regulate microRNA
expression. ROS are involved in every step of miRNA biogenesis. ROS
can induce epigenetic alterations of miRNA genes. For example, ROS
inhibit and enhance the expression of certain miRNA genes through
DNMT1 and HDACs, respectively. ROS can also activate transcription
factors to induce miRNA expression. Moreover, Drosha and Dicer, which
are two essential enzymes for miRNA biogenesis, can be directly or
indirectly regulated by ROS [15] .................................................................. 32
Figure 1-11 The
structural
formula
of
sodium
dichromate
[https://commons.wikimedia.org/wiki/File:Na2Cr2O7.png] ........................ 34
Figure 1-12 Biogenesis, targeting, and composition of exosomes [200] ........................ 38
Figure 1-13 Schematic of the Layer-by-Layer Assembly Process [252] ......................... 45
Figure 2-1 Florescence intensity and distribution of MitoTracker Green FM dye in (A)
sham-control cells, (B) 3 Gy photon treated cells, and (C) 3 Gy proton
treated. (D) The total corrected cell fluorescence (TCCF) indicates that
mitochondrial mass is significantly increased in irradiated cells. Bar, 200
μm. Data represent means+/- SEM for each group (n = 8), *p < 0.05, **p
< 0.01, ANOVA statistical analysis, Tukey’s Honest Significant
Difference test [11] ........................................................................................ 54

xviii
Figure 2-2 Fluorescent microscope images (20×objective lens) of human astrocytes
stained with MitoTracker™OrangeCM-H2TMRos. The nucleus of the
cells was stained with DAPI. (A) Sham-control cells. (B) 3 Gy photon
treated cells. (C) 3 Gy proton treated. (D) The total corrected cell
fluorescence (TCCF) indicates that mitochondrial oxidative activity is
significantly increased in irradiated cells and the fluorescence is increased
after treatment with the positive control 50 μM FCCP. Bar, 200 μm. Data
represent means+/- SEM for each group (n = 8), **p < 0.01, ANOVA
statistical analysis, Tukey’s Honest Significant Difference test [11] ............ 56
Figure 2-3 Effect of proton and photon radiation treatment on OGG1 mRNA
expression in human astrocytes. Compared with the controls, the
expression level of OGG1 was downregulated after treatment with 0.5 Gy
(A) and 3 Gy (B) photon and proton radiation. Data represent means +/SEM for each group (n = 5).*p < 0.05, **p < 0.01, ANOVA statistical
analysis, Tukey’s Honest Significant Difference test [11] ............................ 57
Figure 3-1 Bright-field image of human astrocytes, 10x magnification (A) control, and
(B) treated with 10µM sodium dichromate ................................................... 66
Figure 3-2 Sodium dichromate increases oxidative DNA base damage. The alkaline
comet assay with FPG treatment was used to detect oxidative base damage
following 10 μM Na2Cr2O7 treatment for 16 h (A) and the tail moment
was measured using OpenComet (B). Analysis was performed on one
experiment with at least 70 cells in each experimental group. Error bars
represent SD and **** represents P < 0.0001 using a Student's t-test .......... 68
Figure 3-3 Pre-alignment QA/QC showing average base quality score per reading.The
Phred quality scores of the analyzed samples ranged from 28% to 31%...69
Figure 3-4 Size distribution of raw counts of transcripts ................................................ 70
Figure 3-5 Percentage representation of trimmed bases (quality score cut-off = 28;
minimum read length = 15 ............................................................................ 70
Figure 3-6 Coverage breakdown of raw reads post-trimming ........................................ 71
Figure 3-7 Principal Component Analysis (PCA) plot showing clustering of the
treated and control samples. The two most informative components were
plotted by the Partek® Flow® software ........................................................ 73
Figure 3-8 Volcano plot depicting the distribution of upregulated and downregulated
miRNA genes in treated samples relative to controls ................................... 73
Figure 3-9 Unsupervised hierarchical clustering using the differentially expressed
miRNAs between treated and control samples represented as a heat map.
The heat map colors correspond to microRNA expression as indicated in
the color key: Red (up-regulated) and Green (down-regulated) .................. 74

xix
Figure 3-10 A coherent group of miRNAs target DNA repair proteins. Network
constructed on miRNet 2.0 ............................................................................ 76
Figure 3-11 CNS-associated pathologies mediated by hsa-miR-107. The network was
constructed on MiRNet 2.0 ........................................................................... 78
Figure 4-1 The MirTrap System: Protocol Overview ...................................................... 90
Figure 4-2 RT-qPCR confirmed (A) downregulation of miR-335, and (B)
upregulation of its target mRNA, PARP-1 (p<<0.001), n=3 ........................ 93
Figure 4-3 Effect of sodium dichromate treatment (10µM, 16 hours) on (A) miR1248, P<0.05, (B) OGG1 mRNA expression level (C) OGG1 protein
expression estimated using Protein Simple Wes® system Capillary
western blot results were shown as gel-like images of OGG1 (37kDa) and
GAPDH (37kDa) for control and treated samples. The relative area under
the curve, error bars represent standard deviation, 1µg of protein lysate was
loaded per lane, (n=3) .................................................................................... 94
Figure 4-4 OGG1 and miR-1248 expression analysis after inhibition experiments. (A)
OGG1 upregulation (p<0.01), and (B) miR-1248 downregulation (p<0.05),
after inhibition of miR-1248 in human astrocytes (n = 3) ............................. 95
Figure 4-5 RT-qPCR analysis showing fold enrichment of positive control (AcGFP1)
and negative control (hPlod3) genes after co-transfection of MirTrap
Control vector and miR-132 .......................................................................... 96
Figure 4-6 OGG1 upregulation (p<0.01) after inhibition of miR-103a in human
astrocytes (n = 3) ........................................................................................... 97
Figure 4-7 Dose-dependent increase in OGG1 expression with increasing Na2Cr2O7
concentrations ................................................................................................ 98
Figure 5-1 ExoPRIME probe functionalization workflow [36] .................................... 107
Figure 5-2 Exosome concentration obtained using ExoPRIME probe from enriched
exosome suspension and astrocyte medium (n=3). The numbers of
exosomes shown as isolated per microprobe are differential figures
obtained from subtracting exosomes captured by negative (non-antiCD63-functionalized, NAF) microprobes from exosomes captured by
positive (biotin+anti-CD63-functionalized, BAF) microprobes [36].......... 113

xx
Figure 5-3 Agilent 2100 Bioanalyzer RNA analysis of (A) RNA ladder; (B) Total
human RNA (3ng); (C) ExoPRIME-purified exosomal RNA from
polymer-precipitated exosomes derived from human astrocytes; (D)
ExoPRIME-purified exosomal RNA from exosomes directly captured
from conditioned human astrocytes media. The electropherograms show
the fluorescence intensity (FU) and size distribution of the RNA
nucleotides (nt) [36] .................................................................................... 115
Figure 5-4 RT-qPCR amplification cycles (n=3) of (A) An oxidative stress marker,
miR-21 (CAM 36.2;EXO 38.7); (B) A tumor suppressor gene, miR-let-7b
(CAM 34.4; EXO 33.0), an array of 20 ExoPRIME microprobes [36] ...... 116
Figure C.1 PCA Plot for hsa-miR-21-5p (10 µM NaCr2O7-Treated vs
Non-Treated) .............................................................................................. 128
Figure C.2 PCA Plot for hsa-miR-335-5p (10 µM NaCr2O7-Treated vs
Non-Treated) .............................................................................................. 129
Figure D.1 pMirTrap Vector Map .…………………………………………................ 132
Figure D.2 pMirTrap Control Vector Map ................................................................... 133
Figure D.3 Fluorescent Images at 100 ms Exposure Depicting Efficient Transfection
Consistent with High Expression of DsRed Express (Red Fluorescence)
with
very
negligible
AcGFP1
Co-expression
(Green
Fluorescence)……………………............................................................... 135
Figure E.1 SEM micrographs of the tips (left panels) and stem (middle panels) of
polished plain needles (A, B) and LBL-coated microneedles (D, E),
showing successful and efficient deposition polyelectrolyte bilayers. The
right panels show the corresponding EDX spectra of plain (C) and LBLcoated (F) microneedles [36] ……………………. ..................................... 138
Figure E.2 Fluorescent images confirming successful LBL assembly and Biotin
immobilization
on
microneedles:
(A)
LbL+BiotinEDC+Streptavidin+Biotin-FITC; (B) LbL+Biotin-FITC; (C) Biotin-FITC.
(D) ImageJ analysis of the of the CTPF of A, B, C [36] ........................... 139
Figure E.3 Schematic of exosome immunofluorescence imaging. Exosomes are
selectively captured to the surface of the ExoPRIME microprobes through
antibody-specific interactions of anti-CD63 and CD63 exosomes
receptors. CD9 and CD81 antibodies are used for labeling of the captured
exosomes followed by detection with IgG secondary antibody conjugated
to NL557 fluorophore [36] ......................................................................... 140
Figure E.4 CTFP Image J analysis of fluorescence signal obtained for different
experimental groups (n=4) [36] …………………………………….. .......... 14

xxi
Figure E.5 Comparison of protein profile via SDS-PAGE analysis. The gel legends
indicate BioRad Kalediscope™ protein standard (Std); ExoPRIME
exosome (probe); polymer-percipitated exosomes (Polymer reagent); and
total protein lysate (total protein) at a concentration of 20 µg per
well [36] ...................................................................................................... 142

LIST OF TABLES
Table 1-1 Major Classes of Small Noncoding RNAs ...................................................... 10
Table 1-2 miRNA Nomenclature ..................................................................................... 14
Table 3-1 Top pathways enriched in putative miRNA-targeted genes ............................ 75
Table 3-2 List of differentially expressed BER-associated MicroRNAs (p < 0.05) ........ 77
Table 4-1 Average fold enrichment for miR-103a/OGG1 mRNA target via
immunoprecipitation analysis........................................................................... 97
Table 5-1 Incubation Conditions (Biofluid Type, Incubation Temperature and
Incubation Time) ............................................................................................ 108
Table 5-2 RNA and Protein Concentrations per ExoPRIME probe [36] ....................... 114
Table D.1 Forward and reverse primer sequences for GAPDH and PARP-1................ 131
Table D.2 RT-qPCR Analysis Showing Fold Enrichment of Positive (AcGFP1) and
Negative (hPlod3) Controls, Relative to the GAPDH Internal Control.... 136

xxii

ACKNOWLEDGMENTS
My profound gratitude goes to Chukwu Okike Abiama (The Most High God) in
whom I live and move and have my being. I could not have achieved this feat of bagging
a doctorate degree, considered the pinnacle of academic pursuit, without His unseen hands
steadying and steering my tempest-tossed ship.
The statement is true that “a teacher affects eternity; he can never tell where his
influence stops”. So, I would like to acknowledge the efforts of all my teachers and
academic mentors in forging me into the well-rounded man I am today. The special icing
on this cake is my PhD advisor and mentor, Dr. Gergana G. Nestorova, for her scholarly
critiquing, legendary patience and understanding, responsible and responsive mentoring,
and most importantly, her affability and open-door policy that makes her approachable (I
look forward to future research collaborations with her). Her innovative ideas and the
grants that she attracted through the course of my scholastic foray made these projects
possible. Thus we are thankful to the following funding agencies: the Louisiana Board of
Regents through its Research Competitiveness Subprogram (RCS) support fund, NASA
EPSCoR, the Center for Biomedical Engineering and Rehabilitation Science (CBERS) and
the School of Biological Sciences at Louisiana Tech University.
Under Dr. Nestorova’s tutelage and mentorship, I have evolved into a seasoned
scientist, gaining a wide array of scientific and professional skills which I believe would
be of immense benefit in my chosen career going forward. Furthermore, I would like to

xxiii

xxiv
thank other members of my advisory committee, Dr. Teresa A. Murray, Dr. Scott Poh,
Dr. Jeff Shultz, and Dr. Prerna Dua, for their invaluable inputs to make this dissertation
more sound and robust.
I will not fail to recognize members of Nestorova Lab – my research team, past and
present; they were angels in laboratory coats. Worthy of mention are Saif Ishraq
Mohammed Bari and Ms. Hope Hutson for their specific contributions to certain aspects
of these dissertation projects. My “Shadow Assistant” – my lab coat of 18 years – deserves
honorable mention, having followed me as I traversed and sojourned in three different
continents in pursuit of my Bachelor’s, Master’s, and now, my Doctorate degrees.
Whenever I don this “magical” tuxedo, I am in my elements, firing from all cylinders,
Because every falling leaf rests on its roots, I would like to appreciate my
immediate family members: my Papa, Obiwulu E. Nwokwu and my stepmother, Nkechi
F. Nwokwu – both of whom have been my indefatigable cheerleaders; and my siblings,
Eberechukwu Aniagboso, Ogochukwu Nwosu, and Tochukwu Nwokwu – whose
ceaseless prayers and encouragement infused me with the strength to keep trudging on. I
am indebted in no small measure to my American Mum, Prof. Stephanie Carwile and her
husband, Prof. Guy Carwile – who treated me as their adopted son and greatly helped me
ease through this phase of my life. Indeed, as the Igbo say, “Nwanne di na mba”
(Brotherhood knows no boundaries).
Finally, I extend my heartfelt gratitude to every person and/or circumstance that
inspired me by their action or inaction, or those whose contribution(s) might have passed
unnoticed. God bless you all!

CHAPTER 1
INTRODUCTION

1.1

Goals and Objectives

The overall goal of this study is to investigate the role of short regulatory RNAs in
human astrocytes. The scientific work included the following specific objectives: (1) assess
and compare the impact of proton and photon irradiation on the mitochondrial function and
DNA repair capability of human astrocytes; (2) identify miRNAs that are involved in
mediating oxidative stress-induced DNA repair response in human astrocytes; (3) identify
and validate the functional relationship between novel regulatory miRNAs and the human
base-excision repair protein, hOGG1; and (4) develop a platform for rapid, selective
purification and genetic analysis of antigen-specific exosomal miRNAs.
1.2

Significance

Nucleic acids are susceptible to oxidation by environmental and endogenous
factors. Impairment and mutations in the DNA repair pathways in glial cells are associated
with neurodegenerative disorders and premature aging [1]. Oxidative DNA damage is
repaired primarily by DNA glycosylases, part of the base excision repair pathway which
removes damaged bases in a substrate-specific manner. One of such enzymes is the human
8-deoxyguanosine DNA glycosylase 1 (hOGG1), a bi-functional 8-OHdG-specific
glycosylase that plays an important role in reducing the rate of mutation. By providing the
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first line of defense against oxidative DNA damage, OGG1 plays an important role in
decreasing the detrimental effects of oxidative DNA damage [2]. Therefore, the expression
levels of OGG1 provide an assessment of the cell’s DNA repair capability.
The high lipid content of the brain (phospholipids, polyunsaturated fatty acids),
coupled with its heavy dependence on oxygen and relatively weak antioxidant system,
makes it more susceptible to oxidative stress-induced DNA damage [3]. Astrocytes, a
major glial cell type, play a critical role in modulating synaptic transmissions, regulating
energy metabolism, water and ion homeostasis, and protecting neurons from oxidative
stress [4,5]. Photon and proton radiation therapies are widely used for the treatment of glial
cell primary tumors, however, the biological effect of proton radiotherapy versus photon
radiotherapy on cellular DNA repair capabilities and mitochondrial response in glial cells
is still poorly understood. Astrocytes perform several functions that are essential for normal
neuronal activity, including glutamate uptake and release, K+, and H + buffering, and water
transport [6]. Therefore, astrocyte function can critically influence the survival and the
physiological state of the neurons during radiation-associated brain insults. Previous work
indicates that astrocytes have a higher threshold for apoptotic activation when exposed to
radiofrequency radiation than neurons [7].
Exposure to high-energy radiation leads to an increased production of reactive
oxygen or nitrogen species that are associated with the transmission of radiation damage
among mitochondria [8]. Mitochondrial dysfunction is characterized by reduced oxidative
capacity and diminished ATP production and is a major hallmark of radiation-induced
DNA damage and senescence in neurological tissue [9]. Impaired ability to repair
radiation-induced mtDNA damage is associated with reductions in mitochondrial gene
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expression and ATP generation [10]. Investigating the impact of ionizing radiation on DNA
repair mechanisms and mitochondrial function of healthy human astrocytes is important
for the assessment of the secondary risk of radiation-induced injuries (Figure 1-1) 1.

Figure 1-1 Schematic of experimental workflow. Human astrocytes were treated with
0.5 Gy and 3 Gy proton and photon radiation. (A) Gene expression of OGG1; and (B)
mitochondrial mass and oxidative activity were assessed 16 h post-treatment [11]
MicroRNAs (miRNAs) are small non-coding RNAs (17 – 25 nts) that inhibit gene
expression at the post-transcriptional level [12]. Growing evidence suggests a reciprocal
connection between ROS signaling and the microRNA regulatory pathways. It has been
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K.H. Hutson, K. Willis, C.D. Nwokwu, M. Maynard, G.G. Nestorova, Neurotoxicology
Photon versus proton neurotoxicity : Impact on mitochondrial function and 8-OHdG baseexcision repair mechanism in human astrocytes, Neurotoxicology. 82 (2021) 158–166.
https://doi.org/10.1016/j.neuro.2020.12.011.
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reported that ROS are implicated in various steps of miRNA biogenesis via the control of
transcription factors [13,14], epigenetic regulatory enzymes, and miRNA maturation
proteins [15]. Identification of specific miRNA types with a functional role in modulating
the activity of DNA repair proteins could lead to a better assessment of the response of
glial cells to ROS-induced oxidative damage. Currently, there are no reports on a highthroughput analysis of miRNA expression following exposure of human astrocytes to
oxidative DNA damage. The discovery of ROS-responsive miRNAs provides a potential
novel strategy to specifically overcome ROS-mediated pathological conditions. An
increased understanding of how miRNAs regulate DNA repair in astrocytes will expand
the potential for miRNA-based therapeutics that will substantially improve the outlook for
patients with cancer and age-related neurodegenerative disorders (Figure 1-2).
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Figure 1-2 Schematic of experimental workflow that includes induction of oxidative
DNA damage using sodium dichromate treatment followed by small RNA sequencing,
computational analysis of differentially expressed targets, and the restorative effect of
miR-1248 and miR-103a inhibition on OGG1-mediated DNA repair mechanism
Exosomes (30 – 150 nm) secreted by host cells play an important role in cell-tocell communication since they encapsulate a diverse pool of non-coding microRNAs that
are capable of reprogramming protein expression in recipient cells [16,17]. Compelling
evidence indicates that exosome-mediated transfer of genetic material is superior to direct
contact [18]. Thus, exosomes are considered a promising source of biomarkers for disease
diagnosis including cancer [19,20], glioblastoma [21], diabetic cardiomyopathy [22],
arthritis [23], asthma [24], urinary tract infection [25], and neurodegeneration [26], since
their biological cargo reflects the pathophysiological condition of the host cell. Exosomes
are released under normal physiological conditions, but their number is often increased
upon cellular activation or neoplastic transformation [27]. The ease of access to exosomes
from virtually any biological fluid forms the rationale for their use as non-invasive
biomarkers for disease diagnostics [28,29].
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Exosomal membranes are enriched in tetraspanins (CD63, CD9, and CD81) that
are used as biomarkers for disease diagnostics and prediction of therapeutic response [30].
However, the clinical applications of exosomes have not been fully realized due to
technical challenges associated with traditional and newer methods for exosome isolation
[31,32]. Inefficient purification techniques lead to the extraction of heterogeneous
extracellular vesicles that have different sizes, surface proteins, or cellular origins.
Selective isolation of surface-protein marker-specific exosomal subpopulations for
subsequent genetic analysis is critical in studies to evaluate their clinical relevance [33].
For example, CD63-positive exosomes are present at a higher level in malignant cells
compared to healthy ones [34], while exosomes secreted in cerebrospinal fluid carry
specific markers such as Alix, syntenin-1, heat shock proteins, and tetraspanins [35] that
may provide crucial information for neurodegenerative disorders. Therefore, a technology
that can isolate an exosomal subpopulation that expresses a specific surface marker can be
used as a biomarker detection platform for disease diagnosis and treatment monitoring,
since disease-responsive exosomes encapsulate proteomic and genomic cargoes that are
unique to diseased tissues. Such technology is especially relevant for tissues that are not
directly accessible, such as the central nervous system, offering a precise and non-invasive
approach to liquid biopsy and clinical care.
A solid-phase exosome isolation method circumvents the shear strain from samplereagent mixing and pelletization that increases the likelihood for specimen destruction. The
proposed microneedle-based, antibody-functionalized platform can provide direct
enrichment of intact exosomes from all types of biological fluids with high spatial
resolution that can be leveraged upon for in situ immunofluorescence assays, without
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compromising exosome structure. Furthermore, the microprobe has the prospects for
integration with microfluidics-based standard systems for genomic and proteomic analysis
of exosomal cargoes, thereby offering a potential clinical diagnostic tool at the point of
care (Figure 1-3) 2.

Figure 1-3 A Prototype Design of a Benchtop [Semi-]automated ExoPRIME Technology
depicting Integration with Microfluidics and Bioanalytical Platforms [36]
1.3
1.3.1

Non-Coding RNAs

Types and Physiological Roles
The discovery of non-coding RNAs brought the realization that gene expression is

a much more intricate phenomenon than initially thought. Non-coding RNAs (ncRNAs)
are a class of RNA species that do not encode proteins and so were thought for a long time
to be part of the so-called “junk DNA” [37,38]. However, research in the last three decades

2
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has proven that these RNA transcripts give rise to functional RNAs that impact the
regulation of transcription, RNA processing, and translation and, therefore, play critical
roles in a variety of biological processes [39–41]. The ribosomal RNA (rRNA) directs the
catalytic steps of protein synthesis [42], while the transfer RNA (tRNA) serves as an
adaptor molecule between the amino acids and the mRNA during protein synthesis [43].
Except for ribosomal rRNAs, small nuclear RNAs (snRNAs), small nucleolar
RNAs (snoRNAs), and tRNAs, the remaining ncRNAs are generally grouped into long
ncRNAs (lncRNAs) of more than 200 bases, and the small ncRNAs that are usually less
than 200 bases and include microRNA (miRNA), short interfering RNA (siRNA), and
piwi-interacting RNA (piRNA). Intronic sequences constitute 30% of the human genome
and are the major sources for lncRNAs (intronic lncRNAs); so lncRNAs sequences are
spread over the entire genome and can be found on all chromosomes [44]. Although their
genes are not subject to the same histone modifications (H3K4me3 and H3K36me), the
process of lncRNA transcription and maturation is similar to that of messenger RNA
(mRNA): transcribed by RNA polymerase II, undergoes 3' poly-(A) tailing and 5'endcapping as well as splicing. Unlike miRNAs that have a well-established mechanism of
action, causing translation inhibition or mRNA degradation, lncRNAs have diverse
functionalities depending on their subcellular localization and how they interact with
proteins as well as with RNA or DNA. In their role in nuclear organization, lncRNAs
modulate chromatin function and interfere with signaling pathways. Their association with
ribosomes in the cytoplasm suggests an additional role in mRNA metabolism [45].
Interestingly, lncRNAs are reported to have miRNA binding sites that enable them to
sequester miRNAs and competitively reverse gene repression by miRNAs [46]. Recent
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discoveries point to embedded miRNA sequences within lncRNAs, suggesting that they
could be a source of miRNAs [47].
The first small endogenous ncRNAs (lin-4/let-7) were described in C. elegans in
1993 by Lee and co-workers [48], and these RNAs were eventually called microRNAs
(miRNAs) [49–52]. These single-stranded RNAs are characterized by their size of about
17–25 nucleotides and are highly conserved during evolution [49] in contrast to the poorly
conserved and least characterized lncRNA family [53]. Whole-genome and transcriptome
analysis estimates that there are about 23,000 lncRNAs, comparable to the number of
protein-coding RNAs and much higher than the number of miRNAs (put at approximately
2000) [44,54].
The major classes of small non-coding RNAs, their size, origin, and function are
summarized in Table 1-1.
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Table 1-1 Major Classes of Small Noncoding RNAs
Class

Size

Biogenesis

microRNA
(miRNA)

21 – 23 nt

piwi-RNA
(piRNA)

25–33 nt

Endogenous
silencing RNA
(endo-siRNA)
Small nucleolar
RNA (snoRNA)

21–26 nt

Small nuclear
RNA (snRNA)

150 nt

Transfer RNA
(tRNA)

73–93 nt

Processed by
DICER from 65
to 70 nt
precursors
Nuclear
precursor
amplified by
ping pong
mechanism in
the cytoplasm
Processed from
messenger RNA
transcripts
Processed from
messenger RNA
introns
RNA
polymerase II
and III
RNA
polymerase III

microRNA offsetRNA
(moRNA)
Enhancer RNA
(eRNA)

19–23 nt

60–300 nt

50–2000 nt

Processed from
miRNA
precursor
Nascent RNA
transcription

Number of
Members
(Humans)
>2500

Function

>20,000

Regulation of
retro transposons

Unknown

Regulation of
gene expression

>260

Chemical
modification of
other RNAs
Splicing of other
RNAs

9 families

>500

Unknown

>2000

Regulation of
gene expression

Translation of
mRNA to
protein
Unknown

Regulate
proximal gene
expression

[Adapted from [55]]
1.3.2

MicroRNAs (miRNAs)
Among the short regulatory ncRNAs, miRNAs (approximately 17 – 25 nucleotides

long) have generated the most interest because they exert a pleiotropic and redundant effect
on gene expression, modulating a variety of biological functions, including organismal
development, cellular signaling, and disease pathology [56]. A single miRNA can control
hundreds of target genes, and multiple miRNAs can target a single gene. There are at least
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2000 different kinds of miRNAs and the number is even estimated to be up to 20,000 [57].
It is estimated that more than half of the human transcriptome is under miRNA regulation
[58,59]. These small, non-coding RNAs regulate gene expression in a sequence-specific
manner by inducing mRNA degradation or translational repression [60].
MiRNAs have recently emerged as important regulators of disease progression and
development. MiRNA expression profiles are altered by oxidative stress [61],
cancerogenesis [62], age-related neurological disorders [63], and ionizing radiation [64].
Aberrant miRNA expression is associated with cancer development, progression, and
response to therapy, suggesting the possible use of miRNAs as diagnostic biomarkers.
Moreover, an increasing number of studies demonstrate that miRNAs can function as
potential oncogenes or oncosuppressor genes that intervene in the various aspects of cancer
development and progression, including apoptosis, angiogenesis, and neoplastic
microenvironment (Allegra et al., 2012). While the role of miRNA in carcinogenesis and
neurological disorders is a relatively new area of research, due to its therapeutics potential,
the field is rapidly growing and numerous miRNAs that modulate disease-related
physiological processes have been identified [66].
1.3.2.1

miRNA Biogenesis
Short and long ncRNAs differ in their origin, processing, and mode of action. The

canonical miRNA biosynthetic and maturation pathway is a complex multi-step process
and begins with their transcription by RNA polymerase II (or III for miRNAs encoded
within Alu repeat sequences) [67] into primary miRNAs (priRNAs) from intergenic or
intronic/exonic loci, often during transcription of their host genes [68]. The genomeencoded pri-miRNAs are then processed (cleaved) in the nucleus by an enzyme, Drosha to
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generate approximately 70-nucleotide long precursor miRNAs (pre-miRNAs) which is
hairpin-shaped [69]. Exportin-5, a Ran-GTP-binding nuclear transporter mediates the
transport of pre-miRNAs from the nucleus to the cytoplasm where the RNAse III-like
enzyme Dicer and TARBP2 (TAR binding protein 2) cleaves pre-miRNAs into a transient
duplex of around 17 – 25 nt in size, made up of the functional miRNA strand (guide strand)
and the passenger strand [70,71]. Of these two strands, the “passenger” strand is degraded,
while the other active “guide” strand becomes the mature miRNA that is loaded onto an
Argonaute protein in the RNA-Induced Silencing Complex (RISC).
An alternative, non-canonical pathway for miRNA biogenesis, also called the
Mirtron pathway [72], involves the splicing of intronic sequences and debranching of the
primary miRNA (priRNA) by a lariat debranching enzyme (Ldbr) after which they are
folded into precursor miRNA (pre-miRNA) hairpins, and becomes merged with the
canonical pathway. So, essentially, as short hairpin RNA molecules that are derived from
spliced introns, they bypass the nuclear Drosha-DGCR8 micro compressor complex and
become cleaved by Dicer in the cytoplasm into mature miRNAs. A schematic of the distinct
stages in miRNA processing is depicted in Figure 1-4.
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Figure 1-4 miRNA biogenesis. A.) The canonical pre-miRNA pathway produces
pre-miRNAs through cleavage of pri-miRNA transcripts by the Drosha-DGCR8
microprocessor complex. B.) The non-canonical pathway. Mirtrons are spliced and
debranched by the Ldbr enzyme, after which they fold into pre-miRNA hairpins.
Then, the pathways merge. The green box indicates a miRNA gene; exons 1 and 2
are exons of the host gene encoding intronic miRNA [56]
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1.3.2.2

miRNA Naming Convention
Given the large number of miRNAs that have been and continue to be discovered,

as well as sequence similarities and phylogenetic conservation, universally accepted
nomenclature guidelines were developed [73]. The uniform naming system for miRNA
annotation is described in Table 1-2.
Table 1-2 miRNA Nomenclature
Term
Species identifier

Definition
Abbreviated three or fourletter prefixes

Mature identifier

Mature sequences
processed by dicer are
designated with upper case
R
Precursor hairpins are
lower case R
Sequential numbers are
assigned based on historical
precedent (earlier
discovered miRNAs have
lower numbers and more
recently discovered have
higher numbers). Orthologs
have the same number in
different species
Paralogs that differ in the
mature sequence by 1–2 nt
are given lettered suffixes
following the numerical
identifier
Numbered suffixes

Precursor identifier
Numerical identifier

Paralog identifier

Distinct hairpin
precursors, same mature
miRNA sequence

Example
hsa-miR-101 (Homo
sapiens), mus-miR-101
(Mus musculus), dme-miR101 (Drosophila
melanogaster), cbr-miR101 (Caenorhabditis
briggsae)
hsa-miR-7

hsa-mir-7
mir-1, mir-2, mir-3

mmu-miR-10a and mmumiR-10b are mouse
paralogs of mir-10

dme-mir-281–1 and dmemir-281–2
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Table 1-2 continued
Term
Major form and minor
form

Definition
Major more highly
expressed form is named as
described above, and the
minor form with the
asterisk “*” or star
designation
5 Prime arm and 3 prime The star/* form has been
replaced by a more
arm
unambiguous system where
the mature miRNA in the 5
prime arms of the precursor
is designated 5p and the
mature miRNA from the 3
prime arms is designated 3p
Multiple miRNAs
miRNA cluster
transcribed on a single
RNA, or multiple miRNA
genes located closely on a
chromosome

miRNA families

Defined by matching seed
sequences

Example
mmu-miR-124 for the
major form and mmumiR124* as the minor form

miR-124-5p, miR-124-3p

miR-17-92 contains a
single transcript from
which six miRNA genes
and 12 mature miRNAs are
processed: miR-17, miR18a, miR-19a, miR-20a,
miR-19b-1,miR-92a-1
miRNA families Defined
by matching seed
sequences

[Adapted from [55]]
1.3.2.3

Biological (Epigenetic) Function of miRNAs
Mature miRNAs, through their guide strands, associate with an Argonaute protein

[74] at the core of the RNA-induced silencing complex (RISC) to perform mRNA
regulation. Recognition of target mRNA by miRNA generally depends on complementary
base pairing between miRNA seed sequence (nt 2–8 at the 5’ end of miRNA) and
sequences in the 3’-UTR of the target mRNA [58,59]. However, miRNAs are known to
also bind to non-canonical sites on target mRNAs [75]. MicroRNAs are negative regulators
of gene transcription (i.e. a reciprocal relationship), partially binding to complementary
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sequences in mRNA and resulting in post-transcriptional repression of gene expression, as
illustrated in Figure 1-5. This is called RNA interference (RNAi) or gene silencing [76].

Figure 1-5 A schema portraying miRNA Biogenesis and its Functional Roles in the
context of the RNA-Induced Silencing Complex (RISC) [miRNA (microRNA)
Introduction (sigmaaldrich.com)]
In this way, protein synthesis/expression is inhibited via one or a combination of
these three mechanisms: 1) mRNA endonuclease cleavage: PIWI domain, part of the RISC
protein complex, function as an RNAse H and degrades the target mRNA; 2) mRNA
degradation: removal of poly-A tail from mRNA and degradation by exonucleases; 3)
mRNA translation repression: RISC prevents translation initiation factors or ribosome
from binding to the mRNA. The particular mechanism at any time depends on the degree
and nature of complementarity sites between miRNA and the mRNA target [77,78].
Moreover, evidence exists to support the proposition that translational inhibition precedes
and is necessary for mRNA degradation by miRNAs [79].
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1.3.2.4

RNA-Induced Silencing Complex (RISC) Assembly
RISC is a ribonucleoprotein complex containing members of the Argonaute (Ago)

family of proteins with an endonuclease activity directed against mRNA strands that are
complementary to their bound miRNA fragment (Figure 1-6). The guide miRNA molecule
brings the RISC complex close to the target mRNA and recruits enzymes and cofactors
that mediate RNA silencing [80]. Dicers are large multicomponent proteins (M.W. = 200
kDa): an ATPase/RNA helicase, a DUF283 (Domain of unknown function) domain, two
catalytic RNase III domains (RIIIa and RIIIb), a C-terminal double-stranded RNA-binding
domain (dsRBD), and a PAZ (Piwi, Argonaut and Zwille) domain which binds the
characteristic two-nucleotide 3' overhangs of miRNA and siRNA. The Dicer enzyme can
function as a monomeric unit because its intramolecular RNase III dimer has a single
processing center. Each of the RNase III independently cuts one RNA strand of the duplex
to generate single miRNA strands with 2-nt 3' overhangs [81].
The guide strand from the Dicer-cleaved pre-miRNA stem-loop is loaded onto the
Argonaute protein that is associated with GW182 protein (Glycine-Tryptophan motif of
182 kDa molecular weight, another component of the RISC complex. The presence of other
RISC-associated proteins depends on the particular RISC pathway. In the translation
repression route, poly-A-binding protein (PABC) interacts with GW182 and proteins of
the translational machinery to inhibit translation. On the other hand, the mRNA decay
pathway involves GW182-mediated recruitment of CCR4-NOT1 (C-C Chemokine
Receptor Type 4- Negative Regulator of Transcription 1) complex, containing at least five
CCR or NOT proteins, which acts to deadenylate polyadenylated mRNAs. An mRNAdecapping enzyme 1/2 (DCP1/2) may act afterward to decap m7G mRNAs [82].
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Figure 1-6 Transient interaction of RISC and miRNA/mRNA pair, resulting in miRNA
processing [Source: MirTrap Technology: Technical Notes, Clontech 4.14 IN (633655).
www.clontech.com]
1.4

DNA Damage Response and Repair (DDR)

Genomes are constantly exposed to DNA damage caused by genotoxic agents of
environmental and endogenous origins. Depending on the source of damage, DNA may
accumulate a wide variety of lesions including base modification, single-strand breaks
(SSBs), or double-strand breaks (DSBs) [83,84]. Damage Repair by the DNA damage
response (DDR) pathway comprises three main steps: (i) detection of damage by sensor
proteins; (ii) recruitment of repair factors to sites of damage by signal transducers; and (iii)
repair by effectors [85]. Specific DNA repair pathways include correction of DNA
mismatches (Mismatch Repair, MMR); excision of chemically modified DNA bases (Base
excision repair, BER) [86,87]; correction of more complex lesions such as pyrimidine
dimers and intra-strand crosslinks (Nucleotide excision repair, NER) [88,89]; single-strand
break repair (SSBR) [90]; non-homologous end joining (NHEJ) or homologous
recombination (HR) to repair double-strand breaks (DSBs), which are the most toxic and
difficult DNA lesions.
The DNA Damage Response loop is a kinase-based signal transduction network
that initiates phosphorylation-driven cascades [91]. This DDR group of proteins acts by
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transient coordination of DNA repair, replication, cell cycle progression, telomere
homeostasis, and the subsequent induction of permanent cell cycle arrest or apoptosis if
the damage cannot be repaired [92]. In addition to these normal physiological processes,
the DDR loop serves as a molecular defense mechanism against tumorigenesis [93] and
virus infection [83].
1.4.1

Base Excision Repair (BER) Pathway/Mechanism
To preserve genomic integrity, eukaryotic cells need a complex but synergistic

DNA damage repair and response network of signaling pathways, involving proteins
involved in cell cycle arrest, apoptosis, or DNA repair. The functions of the human DNA
repair genes are well-established [94,95]. Base excision repair (BER) is the mechanism for
the excision and replacement of oxidative DNA damage wherein single nucleotides
modified by methylation, alkylation, deamination, or oxidation are removed [96].
Oxidative DNA damage is repaired primarily via the base excision repair (BER) pathway.
The base excision repair mechanism had evolved to repair the mutations induced by oxygen
radicals. This process is initiated by DNA glycosylases, which remove damaged bases in a
substrate-specific manner. Six glycosylases in humans repair oxidized DNA lesions: MutY
homolog (MYH), 8-deoxyguanosine DNA glycosylase 1 (OGG1), endonuclease three
homolog 1 (NTH1), and Nei endonuclease VIII-like 1, 2, and 3 (NEIL1, NEIL2, and
NEIL3). The repair response involves five key enzymatic steps that aim to remove the
initial DNA lesion and restore the genetic material to its original state: (i) excision of a
damaged base by a DNA glycosylase, (ii) incision of the phosphodiester backbone at the
resulting abasic site by an apurinic/apyrimidinic (AP) endonuclease or AP lyase (iii)
removal of the remaining sugar fragment by a lyase or phosphodiesterase (iv) gap-filling
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to replace the excised nucleotide by DNA polymerase, and (v) sealing of the final,
remaining DNA nick by DNA ligase. Defects in base excision repair components lead to
reduced cell survival and elevated mutation rates [97].
Figure 1-7 shows the mechanism by which the human 8-deoxyguanosine DNA
glycosylase 1 (hOGG1) repairs an oxidized guanine adduct [98]. OGG1, a bi-functional
DNA glycosylase that is specific for 8-OHdG, cleaves the N-glycosidic bond of DNA using
conserved active site lysine (Lys249) and aspartate (Asp268) residues that initiate a
nucleophilic attack on the target nucleotide and forms a covalent protein-DNA
intermediate. The subsequent general base-catalyzed abstraction of the C2 hydrogen then
promotes β-elimination of the DNA strand 3’ to the AP site [99]. By providing the first line
of defense against oxidative DNA damage, OGG1 plays an important role in reducing the
detrimental effects of DNA oxidative damage [2].

Figure 1-7 Oxidative DNA Damage Response and Repair in Cells. (A) Formation of 8OHdG by oxidative stress. (B) Mechanism of ROS-induced G: C to A: T DNA mutation
and OGG1’s substrate-specific excision of the 8-OHdG lesion [98]
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1.4.2

The Role of MicroRNAs in DDR Loop Regulation
Gene regulation occurs at the transcriptional and post-transcriptional levels. Recent

studies indicated that miRNA plays a significant role in post-transcriptional gene regulation
[12] and affect disease development and progression [65]. Changes in miRNA expression
play a pivotal role in DNA Damage Response [100]. DDR proteins regulate miRNA
expression, while also being influenced by miRNAs. The DNA damage response triggers
a complex signaling cascade, which induces the biogenesis of miRNAs at the
transcriptional level via the p53 pathway [101]. Conversely, miR-34 has been shown to
regulate p53 mRNA expression level [102]. The degree of induction of miRNA expression
is predicated on cell type and the nature and severity of DNA damage [64,103]. Changes
in transcription and chromatin structure that are an integral part of DDR are also modulated
by ncRNAs [104].
A knock-down of key proteins associated with miRNA biogenesis and function,
particularly DICER or Ago2, leads to a reduction in survival and checkpoint response after
UV damage suggesting that miRNAs play a major role in the cellular response to DNA
damage [105]. DNA damage-induced miRNAs have been implicated in the regulation of
the cell cycle, apoptosis, and DNA repair, and thus play an integral role in maintaining
genome stability [100]. Increased miRNA expression is correlated with decreased mRNA
target levels and reduced expression of DNA repair proteins. Key DNA repair proteins
such as ATM are regulated by miR-421 and miR-181 [106,107]. MiR-182 expression is
inversely correlated with the breast cancer type 1 susceptibility (BRCA1) protein levels in
breast cancer cells and impairs homologous recombination-mediated DNA repair pathway
[108], while miR-21 targets p53 and TGF-beta in glioblastoma [109].
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Gain-of-function studies determined that miR-1255b, miR-148b, and miR-193b
suppress the homologous directed (HR) DNA repair pathway [110]. MiR-24 regulates the
histone variant H2AX, a protein that has a key role in the double-stranded break DNA
repair [111]. MiR-203 inhibits DNA damage repair via the PI3K/AKT and JAK/STAT3
pathways and contributes to the modulation of radiation sensitivity in human malignant
glioma cells [112]. Overexpression of miR-92 is associated with an increased accumulation
of oxidative DNA damage and immortalization in hepatocellular carcinoma [113].
Astrocytes-derived

miR-181, miR-29, and miR-146a enhance neuron survival after

cerebral ischemia [114].
Bioinformatics analysis identified miRNA binding sites in the 3’-UTRs of DSBs
repair proteins such as RAD51 recombinase [115][116]. While some predictions have been
confirmed, a lot of these predictions have not yet been validated experimentally [117][118].
1.5

Methods and Techniques Employed in MicroRNA Target
Analysis

The human genome encodes over 2000 miRNAs that are estimated to bind to the
3’UTR region and target 60% of mRNA [58,59]. One miRNA can regulate multiple genes
and a single gene can be targeted by multiple miRNAs. Therefore, the identification of
these interactions is important for the development of miRNA-based therapeutics. Mature
miRNAs recognize their target mRNAs by base-pairing between its seed sequence (usually
between nucleotide position 2 – 8) and complementary nucleotides in the 3’-untranslated
region (3’-UTR) of mRNAs (gene coding sequence), thereby leading to translational
repression and mRNA cleavage [119,120]. However, perfect seed pairing does not
necessarily give a reliable prediction for miRNA interactions [121]. New microRNAs’
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target genes are identified via a combination of computational 3’UTR target prediction and
experimental validation. Several experimental approaches are developed to identify
miRNA’s gene targets and to confirm their biological function as summarized in the 4step scheme in Figure 1-8 [122].

Figure 1-8 Proposed Scheme for miRNA target validation. Prediction methods and
validation techniques of both microRNAs and their targets are co-dependent [122]
1.5.1

In silico Prediction of miRNA Targets
Computational analyses based on machine learning techniques are used to predict

miRNA species that selectively hybridize to the 3’ UTR of mRNA transcripts. The in silico
analysis enables researchers to narrow down their miRNA candidates for experimental
validation. There have been cases of failed validation tests despite seed sequence matching
predictions [121], suggesting that some contextual features may also be integral to
miRNA:mRNA interactions. RNA accessibility was shown to be a function of favorable
thermodynamics, which tilts more towards 3’-UTR sites that are devoid of complex
secondary structures. That is, the higher the free energy change (ΔG), the more accessible

24
the mRNA. The free energy change (ΔG) of the 70 nucleotides flanking the 5’ and 3’ sides
of the predicted 3’UTR regions are used to identify prospective miRNA:mRNA pairwise
binding.
1.5.2

Experimental Validation of miRNA-Target mRNA Interactions

1.5.2.1

Chimeric Reporter Gene Assay
The experimental approach is based on cloning of the 3’-UTR of the predicted

target gene immediately downstream of the luciferase or green fluorescent protein (GFP)
open reading frame in a reporter plasmid [123]. The recombinant plasmid and a miRNA of
interest are then transiently co-transfected into a host cell and luciferase activity and
fluorescence are measured 24 – 48 hours after transfection. It is expected that the binding
of a given miRNA to its specific mRNA target site will repress the production of the
reporter protein thereby decreasing its expression/activity which can be measured and
compared to a control reporter plasmid. The disadvantage of this technique includes an
increased number of false-positive and false-negative results due to non-physiologic
interactions [124].
1.5.2.2

Immunoprecipitation Technique
Immunoprecipitation permits the identification of functional miRNA:mRNA

relationship based on their physical interactions using an antibody-mediated “pull-down”
strategy of the complex [124,125]. The Argonaute (Ago) protein family binds to miRNAs
and partially to the complementary sequences in the 3’-UTR of their target mRNAs.
Antibodies against Ago can be used for co-immunoprecipitation of the Ago-bound
mRNAs. A novel and robust immunoprecipitation technique, MirTrap System (Clontech®
Laboratories, Cat # 632017), has been developed for this purpose. The MirTrap technology
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is a powerful discovery tool that helps identify and enrich microRNA targets in mammalian
cells. It is based on the principle of sequence complementarity that allows actual physical
interaction between miRNAs and mRNA transcripts [80]. The system allows the
expression of a dominant-negative subunit of RISC protein that enables a miRNA of
interest to bind to its target mRNA but restricts further processing of the transcript. The
negative subunit is integrated into the endogenous Ago/RISC complex and “locks” a
miRNA-target mRNA in the complex. The flag epitope tag (DYKDDDDK) is linked to the
subunit and allows capture and isolation of the entire Ago/RISC complex, together with
the microRNA/target mRNA pair of interest. Thus, the microRNA and its target can be
effectively immunoprecipitated (enriched) and subsequently identified by next-generation
sequencing or validated by quantitative PCR (qPCR).
1.5.3

Indirect Experimental Validation of miRNA-Target mRNA Interactions
Indirect validation can be conducted at three levels: transcriptomics, proteomics,

and metabolomics.
1.5.3.1

Transcriptomics: miRNA and Target mRNA Inverse Transcription
For the target mRNA to be modulated, it must have an inverse expression level with

its homologous miRNA. An older approach is in situ hybridization, which leveraged the
enhanced efficiency, stability, and discriminatory power of digoxigenin (DIG)-labeled
“locked nucleic acid” (LNA) antisense miRNA-specific probes. Hybridization is
performed utilizing fixed and mounted tissues at 370C overnight, followed by a low
stringency wash [126]. The probe-target complex is visualized by utilizing a digoxigenin
antibody conjugated to alkaline phosphatase acting on the chromogen nitroblue tetrazidium
and bromochloroindolyl phosphate. However, data interpretation can be erratic because of
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the relatively narrow window between signal and background; so it is advisable to be used
as an adjunctive technique. Northern blot analysis using LNA-modified oligonucleotide
probes has also been employed [127]. Real-time quantitative PCR (RT-qPCR) is
considered the gold standard for validation of the expression level of the predicted
miRNA:mRNA complex [128].
1.5.3.2

Gain of Function and Inhibition: Proteomics and Metabolomics Analyses

A typical approach to validate the functional relationship of a miRNA/mRNA target
pair is a transient over-expression (“gain-of-function”) of a given miRNA mimic (a
synthetic double-stranded version of an endogenously expressed mature miRNA) in a cell
type known to express the putative target protein, and subsequently quantifying differences
in mRNA and protein expression using RT-qPCR and Western blot, respectively [129].
Gain of function studies is likely to have “off-target” effects, as aberrant expression of
miRNAs could target genes that would otherwise not be affected under physiological
conditions. Therefore, a two-way experimental validation is often employed (Figure 1-9).
This includes over-expression (using miRNA mimics) and inhibition (using “loss-offunction” studies in which a specific endogenous mature miRNA function can be inhibited
using antisense oligoribonucleotides). These single-stranded RNAs are chemically modified
(i.e. 2′-O′-methoxyethyl phosphorothioate or LNA) to improve stability and potency.
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Figure 1-9 Mechanisms conferring protein loss and toxic gain-of-function effects. The
diagram illustrates pathogenic mutations (repeat expansions, deletions, point mutations)
that may occur either in noncoding or coding regions of the genome (left and right sides,
respectively). (A) Protein loss-of-function. Haploinsufficiency can occur when the level
of a particular mRNA is down-regulated due to mutations in noncoding regions of genes
such as in promoters/introns, or if the promoter is subjected to histone/DNA
modifications (transcriptional repression), but also if mutations in 5′ or 3′ untranslated
regions (UTRs) decrease mRNA stability. Protein loss-of-function can also occur when
mutations in coding regions alter directly the activity of the mutated protein (misfolding,
alteration of the active site). (B) Protein toxic gain-of-functions are caused by mutations
in coding regions that either promote abnormal interactions, increase the interaction of
the mutated protein with its natural binders and/or promote misfolding/aggregation
[Adopted from [130]]
The choice of cells utilized for performing gain-of-function and loss-of-function
studies is important as each cell line has varying levels of endogenous miRNA and target
gene expression [131–133]. Since miRNAs modulate gene expression by both translational
repression and mRNA cleavage, the effect of a miRNA mimic can be assayed at the protein
and metabolic levels. If a given mRNA is the correct biological target of a specific miRNA,
it stands to reason that fluctuations in the miRNA level should give rise to an inversely
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corresponding change in the protein encoded by the target mRNA, and invariably, its
phenotypic expression. Once the impact of miRNA on the gene and protein level of the
target mRNA has been confirmed, the impact on the relevant cellular processes is
investigated.
Depending on the protein target of interest, biological assays could investigate
different signaling pathways, cell proliferation [134], cell differentiation [135], apoptosis
[136]. However, since this is an indirect measure of miRNA's effect on protein levels, the
phenotypic assay must be preceded or accompanied by a direct protein assay. Moreover, to
further identify whether a miRNA species modulate the protein expression of its target
mRNA, a “rescue assay” can be carried out whereby the effect of a given miRNA can be
rescued by overexpression of that protein [122]. Conversely, a knock-out (gene silencing)
study can be carried out by the use of small interfering RNAs (siRNAs) targeted at
complementary regions on the mRNA transcript. The binding of siRNA effectively silences
the expression of the gene, and thus, the protein, so that with inhibition of the miRNA, and
the consequent under-expression of the target gene and its encoded protein, the amount of
protein produced should be higher than without the inhibition.
1.6

Cellular Oxidative Stress

Oxidative stress is generally defined as an imbalance in oxidative metabolism
whereby the scavenging capacity of the cell’s antioxidant system can not keep up with the
rate of reactive oxygen species (ROS) production in high oxygen-demanding organelles
like the mitochondria, peroxisomes, endoplasmic reticulum, and during inflammatory
processes, mainly in macrophages [137],. Nucleic acids are susceptible to oxidation by
environmental and endogenous factors, and several types of ROS, such as singlet oxygen
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(O2−) and hydroxyl radicals (OH−), generated as byproducts of normal oxidative
metabolism, especially in the mitochondria [138], or by ionizing radiation exposure (e.g.
X-rays and γ-rays), can induce oxidative modification of the DNA bases, producing lesions
including the ring-opened formamido-pyrimidine derivatives of guanine and adenine, 8hydroxy-2'-deoxyguanosine (8-OHdG), formyluracil, dihydroxyuracil, and thymine glycol
[139]. Despite the body’s antioxidant enzymes mitigating the cell’s hyper-oxidative state
to preserve the cell’s functionality, an imbalance between the production of ROS and the
biological repair of the oxidative damage can result, and thereby causes mutations to DNA
which plays a pivotal role in cancer development and progression, as well as aging and
age-related neurological disorders [140].
1.6.1

8-OHdG as an Oxidative Stress Biomarker
Among the five nucleobases, guanine is the most susceptible to oxidation because

of its high electron density. The most common biomarker of ROS-induced DNA damage
is the mutagenic base byproduct, 8-OHdG, an oxidized derivative of deoxyguanosine
[141]. Thus, the concentration of 8-OHdG within a cell is a well-established marker of
nucleic acid oxidative damage and an indicator of oxidative stress [142]. Elevated levels
of 8-OHdG have been reported in leukemia [143], breast cancer [144], colorectal cancer
[145], lung cancer [146], Parkinson disease [147], and Alzheimer’s disease [148].
8-OHdG is highly mutagenic, causing DNA mutations by incorporation of adenine
instead of cytosine during DNA replication that leads to C: G to A: T substitutions in the
nucleic acid sequence. The human 8-deoxyguanosine DNA glycosylase 1 (hOGG1) is a bifunctional 8-OHdG-specific glycosylase that plays an important role in nicking off 8OHdG mutations (Figure 1-7). Thus OGG1’s expression level in cells is equally a gauge
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of the DNA repair capability of cells [2]. Decreased expression levels of OGG1 correlate
with a high frequency of 8-OHdG adducts and DNA mutations [149]. A single nucleotide
polymorphism caused by oxidation of the cysteine residue-326 [Cys-326] has been linked
to deficient OGG1 activity, and thus, has been used as a marker of individual susceptibility
to oxidative DNA damage [150]. However, the focus of these published studies was on the
genetic changes that influence OGG1 activity in cells and didn’t consider non-coding RNA
regulation.
1.6.2

The Brain’s Susceptibility to Oxidative Stress
The brain is a prime target of reactive oxygen species, and so of the resulting

oxidative stress, because of its heavy oxygen dependence, high energy requirements (high
glucose metabolism), extensive lipid composition, and more importantly, its relatively
weak antioxidant system, in comparison to other tissues [3]. The relatively slower rate of
8-OHdG clearance from brain tissues makes it even more vulnerable to oxidative stress
[151]. Neural cells are continuously challenged by ROS, and effective repair of ROSinduced 8-OHdG accumulation is critical to maintaining brain function and reducing the
rate of C: G to A: T transversion mutation (Refer to Figure 1-7). The base excision repair
is one of the mechanisms that protect the brain cells from oxidative lesions by preventing
both nuclear and mitochondrial mutations [2]. The reduced cellular capacity of DNA
damage repair is implicated in the process of neurodegeneration [152].
1.6.2.1

Astrocyte as a CNS Model for Oxidative Stress
Astrocytes are the most abundant glial cells in the central nervous system. They

maintain electrolyte-water balance, energy metabolism and homeostasis, defense, synaptic
transmissions, and regeneration of the CNS [4,5]. Therefore, human astrocytes are an ideal

31
biological model to investigate the relationship between oxidative stress, DNA damage and
repair, miRNA and OGG1 mRNA, and protein expression levels. Understanding the
epigenetic regulation of astrocyte DNA repair mechanisms could lead to the identification
of novel targets for the treatment of CNS disorders. Considering the important role in
maintaining brain activity, astrocytes can be regarded as a potential target for therapies
aimed at the prevention and cure of age-related neurodegenerative diseases [97].
1.6.3

Crosstalk Between ROS and MicroRNAs
Changes in microRNA expression profile and ROS signaling have been associated

with tumor development, progression, metastasis, and therapeutic response, prompting
investigations into possible crosstalk between ROS and microRNAs. Emerging evidence
suggests a reciprocal connection between ROS signaling and the miRNA pathway whereby
ROS induces epigenetic alterations of miRNA genes [153]. It has been proposed that ROS
are involved in various steps of miRNA biogenesis via several mechanisms which include:
inhibition and enhancement of the expression of certain miRNA genes through the
epigenetic regulatory enzymes, DNMT1 and HDACs; the regulatory activation of stressrelated transcription factors such as p53, nuclear factor (NF)-κB to induce miRNA
expression [13,14]; and the recruitment of the miRNA processing machinery, Drosha and
Dicer, which can be directly or indirectly regulated by ROS [15].
Figure 1-10 elucidates the proposed mechanism to explain this complicated and
poorly understood mechanism underlying ROS-regulated microRNA expression.
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Figure 1-10 Schematic model showing mechanisms in which ROS regulate microRNA
expression. ROS are involved in every step of miRNA biogenesis. ROS can induce
epigenetic alterations of miRNA genes. For example, ROS inhibit and enhance the
expression of certain miRNA genes through DNMT1 and HDACs, respectively. ROS
can also activate transcription factors to induce miRNA expression. Moreover, Drosha
and Dicer, which are two essential enzymes for miRNA biogenesis, can be directly or
indirectly regulated by ROS [15]
1.6.4

Chromium Toxicity
The industrial use of heavy metals and mainly chromium-based products in the

world is increasing rapidly. This poses a risk of oxidative damage in brain cells that is
correlated with the development of neurological disorders [154]. Chromium has been the
subject of multiple toxicological investigations following the increase in an occupational
exposure and the release of the chemical into the environment [155]. While the biological
effects of chromium have been extensively studied both in vitro and in animal models,
including spermatotoxicity [156], hepatotoxicity and neurotoxicity [157], the genetic and
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epigenetic response of the cells of the central nervous system have not been sufficiently
characterized.
Among heavy metals, chromium poses a particularly serious threat due to its high
oxidation resistance. In combination with iron and oxygen, chromium is deposited as
ferrochrome ore, ranking as the sixth most abundant element in the earth’s crust. Its
ubiquity and persistence in the environment increase the risk of chromium exposure and
toxicity in the general population [158]. According to a Toxics Release Inventory of 3,391
large processing facilities in the United States, chromium accounted for 94.1% of total
environmental release into the soil (30,862,235 pounds) and 0.3% into water (111,384
pounds). The survey reported a 0.4 – 8.0 µg L-1 concentration of chromium in tap water in
U.S. households [159]. Other environmental sources of chromium are buildings plastered
with chromium-containing cement, asbestos roofing, emissions from chromium-based
automotive catalytic converters, and tobacco smoke [160]. In nature, chromium is present
in its stable trivalent form (Cr+3). Hexavalent chromium (Cr+6) is considered the most toxic
form, because it has a high oxidation potential, high solubility, and can easily cross the cell
membrane [161]. Cr+6 in the environment is almost totally derived from anthropogenic
sources [162,163]. Absorbed chromium is carried in the bloodstream, eventually being
distributed to all tissues. The dual factors that determine the toxicity and biodistribution of
chromium compounds are oxidation state and solubility [164].
The mechanism of chromium (VI)-induced enhanced production of reactive
oxygen species, as well as the resulting oxidative tissue and DNA damage are well
documented [154,165]. Several types of chromium-induced structural DNA damages have
been reported including DNA strand breaks [166,167], DNA-protein crosslinks [168,169],
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and the formation of chromium-DNA adducts, which lead to repair errors [170]. The
genotoxic effects of chromium are mediated by the formation of intermediates during the
reduction of Cr+6 to Cr+3. The free radical species produced during the process attack and
cause oxidation of macromolecules such as DNA and lipids, with negative consequences
for human health, including neurotoxicity, hepatotoxicity, nephrotoxicity, genotoxicity,
carcinogenicity, and immunotoxicity [171,172].
1.6.4.1

Sodium Dichromate
Sodium dichromate (Chromic acid or Disodium salt) is an odorless, red or orange-

red crystalline inorganic compound, with a molecular weight of 261.97 g/mol in its
anhydrous form (Na2Cr2O7, CAS No. 10588-01-9), and 298.00 g/mol in its dihydrate form
(Na2Cr2O7·2H2O, CAS No. 7789-12-0). Its structural formula is represented in Figure 111. Owing to its oxidizing potential, sodium dichromate is used as a corrosion inhibitor
and to make virtually all chromium-based compounds and materials [173,174], and are
thus, widely employed in various industrial processes including electroplating operations,
leather tanning, textile manufacturing, stainless steel welding, wood treatment, and in paint
pigment production [175].

Figure 1-11 The structural formula of sodium dichromate
[https://commons.wikimedia.org/wiki/File:Na2Cr2O7.png]
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Hexavalent chromium, as typified by sodium dichromate, has been classified as a
Group 1 human carcinogen [176]. Sodium dichromate is associated with oxidative DNA
damage in human lymphocytes [177], and induced OGG1 downregulation in human A549
lung carcinoma cells [178]. As shown in previous studies, Cr+6 can lead to increased lipid
peroxidation in the brain [179,180], and hence, neurotoxicity [181–183]. Since the central
nervous system is a target for exposure to chromium or its compounds, it is necessary to
assess its toxicity response for human safety assessment near hazardous waste sites.
1.6.5

Radiation Toxicity
Reactive oxygen species (ROS) produced as a result of radiation exposure lead to

DNA mutations including oxidized nucleobases, as well as single-strand and double-strand
breaks in normal cells. If these lesions remain unrepaired, the cell will either enter
apoptosis or the resulting DNA mutations will be passed on to progeny cells, leading to
deleterious changes in the phenotype [184]. Mitochondria, double-membrane organelles
that provide cellular adenosine triphosphate (ATP), are proposed to play a key role in
radiation-induced genomic instability. Accumulating evidence suggests that radiationinduced mitochondrial damage is more extensive than radiation-induced nuclear damage
[185,186]. Previous studies have indicated that exposure of neurons to radio-frequency
radiation resulted in an increased production of reactive oxygen species causing mtDNA
damage as quantified by a decrease in DNA copy number [187]. There are approximately
2 – 10 copies of the mitochondrial genome per mitochondrion and tens to hundreds of
mitochondria per cell, such that one cell may contain up to several thousand mitochondrial
genomes. Mitochondrial DNA (mtDNA) is believed to be more susceptible to ROS damage
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because of the lack of protective proteins and histones leading to the accumulation of more
oxidative mtDNA damage relative to nuclear DNA [188].
1.6.5.1

Radiation Therapy: Risks and Benefits
Proton radiotherapy differs from photon radiotherapy in the use of charged

particles, with a finite, energy-dependent range that can be adjusted to match the depth of
the target, allowing for better targeting of diseased tissue and avoidance of healthy tissue.
Clinically, this leads to reduced damage to non-target tissues and better clinical outcomes
[189]. Due to its off-target effect, radiation therapy can cause disruption of the
hypothalamic-pituitary axis and an increased risk of secondary malignancy. However,
proton therapy is reportedly associated with improved outcomes in patients with gliomas
and is associated with a decreased risk of late effects from treatment, including
neurocognitive decline, endocrinopathy, and secondary malignancies in pediatric brain
tumor patients [190,191]. High-throughput transcriptome analysis indicated that treatment
with 2 Gy X-ray radiation causes alteration of several key pathways involved in cancer
development and radiation resistance that include P53, TGF-β, VEGF, Hippo, and
serotonergic synapse pathways [192]. Another study confirmed that the suppression of
mitochondrial function is associated with the acquisition of radioresistance in glioma cells
[193]. The radiation-induced bystander effect is associated with the increased rate of ROS
production mitochondrial impairment, and DNA damage [194]. Additionally, radiotherapy
has been implicated in the development of secondary brain tumors under a wide range of
doses and treatment conditions [195]. The dose/fractionation of radiotherapy for the
treatment of glial tumors is constantly evolving as a result of advances in imaging methods
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and personalized medicine. While standard therapy includes a total dose of 60 Gy, daily
radiation treatments can vary between 1.8 Gy–3.5 Gy [196].
1.7

Extracellular Vesicles (EVs)

Extracellular vesicles were erroneously thought to be storage compartments for
cellular waste material, until their recently discovered role in cell-to-cell communication
[16,18,197]. The term is used to broadly describe a heterogeneous population of cellderived vesicular bodies, whose origin is either from endosomal compartments (exosomes,
size range ~ 30 to 150 nm) or plasma membrane shedding (ectosomes, size range ~ 50 nm
to 1 μm). The latter constitute microvesicles, oncosomes, and apoptotic bodies [198].
Considering their biological roles in cell-cell communication, the clinical applications of
extracellular vesicles for biomarkers assessment and drug delivery are being explored [19].
1.7.1

Exosomes: Biogenesis and Mechanisms of Action
Exosomes are the smallest category of extracellular vesicles (30 – 150 nm diameter)

that originate from the endocytic pathway of their host cells as intraluminal vesicles (ILVs),
formed by inward budding of maturing early endosomes (EEs) or late endosomes (LEs) to
yield multivesicular bodies (MVBs) (Figure 1-12). Cargoes are sorted into the ILVs by
mechanisms mediated by the endosomal sorting complex required for transport (ESCRT)
and other associated proteins, or by ESCRT-independent (lipid-driven) mechanisms. While
some of the MVBs get fused and degraded by lysosomes, some fuse with the plasma
membrane from where they are released as exosomes [199].
In the extracellular space, the secreted exosomes can influence the physiological
response of the nearby recipient cell (paracrine signaling) or circulate in the extracellular
fluid to remote sites in the body. Interaction with recipient cells is by one of three ways
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[200]: 1) receptor-mediated exchange whereby exosomes bind and activate surface
receptors on the recipient cell; 2) membrane fusion via a connexin-dependent mechanism
that transfers exosomal cargoes to recipient cells, or 3) endocytosis/micropinocytosis
which involves internalization of exosomes and their subsequent fusion with endosomal
compartments to transfer their cargo. Endocytosis is usually the preferred route for those
cells that do not possess antigen-presenting capacity, like some microglial cells [201].

Figure 1-12 Biogenesis, targeting, and composition of exosomes [200]
The ease of access to exosomes from virtually any biological fluid forms the
rationale for the use of exosomes as non-invasive biomarkers for assessment of disease
status and toxicity [21,29]. Exosomes are released by the cells into a wide variety of body
fluids, including ascites, breast milk, amniotic fluid, tears, synovial fluid [202,203], blood
[204], semen [205], urine [206], saliva [207], and cerebrospinal fluid [208].
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1.7.2

Exosomal Cargoes
Exosomes encapsulate nucleic acids (DNA, mRNA, and miRNA), proteins, and

lipids, and other metabolites, depending on the cell type, location, and physiological or
pathological state of the cell. Generally, exosomes are enriched in cytosolic proteins
involved in MVB formation, membrane trafficking and fusion, and tetraspanins (CD9,
CD,63, CD81) [30]. Several comprehensive databases that are annotated with the
International Society for Extracellular Vesicles’ (ISEV) minimal experimental
requirements for the definition of extracellular vesicles are available for exosome
researchers to validate or update the proteomic and genomic contents of exosomes released
from different cell types and experimental conditions. Exocarta [209] and Vesiclepedia
[210] are manually curated web-based compendium of exosomal cargoes (RNA, proteins,
and lipids) that also catalog the mode of purification and characterization of the exosomes.
Additionally, ExoCarta (http://www.exocarta.org) features dynamic protein-protein
interaction networks and biological pathways of exosomal proteins. These databases are
especially useful for comparing obtained data and assessing the purity of an exosomal
preparation [211]. For instance, the simultaneous presence of canonical, endosome-specific
proteins like Rab5 and the exosomal tetraspanins in exosomes from a particular cell or
tissue sample, can be used to exclude the presence of membrane vesicles derived from
membrane shedding (ectosomes) and disruption (necrosis and apoptosis) [212].
1.7.3

Biomedical Applications of Exosomes
Exosomes are released under normal physiological conditions, but their number is

often increased upon cellular activation or neoplastic transformation [27]. Clinical
investigators have demonstrated that during viral infections, the number of extracellular
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vesicles secreted by infected cells increases and that the EVs are used as delivery vectors
of viral materials [213]. Because exosomes reflect the state of their originating cells, their
contents may potentially be useful as cell-type-specific biomarkers for various diseases.
Exosomal miRNAs can be measured using RT-qPCR, microarrays, or small RNA
sequencing and serve as biomarkers for the development and progression of pathological
conditions [214]. Therefore, exosome-based diagnostics could become an integral part of
a personalized and precise medical approach.
The diagnostic utility and therapeutics delivery potential of exosomes have been
investigated in medical and clinical settings. These studies include investigations into
sperm maturation along the male reproductive tract [215], HIV-1 inhibition [205], immune
response stimulation for cancer immunotherapy [216], mediation of inter-organ cross-talk
in metabolic diseases like obesity and diabetes [217], propagation of pathogenicity by brain
exosomes via enrichment in neurotoxic proteins which contributes to neurodegeneration
[218], detection of exosomes in the tumor microenvironment where they regulate
angiogenesis, immunity, and metastasis in cancer [219], exosomal evasion mechanisms
driving chemotherapeutic resistance in aggressive B-cell lymphoma [220]. The
heterogeneity, endogenous origin, and ubiquitous distribution of exosomes in all biological
fluids make them an accessible source of biomarkers for disease diagnosis [221,222].
The area of miRNA therapeutics is rapidly developing and offers novel strategies
to modulate genetic instability by delivering synthetic miRNA mimics to correct abnormal
miRNA expression [223,224]. MiRNAs represent attractive therapeutic targets since they
can be easily synthesized both in their sense and antisense (inhibitory) orientation, and
delivered by biocompatible nano-vehicles. In addition to its immense potential in the areas
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of liquid biopsy, exosomes have also found application in targeted therapeutics delivery
due to their ability to protect nucleic acid and proteins from degradation. Relative to other
lipid-based drug excipients such as liposomes, exosomes have a more efficient cellular
uptake [225,226] and payload delivery [227], and are generally well tolerated by cells, with
minimal immune clearance [228].
1.8
1.8.1

Purification of Extracellular Vesicles (EVs)

The Need for Pure Exosome Populations
The analysis of exosome-specific transcriptomes and proteomes is critical for

obtaining accurate clinical data. Inefficient purification techniques lead to the extraction of
both exosomes and other extracellular vesicles that have different sizes and cellular origins.
The most commonly used procedures involve multiple series of high-speed
ultracentrifugation steps to remove cellular debris and separate and pellet the exosomes.
The disadvantage of this technique is that it does not separate the exosomes from other
vesicular structures and larger protein aggregates due to overlapping biophysical properties
[229].
Antigen-specific isolation and genetic analysis of disease-responsive exosome
subpopulations that express the same surface protein markers are essential to evaluate their
clinical relevance [33]. Exosomes are released in normal physiological conditions, but their
number is often increased upon cellular activation or neoplastic transformation [27]. CD63positive exosomes are present at a higher level in prostate cancer cells compared to normal
prostate cells [230], and their selective isolation would be of paramount importance in
tissues that are not accessible to direct examination, such as the central nervous system.
Particular cell lineages of the CNS, for instance, neurons, secrete exosomes in the
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cerebrospinal fluid which carry specific markers such as the L1 cell adhesion molecule, the
GPI-anchored prion protein, and the glutamate receptor, GluR2/3 [231]. Selective
purification of this subpopulation will enable researchers to look into the
(patho)physiological response of neurons in neurodegenerative disorders. In early
Alzheimer’s disease, increased levels of phosphorylated tau protein are detected in the
exosome fraction of the cerebrospinal fluid [26]. This is a very promising finding and
points to the possibility for an early diagnosis of Alzheimer’s disease through analysis of
the pure exosomal content of biological fluids.
The development of a technology for the isolation of a pure population of exosomes
will facilitate the studies of their function in the development and progression of biological
disorders. A rapid, and antigen-selective technology that provides high purity devoid of
remnant matrices from current column chromatographic methods [232], will lead to more
accurate data. Such an innovation would be a versatile platform with applications in disease
diagnostics and monitoring of treatment response.
1.8.2

Existing Purification Methods: Advantages and Disadvantages
The

most

widely

used

methods

for

exosome

purification

include

ultracentrifugation, size-exclusion techniques, polymer precipitation, immunoaffinity
separation, and microfluidics [233].
Considered the gold standard in exosome isolation, high-speed ultracentrifugation
(differential and density-gradient) gained widespread usage due to its operational
simplicity. The main disadvantages of this technique are its high-cost equipment, lengthy
run-time, and low yield. Moreover, co-isolation of non-exosomal vesicles and proteins is a
common issue, since vesicle subpopulations are not thoroughly defined due to overlapping
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biophysical properties [229,234–236]. The polymer precipitation technique, on the other
hand, doesn’t require a sophisticated setup and provides a relatively high total product
yield. This method, however, has a low sample to reagent volume and produces exosomal
samples with low purity [237].
Solid-phase exosome purification (SPEP) is the most promising alternative
technology that could help to address the present technical challenges encountered in
traditional liquid-phase separation techniques. Some solid-phase methods have made
interesting attempts that scratched the surface of these challenges but fell short of
holistically tackling all identified challenges. Although size-exclusion chromatography
[238] has a simpler protocol that involves more readily available equipment as well as
yields a purer exosome subpopulation compared to ultracentrifugation, it still has a low
total yield and is a non-specific capture method [239].
Immuno-affinity techniques are quite labor-intensive and involve the use of
antibody-coated fixed-phases like nanocubes [240], the surface of plastic plates [241] or
magnetic beads [242], which are target-specific and can be used for almost any biological
media. This method, typified by the well-known Dynabeads® magnetic separation
technology, is highly specific and has a highly concentrated yield and purity at the time of
capture, in addition to ensuring the integrity of isolated exosomes [243]. However, the pH
and ionic concentrations of the reagents required to elute the exosomes from the stationary
phases for downstream analysis can easily alter the properties of most of the exosome
products, rendering them inadequate as best-practice models for exosome utilization [244].
The greatest limitation to widespread adoption of the immunoaffinity-based method is its
high reagents cost that limits the sample volume being analyzed.
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Microfluidics strategies for exosome isolation [245] integrate already established
purification methods on a lab-on-a-chip platform. Some reported microfluidics systems are
based on the applications of immunomagnetic beads [20], nanoporous membranes [246],
and size-dependent displacement of extracellular vesicles [247,248]. This method,
however, has no standardized protocol and yields a variety of experimental results. Thus,
the challenge to develop a purification technique that can selectively isolate exosomes
rapidly, reproducibly, efficiently, and in a clinically advantageous manner has been
recognized as a perennial problem [249].
To overcome the identified technical challenges, traditional exosome purification
technologies are sometimes used in combination in an attempt to provide a simple, fast,
efficient, and affordable technique to isolate exosomes in a solid phase [250]. A novel
ultrafast-isolation system called EXODUS, consisting of a low-cost disposable module and
an automated workstation, employs a nanoporous membrane to rapidly isolate and
concentrate exosomes from biofluids via acoustofluidic streaming [251]. Despite
advantages over existing methods, the negative oscillatory pressure applied to the sample
could lead to reduced integrity of the exosomes in the sample. Also, the cost and technical
barriers associated with this method can be limiting factors to their extensive application.
To date, no one has successfully developed a microprobe-based, antigen-specific
technology for single-step and high-throughput purification of intact exosomes that is also
cost-friendly.
1.9

Layer-by-Layer (LbL) Assembly

Layer-by-layer self-assembly is an iterative thin film fabrication technique that is
based on electrostatic adsorption of alternating layers of oppositely charged
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polyelectrolytes (Figure 1-13) to form a substrate architecture for a variety of biosensing
applications [252]. Electrostatic attraction and molecular interactions have been attributed
as the driving force for the precisely controlled multilayer buildup with a nanometer
resolution. Alternate adsorption cycles do not occur between polyelectrolytes of identical
charges but rather with oppositely charged polyions, leading to a repeatable increment in
the film’s thickness at each step.

Figure 1-13 Schematic of the Layer-by-Layer Assembly Process [252]
According to pioneer work in this field [253], linear growth regime is reproducible
up to 25 molecular layers, after which long-range dimensional instability might set in.
Although films with high numbers of bilayers have been shown to exhibit good stability,
it is not necessarily the case in all situations [254]. As such, modulating and optimizing the
number of layers in a thin film becomes germane in any LBL procedure. Non-linear film
growth has been widely reported at the first two to three layers before saturation kinetics
comes into play to ensure uniform deposition [255,256]. Previous studies indicate that a
minimum of four bilayers is required for uniform substrate coverage and that polyion films
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are thermostable at up to 200 0C temperature and are insoluble in water and many organic
solvents [257,258].
Thin-film deposition over surfaces via LBL assembly provides a multilayer
architecture that has been applied in diverse biomaterials encompassing biosensors,
biocatalysts, tissue scaffolds, and microporous capsules which presents the prospects of
controlled drug delivery in the presence of appropriate stimuli like pH change or irradiation
[259]. In this study, the LBL protocol will be used to immobilize biotin on the surface of
stainless-steel microneedles for subsequent covalent attachment of streptavidin-conjugated
anti-CD63 antibodies.

CHAPTER 2
IMPACT OF PHOTON AND PROTON IRRADIATION ON
MITOCHONDRIAL FUNCTION AND 8-OHDG
BASE-EXCISION REPAIR MECHANISM
IN HUMAN ASTROCYTES

2.1

Motivation

Previous studies have indicated that 8-OHdG mutations increase in cancer patients
exposed to radiation therapies [260]; however, how the rate of DNA damage accumulation
corresponds to the source of radiation treatments has not yet been established. Since proton
and photon radiations are two of the most common treatments for cancer patients [261],
these radiotherapies will be investigated in this study. Comparative information regarding
low-dose proton and photon radiation treatment on mitochondrial biogenesis and baseexcision DNA repair capabilities of human astrocytes is lacking. Understanding the cellular
response and exploring the underlying mechanism for radiotherapy-induced cytotoxicity
of healthy astrocytes will contribute to the development of optimized treatment.
2.2

Specific Objectives

This study aims to assess and compare the effects of proton and photon radiation
on the changes in mitochondrial mass and oxidative activity, as well as gene expression
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levels of the base-excision repair protein, 8-oxoguanine DNA glycosylase (hOGG1) in
healthy human astrocytes.
Radiation-induced changes in mitochondrial mass and oxidative activity will be
assessed using MitoTracker™ Green FM and MitoTracker™ Orange CM-H2TMRos dyes,
respectively. MitoTracker™ Green FM is non-fluorescent in aqueous solutions and
becomes fluorescent only when it accumulates in the mitochondrial lipid environment.
MitoTracker™ Orange CM-H2TMRos is oxidized by molecular oxygen in actively
respiring cells and allows assessment of in vitro oxidative activity of mitochondria. RTqPCR will be employed to quantify OGG1 expression as an assessment of the DNA-repair
status of the irradiated cells.
2.3
2.3.1

Materials and Methods

Proton and Photon Irradiation of Cultured Astrocytes
Human primary astrocytes (Sciencell, Carlsbad, CA) were cultured at 37°C, 95%

humidity, and 5% CO2/air in Astrocyte Medium (Sciencell, #1801), supplemented with 1%
penicillin/streptomycin solution (Sciencell, #0503), 2% Fetal Bovine Serum (Sciencell),
and 1% astrocyte growth supplement (Sciencell #1852). When cells reached 80%
confluence, they were transported to Willis Knighton Cancer Center in Shreveport,
Louisiana, USA for radiation treatment with 0.5 Gy and 3 Gy proton and photon radiation.
Cells were transported and irradiated in standard T-25 cell culture flasks filled with 35 mL
cell media. Before irradiation of actual cell cultures, a “blank” T-25 flask filled with 35 mL
of water was provided to WKCC so that appropriate irradiation parameters could be
established. The blank flask underwent a workflow similar to that of a cancer patient,
including 1) computed tomography (CT) scans (CT Big Bore, Philips, Amsterdam) using
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straightforward, reproducible setup geometries tailored to proton and photon irradiations
and 2) development of several “treatment plans” within the WKCC treatment planning
system (Raystation™, Raysearch Laboratories, Stockholm) to achieve the desired dose
levels. All the treatment plans utilized a single anterior-posterior treatment field, i.e. the
radiation was directed downward toward the flask as it lay flat on the treatment couch. All
treatment plans were also generated in a manner that allowed for approximately 5 mm in
setup uncertainty during the actual irradiation scenarios. X-ray photon doses were
delivered with a 6X energy beam using a VersaHD™ clinical linear accelerator (Elekta,
Stockholm). Proton doses were delivered with energies ranging from 87 MeV to 111 MeV
using a ProteusONE™ clinical proton therapy gantry (Ion Beam Applications, Louvain-laNeuve).
2.3.2

Cell Viability Assays
Cell viability was quantitated by assessing the number of cells containing nuclear

changes indicative of apoptosis (chromatin condensation and nuclear fragmentation) after
staining with DAPI (ThermoFisher Scientific, cat.#62248). Human astrocytes were seeded
in 6-well plates at a density of 300,000 cells per well. After treatment with 3 Gy Proton
and photon radiation, DAPI was then added to each well at a final concentration of 1 μg
ml−1 . After a 10-min incubation in the dark at 20 ◦C, cells were washed with PBS and
examined by fluorescence microscopy (EVOS FL, ThermoFisher Scientific) using DAPI
EVOS™ Light Cube settings. Three biological replicates were included in each treatment
group and six high power fields from each well were averaged for each replicate.
The percentage of senescent cells in untreated and radiation-treated cells was
assessed using Cell Event™ Senescence Green Detection Kit (ThermoFisher Scientific,
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cat.# C10850) according to the vendor’s guidelines. The cells were seeded on a 6-well plate
at a density of 300,000 cells per well and incubated overnight. The wells were washed with
PBS and fixed with 1 mL per well of 2% paraformaldehyde solution for 10 min at room
temperature. The cells were washed, with 1 mL 1% BSA in PBS, followed by adding 1 mL
working solution (1:1000 dilution, 25 μM). The plate was incubated for 2 h at 37 ◦C without
CO2, protected from light. The fluorescein-based probe containing two galactoside
moieties serve as a target for β-galactosidase, a common biomarker for senescent cells. The
enzymatically cleaved product would be retained within the cell due to the covalent binding
of intracellular proteins and emit a fluorescent signal with absorption/emission maxima of
490/514 nm. After incubation, the cells were washed 3 times with PBS to remove the
working solution, and then subsequently stained with DAPI (1 μg mL−1) for 5 min at room
temperature to label the nucleated cells for accurate counting. The cells were washed
thoroughly with PBS to remove excess DAPI, and Fluorobrite DMEM media was added
before imaging. The percentage of senescent cells in each treatment group was determined
as a ratio of the DAPI-stained green-labeled (senescent) to DAPI-stained unlabeled cells.
Three biological replicates were analyzed and averaged for each treatment group. The
images were acquired using the EVOS FL imaging system equipped with GFP EVOS™
Light Cube.
2.3.3

Determination of Mitochondrial Mass
Mito Tracker™ Green FM (Thermo Fisher Scientific, cat. #M7514) which localizes

in the mitochondria regardless of membrane potential was used to monitor the
mitochondrial mass. Control and 3 Gy proton treated cells were incubated for 45 min with
200 nM MitoTracker™ Green FM in a CO2 incubator followed by fixation with 2%
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paraformaldehyde and 5 min incubation with 1 μg mL−1 of DAPI. The cells were imaged
in FluoroBrite DMEM Media using an EVOS FL imaging system using DAPI and GFP
EVOS™ Light Cubes. Using ImageJ (v1.52a, NIH), an outline was drawn around each cell
and circularity, area, mean fluorescence measured, along with several adjacent background
readings. The total corrected cellular fluorescence (TCCF) = integrated density – (area of
selected cell × mean fluorescence of background readings), was calculated.
2.3.4

Assessment of Oxidative Capacity of Mitochondria
The mitochondrial oxidative activity was assessed using the reduced

MitoTracker™ Orange CM-H2TMRos fluorescent probe (Thermo Fisher Scientific, cat. #
M7511). The probes were dissolved in dimethylsulfoxide (DMSO; Sigma Aldrich) to a 1
mM stock solution before use. Control and 3 Gy treated cells were seeded in a 6-well
culture plate and stained with 200 nM MitoTracker™ Orange CM-H2TMRos for 30 min
in a CO2 incubator followed by fixation with 2% paraformaldehyde and 5 min incubation
with 1 μg mL−1 of DAPI (ThermoFisher Scientific, cat. #62248). After staining, the dye
solution was replaced with 1 mL FluoroBrite DMEM Media (Thermo Fisher Scientific,
cat. # A1896701). Images were obtained using using an EVOS FL imaging system using
DAPI and RFP EVOS™ Light Cubes. To confirm that the accumulation of the dye in the
cells was associated with the accumulation of ROS, the cells were incubated with 50 μM
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; Sigma Aldrich). FCCP
enhances the potential for auto-oxidation, increases the production of ROS, and reduces
the mitochondrial membrane potential [262]. ImageJ analysis was conducted as already
described above.
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2.3.5

Gene Expression Analysis
RNA from radiation-treated and control cells was extracted using a Qiagen RNeasy

kit (Cat. #74104). The primers for one-step reverse transcription PCR were purchased from
Integrated DNA Technologies, Coralville, IA. Amplification of the OGG1 gene was
performed using primer sequences:5′ - ACT CCC ACT TCC AAG AGG T-3′ and 5′ -GAG
GAA CAG ATA AAA GAG AAA AGG C-3′ . The housekeeping gene glyceraldehyde 3phosphate dehydrogenase (GAPDH) was amplified using the following sequences for
forward and reverse primers: 5′ -ACA TCG CTC AGA CAC CAT G-3′ and 5′ -TGT AGT
TGA GGT CAA TGA AGG G-3′ . The one-step reverse-transcription PCR reaction was
performed using the Luna Universal RT-qPCR kit (New England Biolabs, cat. # E3005S).
Twenty nanograms of total RNA were reverse-transcribed for 10 min at 55 ◦C followed by
inactivation for 10 s at 95 ◦C. The amplification segment consisted of 40 cycles of 30 s at
60 ◦C and 10 s at 95 ◦C at a ramp heating rate of 0.2 ◦C/second. The relative quantification
of OGG1 was normalized to the gene expression levels of GAPDH using the 2−ΔΔCT
method.
2.3.6

Statistical Analysis
Data are expressed as mean ± SEM with n denoting the number of experiments.

Statistical significance between sham-control, proton, ad photon irradiated groups was
tested using one-way ANOVA with Tukey’s posthoc analysis, and p values less than 0.05
were considered as statistically significant.
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2.4
2.4.1

Results

Irradiation Induces Moderate Cellular Senescence and Apoptosis in Human
Astrocytes
The percentage of senescent cells was assessed in the sham-control and radiation-

treated groups before MitoTracker straining to assess the effect of radiation treatment on
the percentage of senescent cells in the population. It was estimated that the average
percentage (n = 3) of senescent cells was 6.5 %, 12.5 %, and 11.6 % in the control-, 3 Gy
photon-, and 3 Gy proton-treated cell lines. Due to their limited replicative cycles, normal
cells can become senescent and enter cell cycle arrest. But they remain metabolically active
without undergoing apoptosis or mitosis, adopting a unique phenotype that includes the
appearance of multinucleated cells, increased vacuolization, expression of pH-dependent
β-galactosidase, and morphological changes where cells become unusually enlarged and
extended [263].
Cell viability, as measured by the capacity of the cells to maintain membrane
integrity and exclude DAPI, was estimated in all treatment groups. The percentage of
apoptotic cells in the sham-control, 3 Gy photon, and 3 Gy proton irradiated cells was 12%,
37%, and 29% respectively. These data suggest that moderate doses of X-rays and proton
reduce cell viability in vitro in human astrocytes as the impact is more pronounced after
photon treatment.
2.4.2

Low-dose Irradiation is Associated with an Increase in Mitochonrial Mass
To assess mitochondrial function, the mitochondrial mass of the astrocytes was

assessed using MitoTracker™ Green FM staining. The total cell fluorescence of the 3 Gy
photon radiation-treated cells was more significantly increased when compared to the 3
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Gy proton and control groups (Figure 2-1). These results indicate that the oxidative stress
induced by the ionizing radiation leads to an increase of the mass of the mitochondria, most
likely related to the stimulation of biogenesis as a protective mechanism to maintain
cellular energy status.

Figure 2-1 Florescence intensity and distribution of MitoTracker Green FM dye in (A)
sham-control cells, (B) 3 Gy photon treated cells, and (C) 3 Gy proton treated. (D) The
total corrected cell fluorescence (TCCF) indicates that mitochondrial mass is significantly
increased in irradiated cells. Bar, 200 μm. Data represent means+/- SEM for each group
(n = 8), *p < 0.05, **p < 0.01, ANOVA statistical analysis, Tukey’s Honest Significant
Difference test [11]
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2.4.3

Mitochondrial Oxidative Activity Increases with Photon and Proton Radiation
The real-time changes in oxidative activity in the mitochondria of human astrocytes

were investigated using a MitoTracker™ Orange CM-H2TMRos, a reduced version of
MitoTracker™ Orange that fluoresces upon oxidation. The dye is oxidized by intracellular
ROS into fluorescent MitoTracker™ CMTMRos, which is sequestered in mitochondria by
thiol reactivity of its chloromethyl moiety. Measurements of MitoTracker™ Orange
fluorescence revealed a significant increase in the oxidative activity in the mitochondria of
the 3 Gy proton and photon-treated cells in comparison to the sham-control. FCCP, an
uncoupler of mitochondrial oxidative phosphorylation, causes a marked increase in
intracellular ROS and apoptosis [262]. Therefore, it was selected as a positive control to
confirm that the staining protocol reflects ROS levels in the mitochondria. Sham-control
cells were treated with 50 μM FCCP just before the staining. This caused an increase in the
fluorescence intensity due to the increase in the oxidative burden caused by FCCP (Figure
2-2).
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Figure 2-2 Fluorescent microscope images (20×objective lens) of human astrocytes
stained with MitoTracker™OrangeCM-H2TMRos. The nucleus of the cells was stained
with DAPI. (A) Sham-control cells. (B) 3 Gy photon treated cells. (C) 3 Gy proton
treated. (D) The total corrected cell fluorescence (TCCF) indicates that mitochondrial
oxidative activity is significantly increased in irradiated cells and the fluorescence is
increased after treatment with the positive control 50 μM FCCP. Bar, 200 μm. Data
represent means+/- SEM for each group (n = 8), **p < 0.01, ANOVA statistical analysis,
Tukey’s Honest Significant Difference test [11]
2.4.4

Proton and Photon Irradiation Downregulates OGG1 Gene Expression
To investigate whether high energy radiation affects the base-excision repair

capabilities of human astrocytes, mRNA expression levels of OGG1 were examined via
real-time RT-qPCR. As shown in Figure 2-3, a significant downregulation of OGG1 was
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observed after treatment with 3 Gy of proton and x-ray photon radiation. Lower proton
radiation dosage did not significantly decrease OGG1 expression; however, 0.5 Gy of
photon treatment caused a significant decrease in OGG1 expression. These results suggest
that both proton and photon radiation interfere with the base-excision repair capabilities of
healthy, human glial cells in a dose-dependent manner. The detrimental effects are more
pronounced after exposure to x-ray photons than with the proton beam.

Figure 2-3 Effect of proton and photon radiation treatment on OGG1 mRNA expression
in human astrocytes. Compared with the controls, the expression level of OGG1 was
downregulated after treatment with 0.5 Gy (A) and 3 Gy (B) photon and proton radiation.
Data represent means +/-SEM for each group (n = 5).*p < 0.05, **p < 0.01, ANOVA
statistical analysis, Tukey’s Honest Significant Difference test [11]
2.5

Discussion

The present study aimed to assess the changes in the mitochondrial mass, ROS
levels, and DNA base-excision repair capabilities of human astrocytes treated with proton
and photon radiation. Prior studies support proton radiation therapy as a more targeted,
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viable approach to cancer treatment [189]. Several studies associate proton treatment with
reduced tumor recurrence and neurocognitive late effects as a result of reduced damage to
surrounding tissues [190,191]. Radiation treatment was associated with an increased level
of mitochondrial ROS production and larger mitochondrial mass, parameters that are
indicative of elevated mitochondrial stress.
Reactive oxygen species produced in radiotherapy induces a variety of DNA
lesions, including oxidized base damage, single-strand breaks, and double-strand breaks in
normal cells. If these lesions remain unrepaired, it may result in cell death through mitotic
catastrophe and apoptosis. A high percentage of oxidative DNA damage induced by
radiation is repaired by the base-excision repair pathway [264]. The results from this study
indicate that both types of radiation caused impairment of the base-excision repair
capabilities of the glial cells (Figure 2-3), but the detrimental effects were less pronounced
after proton treatment. Inhibition of OGG1 post-irradiation can result in suppression of the
other genes (APEX 1, XRCC1) involved in this DNA repair pathway and lead to the
accumulation of unrepaired adducts. Multiple studies indicate that this leads to an increase
in DNA mutations in both nuclear and mitochondrial genomes that result in carcinogenesis
and mitochondrial impairment [265]. Genomic 8-OHdG accumulation increases after
treatment with UV radiation [266], X-rays [267], and γ-radiation [268]. Previous studies
have indicated that epigenetic mechanisms are involved in regulating the activity and the
expression levels of OGG1. Histone deacetylases class I (HDACI) interacts with and
deacetylates OGG1, enhancing its cleavage activity [269]. Impairment of oxidative DNA
repair mechanisms is regulated by miR-200 via suppression of OGG1 expression levels
[270].
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Oxidative stress is generally defined as an imbalance that favors the production of
ROS over antioxidant defenses. The results of this study indicated that ROS levels
significantly increased after photon irradiation. Treatment with the FCCP, an ionophore
and uncoupling agent, leads to increased production of cellular reactive oxygen and a
pronounced rise n fluorescence in both treated and control cells (Figure 2-2). Ionizing
radiation alters the atomic structure of the cellular macromolecules either through direct
interactions or via products of water radiolysis. To cope with the induced stress and the
changes in the redox environment, the cells respond at the molecular levels to counteract
the toxic effects of radiation. These include changes in mitochondrial membrane potential,
mitochondrial respiration, and mitochondrial ATP production, which indicate radiationinduced upregulation of the mitochondrial electron transport chain [271]. While the
majority of ROS are produced during normal mitochondrial respiration, the mitochondria
are the primary source of radiation-induced oxidative burden and the main target for its
damaging effects. This leads to changes in mitochondrial biogenesis, mtDNA mutation,
diminished ATP production, and impaired function [272].
The observed increase in the mass of mitochondria is probably a cellular response
mechanism to counteract oxidative stress and the loss of mitochondrial function, and to
recover ATP synthesis capacity. The data from this study indicate a statistically significant
increase in mitochondrial mass after treatment with 3 Gy dosage of both photon and proton
sources relative to the control (Figure 2-1). Other studies have demonstrated that
mitochondrial mass is increased in cells both directly treated with gamma radiation source
or exposed to the bystander effect [273]. Mitochondrial mass is increased under oxidative
stress suggesting that this cellular response results from an increase in ROS production.
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The change in mitochondrial size is dependent on both de novo synthesis of nuclear DNA
encoded proteins and their import into mitochondria that is dictated by the membrane
potential of mitochondria. The increase in the mitochondrial mass of cells under oxidative
stress is not dependent on the presence or function of mtDNA [274].
Our senescence-associated data, measured in response to both proton and photon
radiation treatments, is likely associated with impaired mitochondrial dysfunction and
oxidative stress. The photon treatment had a greater overall effect on mitochondrial
function than the proton irradiation. These results are not attributable to the defects of
mitochondrial biogenesis, because MitoTracker Green FM staining showed that the mass
of mitochondria increased, not decreased. An increase in mitochondrial mass does not
necessarily correlate with an increase in mtDNA content. Previous work indicates that
mitochondrial DNA replication is independent of and uncouples from mitochondrial
fission [275]. Because mitochondria contain proteins synthesized by both nuclear and
mitochondrial DNA, the nuclear proteins can still be produced even though the
mitochondrial DNA is defective. In response to mitochondrial dysfunction, there may be a
disproportional synthesis of nuclear-encoded proteins that may contribute to the increase
in mitochondrial mass, even when the mitochondria may lack mitochondrial DNA due to
replication impairment [186,276]. Therefore, the number of mitochondrial genomes per
mitochondria must be even lower when compared to the sham-control cells.

CHAPTER 3
IDENTIFICATION OF MIRNA-MRNA REGULATORY NETWORK
ASSOCIATED WITH OXIDATIVE DNA DAMAGE
IN HUMAN ASTROCYTES

3.1

Knowledge Gap

While the role of miRNAs in carcinogenesis and neurological disorders is a
relatively new area of research, due to its therapeutic potential, the field is rapidly growing
and numerous miRNAs that modulate disease-related physiological processes have been
identified [65,66]. Thus, understanding the epigenetic regulation of astrocyte DNA repair
mechanisms could lead to the identification of novel targets for the treatment of
neurological and neurodegenerative diseases. Although much progress has been made in
elucidating the function of various miRNAs, there is a paucity of scientific data regarding
the specific miRNAs that regulate the proteins involved in the base excision repair
pathway.
3.2

Hypotheses and Specific Objectives

DNA damage regulates the biogenesis of miRNA expression at the transcriptional
level via the p53 pathway [101]. With the cross-talk between ROS and miRNA-processing
enzymes [15], there is a very high possibility that closely related miRNAs and their target
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genes would be involved in mediating the oxidative stress-induced cellular response.
Therefore, it is hypothesized that ROS-induced DNA damage will alter the epigenomic
(miRNA expression) patterns of affected cells and modulate functionally related DDRassociated genes. This study, therefore, aims to perform high throughput small RNA
sequencing and functional analysis to identify novel ROS-induced differentially expressed
miRNAs that modulate the expression of genes that are associated with the DNA repair
mechanism in human astrocytes.
It is also hypothesized that increased accumulation of nuclear 8-OHdG adducts in
the astrocytes will correspond with sodium dichromate treatment. This scientific
hypothesis will be tested by quantifying genomic 8-OHdG accumulation as a function of
ROS-induced DNA damage.
3.3
3.3.1

Materials and Methods

Cell Culture
Human primary astrocytes (Sciencell, Carlsbad, CA) were cultured in T-25 flasks

containing 5 mL of Astrocyte Medium (Sciencell, #1801), supplemented with 1%
penicillin/streptomycin solution (Sciencell, #0503), 2% Fetal Bovine Serum (Sciencell),
and 1% astrocyte growth supplement (Sciencell #1852). The cells were grown at 37°C,
95% humidity, and 5.0% CO2/air until they reached 80% confluence. Uniform seeding
density of 2.1×106 cells per flask was maintained during subculture using Countess II FL
Automated Cell Counter (ThermoFisher Scientific, Waltham, MA).
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3.3.2

Sodium Dichromate Treatments
Depending on the specific experiments, cells were treated with various

concentrations of sodium dichromate (10 µM, 10 mM, and 100 mM), and incubated for 16
h before being harvested for analysis. Non-treated cells were maintained in parallel and
used as control.
3.3.3

Cytomorphological Evaluation
Before cell harvest, images of control (non-treated) and 10 µM Na2Cr2O7- treated

cells were captured using an inverted phase-contrast light microscope, to evaluate the
changes in cell morphology following the treatment.
3.3.4

Comet Assay
Human astrocytes were grown in T-25 flasks to 80% confluency and treated with

10 µM sodium dichromate for 16 h. Trypsin was added to both the control (non-treated)
and treated cells for 5 min at 37°C to detach the cells. 15,000 cells were then collected and
centrifuged for 5 minutes at 4°C. The cell pellets were suspended in 200 µL of 6% lowmelting-point agarose (pre-warmed to 37°C). The agarose cell suspension (60 µL) was
pipetted onto an agarose-coated coverslip and placed over a slide. The coverslip was
removed after 10 min and the samples were placed in lysis buffer (100 mM EDTA, 2.5 M
NaCl, 10 mM Tris-HCl, 1% Triton-X, pH 10) at 4°C overnight. The slides were placed in
chilled ddH2O for 5 min, rinsed one more time with chilled ddH2O for 10 min, and washed
with enzyme reaction buffer (40 mM HEPES, 0.1 M KCL, 0.6 mM EDTA, 0.2 mg mL-1
BSA, pH 8). Formamidopyrimidine [fapy]-DNA glycosylase (FPG, New England Biolabs)
was diluted in the enzyme reaction buffer to a final concentration of 8 U mL-1. Both treated
and control samples were incubated with either enzyme reaction buffer or FPG for 30 min
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at 37°C. The slides were placed in the electrophoresis buffer for 20 min to allow
equilibration and gel electrophoresis was performed for 20 min at 30 V and 300 mA. The
slides were placed in a neutralization buffer (0.4M Tris-HCL, pH 7.5) for 20 min, rinsed
with ddH2O for 10 min, and allowed to dry overnight at 37°C. The samples were rehydrated
in water the next day and stained with 2.5mg mL-1 propidium iodide (ThermoFisher
Scientific, cat. #P1304MP). After 20 min of incubation with the dye, the slides were rinsed
with ddH2O for 10 min and dried overnight at 37°C. Comets were visualized using a Nikon
Eclipse Ti microscope at 150X magnification. The OpenComet plugin for Image J was
used to quantify the tail moment from the tail length and staining intensity of the head and
tail [277,278]. At least 70 cells were analyzed for each condition.
3.3.5

High-Throughput Small RNA Sequencing and Analysis

3.3.5.1

Library Preparation and Ion TorrentTM Sequencing
The human astrocytes (Non-treated, 10 µM, and 10 mM Sodium Dichromate-

treated) were lysed and the small RNA fractions were enriched using mirPremier®
MicroRNA Isolation Kit (Sigma-Aldrich, Cat. # SNC10). Six samples were processed for
Small RNA sequencing analysis that includes 3 biological replicates in the treatment and
control. The concentration of small RNA fraction was determined using a Qubit RNA HS
Assay Kit (ThermoFisher Scientific, Cat. # Q32852) using Qubit 4 Fluorometer
(ThermoFisher Scientific, cat. #Q33238). Next-generation sequencing (NGS) small RNA
libraries were size-selected to enrich for constructs containing mature miRNAs. The
sequencing was performed on Ion Torrent™ next-generation sequencing systems
(ThermoFisher Scientific, Waltham, MA).
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3.3.5.2

MicroRNA-Seq and QA/QC Analyses
Computational analysis of FASTQ data files that include the raw data was

performed using the microRNA-Seq algorithms of the Partek® Flow® software, v10.0
(Partek Inc., 2020), an intuitive visual interface that allows the queuing and execution of a
string of pipeline commands. Quality control parameters were checked to obtain the
average base quality score per reading (Phred quality score), distribution of the raw read
lengths to assess enrichment in microRNAs; base trimming and coverage breakdown were
also carried out to confirm that the reads mapped reasonably within a microRNA.
3.3.5.3

Differential miRNA Analysis and Visualization
The reads were aligned using the Bowtie algorithm that allows for 1 mismatch and

processed via Partek’s default MicroRNA-Seq pipeline that mapped the reads to a
reference genome (Homo sapiens, hg38) indexed to miRBase Mature MicroRNA (version
21). The differential gene expression analysis was performed using Partek’s Gene Specific
Analysis (GSA) algorithm, which applies multiple statistical models to each gene to
account for each gene’s varying response to different experimental factors (in this case,
sodium dichromate treatment), and differing data distributions. The miRNA gene list
obtained was further filtered such that only miRNAs that meet the set threshold (≥ 2-fold,
FDR< 0.01, p-value < 0.05) were selected.
Hierarchical clustering and visualization plots were generated on the platform to
aid visualization and interpretation of the data: a principal component analysis (PCA) plot
was generated to identify outliers between the Non-treated and 10 µM Sodium Dichromatetreated groups; a Volcano plot was plotted to show the distribution of upregulated and
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downregulated miRNA genes; while a heatmap diagram was generated to visualize sample
clustering among the differentially expressed miRNAs.
3.3.5.4

miRNA Functional Enrichment Analysis
The biological processes and genes targeted by the differentially expressed

miRNAs were identified using miRNet 2.0 [280].
3.4
3.4.1

Results

Sodium Dichromate Induces Oxidative DNA Damage in Astrocytes
Sodium dichromate treatment was associated with reduced growth and distinct

morphological changes in human astrocytes (Figure 3-1). Phase-contrast microscope
images obtained after 16 hours of 10 µM sodium dichromate treatment (Figure 3-1B)
shows cytomorphological changes, cytoplasmic granulation, and reduced proliferative
density, indicative of stressor effects – unlike the normal spindle-like astrocytes which
displayed a typical cellular structure (Figure 3-1A).

Figure 3-1 Bright-field image of human astrocytes, 10x magnification (A) control, and
(B) treated with 10µM sodium dichromate
A formamidopyrimidine-DNA glycosylase (FPG) modified comet assay was
performed to assess the sodium dichromate-induced oxidative DNA damage. The comet
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assay detects DNA strand breaks by measuring the migration of DNA from individual
nuclei in an alkaline environment, and can also detect oxidative DNA damage when the
nuclei are treated with a DNA glycosylase enzyme (Amanda J. Lee et al., 2004). The
average tail moment was used as a measurement of the magnitude of strand breakage (FPG) or oxidative DNA damage (+FPG). The sodium dichromate-treated cells displayed
longer tail lengths and tail moments in comparison to the control samples (Figure 3-2).
Elongated tails and larger tail moments are consistent with the fragmentation of nuclei due
to strand breakage or recognition and removal of damaged bases by FPG that recognizes
7, 8-dihydro-8-oxoguanine (8-oxoguanine), 8-oxoadenine, fapy-guanine, methy-fapyguanine, fapy-adenine, 5-hydroxy-cytosine, and 5-hydroxy-uracil [281].
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Figure 3-2 Sodium dichromate increases oxidative DNA base damage. The alkaline
comet assay with FPG treatment was used to detect oxidative base damage following 10
μM Na2Cr2O7 treatment for 16 h (A) and the tail moment was measured using
OpenComet (B). Analysis was performed on one experiment with at least 70 cells in
each experimental group. Error bars represent SD and **** represents P < 0.0001 using a
Student's t-test
3.4.2

Pre-Alignment QA/QC Charts

In all 6 samples (3 replicates each of 10 µM-treated and Non-treated), the average
Phred quality score ranged from 28% to 31% (Figure 3-3). Fragments with a Phred score
of 20% signifies that the specific base call is 99% accurate, while 30% means it is 99.9%
accurate, so the raw data is well within acceptable limits. The distribution of the raw read
lengths showed that they are relatively short, with greater enrichment for microRNAs
(Figure 3-4). Using a quality score cut-off of 28 and a minimum read length set at 15, the
quality of the reads was improved by base trimming from both ends (Figure 3-5). To assess
the improved read quality, a coverage breakdown for each sample confirmed that a good
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portion of the reads mapped fully or partly within a microRNA (20% on the average), while
a sizeable portion did not map within a microRNA (Figure 3-6). This is not unexpected,
especially for the human genome that includes large segments of intronic regions
interspersing the gene-coding sequences [282].

Figure 3-3 Pre-alignment QA/QC showing average base quality score per reading.
The Phred quality scores of the analyzed samples ranged from 28% to 31%
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Figure 3-4 Size distribution of raw counts of transcripts

Figure 3-5 Percentage representation of trimmed bases (quality score cut-off = 28;
minimum read length = 15
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Figure 3-6 Coverage breakdown of raw reads post-trimming
3.4.3

Small RNA Sequencing Identifies a Large Number of Differentially
Downregulated MicroRNAs
The differential gene expression analysis identified a list of significantly

differentially expressed miRNAs (≥ 2-fold, FDR< 0.01, p-value < 0.05) following 10 µM
sodium dichromate treatment: 231 miRNAs were found to be downregulated, while only 2
were upregulated (Appendix C.1).
The MicroRNA-Seq data analysis for the 10 mM sodium dichromate-treated cells
vis-à-vis non-treated cells yielded 56 downregulated miRNAs (which include miR-7, miR17, miR-103a, miR-155, miR-182, miR-let-7d, miR-let-7e, etc.) and 6 upregulated
miRNAs (miR-25, miR-30c, miR-153, miR-204, and miR-365a) (Appendix C.2).
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3.4.4

Hierarchical Clustering Plots
A principal component analysis (PCA) plot was generated to identify outliers

among the two treatment groups (Figure 3-7), while a Volcano plot delineated the
distribution of upregulated and downregulated miRNA genes (Figure 3-8). Hierarchical
sample clustering via heatmap diagram was generated to visualize the sample clustering
of the differentially expressed miRNAs (Figure 3-9). Essentially, PCA compresses the
expression data from thousands of genes to represent the overall variation in expression
as a single dot on a graph – one dot per sample being analyzed. Each dot represents the
number of reads multiplied by the influence of each corresponding gene on the overall
variation in expression, in terms of the two most important dimensions of variation (the
two axes), called principal components. Genes with the largest variation between samples
will have the most influence on the principal components. That is, genes that are much
more highly expressed in one group than in another group will have a high degree of
influence on the principal components. Samples with similar noncoding RNA expressions
that correlate with the treatment conditions cluster together in a PCA plot and heat map,
as shown in Figures 3-7 and 3-8.
Other PCA plots for specific miRNAs known to be involved in oxidative DNA
damage, miR-21 [283] and miR-335 [284], also showed delineated clustering
(Appendices C.6 and C.7).
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Figure 3-7 Principal Component Analysis (PCA) plot showing clustering of the treated
and control samples. The two most informative components were plotted by the Partek®
Flow® software

Figure 3-8 Volcano plot depicting the distribution of upregulated and downregulated
miRNA genes in treated samples relative to controls
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Figure 3-9 Unsupervised hierarchical clustering using the differentially expressed
miRNAs between treated and control samples represented as a heat map. The heat map
colors correspond to microRNA expression as indicated in the color key: Red (upregulated) and Green (down-regulated)
3.4.5

Gene Ontology Analysis Identifies Biologically Significant miRNAs
The annotation feedback came from three combined databases (miRTarBase v8.0,

TarBase v8.0, and miRecords) hosted on miRNet 2.0, and used the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database option, with an “all genes” hypergeometric test
setting.
3.4.5.1

miRNA-Gene/Pathway Analyses
The search results returned 49 miRNAs and 13,585 target genes involved in

molecular pathways associated with signaling, cell cycle control, and DNA damage and
repair, etc. (Appendices C.1 and C.3). The most statistically significant pathways include
cancerogenesis and cell cycle control (Table 3-1).
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Table 3-1 Top pathways enriched in putative miRNA-targeted genes
Biological Process/Pathway
Pathways in cancer
Cell cycle
Neurotrophin signaling pathway
Wnt signaling pathway
ErbB signaling pathway
RNA transport
Glioma
Axon guidance
p53 signaling pathway
Jak-STAT signaling pathway
MAPK signaling pathway
mTOR signaling pathway
Pyrimidine metabolism
RNA degradation
Ribosome biogenesis in eukaryotes
Purine metabolism
Apoptosis
Alzheimer's disease
Prion diseases
mRNA surveillance pathway
Huntington's disease
VEGF signaling pathway

Adj. p-Value
2.11E-16
2.79E-11
3.24E-07
3.19E-06
8.73E-06
1.15E-05
1.29E-05
1.71E-05
3.11E-05
0.000241
0.000362
0.001303
0.001896
0.001896
0.004891
0.004891
0.006644
0.015065
0.016875
0.027838
0.03759
0.05427

Genes
285
120
114
129
81
113
62
106
64
88
218
42
87
54
49
134
71
43
20
68
25
62

Among the differentially expressed microRNAs (Appendix C.1), 10 downregulated
miRNAs were identified to target DNA repair proteins, according to miRNet 2.0’s curated
database of proven interactions. These include miR-15a-5p, miR-16-5p, miR-17-5p, miR93-5p, miR-125a-5p, miR-125b-5p, miR-128-3p, miR-155-5p, miR-335-5p, let-7b-5p
(Figure 3-10, Table 3-2). The annotations for two upregulated miRNAs, miR-1248 and
miR-4284, were discovered on miRDB [285].
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Figure 3-10 A coherent group of miRNAs target DNA repair proteins.
Network constructed on miRNet 2.0
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Table 3-2 List of differentially expressed BER-associated MicroRNAs (p < 0.05)
Post-Treatment miRNA ID
Regulation
Downregulated
hsa-miR-16-5p
hsa-miR-128-3p
hsa-miR-17-5p
hsa-miR-93-5p
hsa-miR-125b-5p
hsa-miR-125a-5p
hsa-miR-15a-5p
hsa-miR-155-5p
hsa-miR-335-5p
hsa-let-7b-5p
Upregulated
hsa-miR-4284 3
hsa-miR-1248 3
3.4.5.2

Fold
Change
10.1
8.05
7.97
5.89
5.78
4.29
4.28
3.19
2.81
2.48
6.33
2.82

Experimentally validated DNA
repair gene targets
UNG/UDG, MBD4, NTHL1
APEX1
APEX1
NTHL1, MPG
UNG/UDG, TDG
TDG
MBD4
MUT
PARP1
MPG, FEN1
No Hit
OGG1 3

miRNA-Disease Associations
Further analysis of the miRNA-disease associations identified 21 mRNAs that were

experimentally validated to be linked to 143 pathologies (Appendix C.4). miR-107, with a
betweenness value of 9972.589 and 102 degrees, was linked to more brain-linked
pathologies than all of the other miRNAs (Figure 3-11), followed by miR-9-5p, miR-1283p, miR-125b-5p, miR-181b-5p, and miR-139-5p.

3

No hits were found on the miRNet-hosted databases as the miRNAs have not been
annotated. Both miRNAs had several hits on miRDB. Only miR-1248 had a BER target
protein, OGG1.
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Figure 3-11 CNS-associated pathologies mediated by hsa-miR-107. The network was
constructed on MiRNet 2.0
3.4.5.3

Protein-Protein Interaction (PPIs)
Empirically proven protein-protein interactions (PPIs) were also investigated on

miRNet-hosted STRING Interactome, v11 [286], set at a confidence score cutoff of 500.
A list of 18,553 proteins interacting with one another was generated (Appendix C.5).
3.5

Discussion

The brain is intrinsically vulnerable to ROS-induced oxidative stress. Cell
shrinkage, cytoplasmic granulation, nuclear fragmentations, and cell lysis are the major
visible hallmarks of apoptosis [287]. This study indicated that that sodium dichromateinduced oxidative DNA damage resulted in varying degrees of cell shrinkage and changes
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in cell morphology in the human astrocytes. Incorporation of mismatched base pairs occurs
frequently during DNA replication while a cascade of self-destructing cellular events is
initiated to prevent the replication and transfer of damaged DNA to daughter cells.
Therefore, oxidative stress-induced ROS activates the proapoptotic cellular machinery
[288]. Previous work confirmed the relationship between the TNF-related apoptosisinducing ligand (TRAIL) expression in human astroglial cells and immune cell effector
functions [289]. Other members of the death ligand/receptor pairs like the Fas/Faslg pair
are also recruited following oxidative stress, and this is supported by our PPI data
(Appendix C.5). The apoptotic mechanisms are synergistic and act either through
sensitivity priming [290] or through bystander cytotoxicity [291].
Our findings indicate that there is a trend towards a decrease in miRNA expression
in treated cells, suggesting an underlying upregulation in the transcription of multiple
genes. Logically, at the center of this phenomenon could be the involvement of ROS in the
pathways of microRNA biogenesis, especially at the transcription level via p53’s
regulatory effect on the Drosha enzyme, as have been variously reported [15,101]. Since
the p53 signaling pathway is among the top pathways highlighted by our Gene Ontology
analysis (Table 3-1), p53 could be responsible for the global downregulation of miRNAs
through a negative feedback loop mechanism. In a previous study, exogenous H2O2
exposure has been shown to cause a significant decrease of Dicer expression resulting in
the downregulation of 89% of microRNAs that are normally expressed in
cerebromicrovascular endothelial cells [292].
Functional enrichment analysis identified physiological and pathological processes
that are regulated by differentially expressed miRNAs. The biological processes that are
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highly regulated by the miRNA network include genes regulating cell cycle control, protein
processing in the endoplasmic reticulum, axon guidance, and neurotrophin signaling which
promotes survival, growth, and differentiation of neurons and neurites (Table 3-1). In
addition to supporting neuronal growth, neurotrophins play an important role in the
pathophysiology of many neurodegenerative and psychiatric disorders [293]. This
indicates that genes involved in the cell cycle and CNS response may be regulated by
stress-induced miRNAs. Pathways in cancer accounted for the highest hits (285 genes),
supporting the correlation between oxidative stress and cancer that has been established by
multiple groups [14].
Non-coding RNA-mediated expression of the genes associated with apoptosis that
include the Caspase protein family, TP53, BAX, BCL2, FADD, ATM, FAS, FASLG,
corresponded with the decrease in cell density and cytoskeleton architectural changes in
treated cells (Figure 3-1). Genes involved in RNA metabolism and transport were also
deregulated. These included UPF1, the gene that codes for RNA helicase and translocase
enzyme that is essential for nonsense-mediated decay, mediating both mRNA nuclear
export and mRNA surveillance through ribonucleoprotein (RNP) remodeling [294]. Posttranscriptional regulation of gene expression in response to cellular stress occurs on RNP
granules [295]. This could be used for the development of stress-adaptive miRNA-based
therapeutics by recreating the concentration- and phase-dependent assembly of these
membranous compartments in cells of interest.
This study identified numerous, and often, overlapping targets for the dysregulated
miRNAs (Table 3-1). It is a well-established fact that miRNAs are pleiotropic and
redundant regulators, and therefore one miRNA can target multiple genes, as well as
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multiple miRNAs can target a single gene [56]. MicroRNAs that target genes within the
DNA damage repair (DDR) loop were mostly downregulated, indicating an activation of
the DDR transcriptome. Functional enrichment analysis showed that the majority of the
targeted genes are associated with signaling, cell cycle control, and maintenance of DNA
integrity. This supports our hypothesis that oxidative stress alters the miRNA expression
signature to reflect bloc activation of coherent, functionally related pathways. Members of
the DDR loop, a kinase-based functional network that initiates phosphorylation-driven
cascades [91], were over-represented in the analyzed data sets. Key players within the DDR
loop that were captured in our data set include PI3K, ATM, ATR, which are essential in
maintaining genome stability and reducing pathological processes [92,296,297]. This
presents a veritable lead for the investigation and development of molecular mechanistic
models for DDR loop activation. DNA-damage response RNAs (DDRNAs) have been
proposed as a requirement to fully activate the DDR response [298,299]. These DDRNAs,
like miRNAs, are generated by Drosha and Dicer processing, and they have the same
sequence as their cognate damaged DNA. Thus, this sequence specificity may help them
to act as guides for the localization and activation of DDR proteins.
Because of its therapeutic target potential, microRNAs are actively being explored
for the management and treatment of major neurodegenerative disorders. Specifically,
miR-155 upregulation has been implicated in amyotrophic lateral sclerosis (ALS), and its
inhibition slowed down disease progression in pre-clinical models [300]. Downregulated,
as per our results, tinkering with safe serum or CSF-infused chromium levels may be a
viable supplemental strategy to inhibit miR-155 in the therapeutic regimen for ALS
patients and may be potentially applied to other neurological disorders where miR-155 is
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increased, including multiple sclerosis [301] and glioblastoma [302]. One way to achieve
this may be via the manipulation of chromium bioavailability, as have been done in a
sorption study that demonstrated the reduced bioavailability of chromium by binding to
iron particles in an acidic medium [303]. However, variability in individual responses to
sodium dichromate has been observed [304], which may need to be factored into such
clinical approaches.
Most drinking water supplies in the United States contain < 5 µg/L of chromium
since hexavalent chromium is a common disinfection by-product, raising safety concerns.
Cr(III) is oxidized to Cr(VI) by added oxidants (such as potassium permanganate) and
disinfectants (chlorine, chloramine) used in water treatment plants [305,306]. Chromium
(III) ion is classified as an essential nutrient that is normally present in blood and urine in
trace amounts and required for normal energy metabolism. Moreover, the Institute of
Medicine of the National Academy of Sciences recommended an adequate intake of
chromium(III) of 20 – 45 µg/day for adolescents and adults [307]. Therefore, the findings
from this study can be used by environmental and health agencies to make informed safety
and dietary recommendations.

CHAPTER 4
MICRORNAS AND DNA REPAIR GENES: TARGET
PREDICTION AND VALIDATION

4.1

Overview and Hypotheses

The results from the next-generation small RNA sequencing experiments indicate
that sodium dichromate-induced oxidative stress is associated with differential expression
of multiple miRNAs.
Base excision repair (BER) is one of the mechanisms that protects the brain cells
from oxidative stress by preventing both nuclear and mitochondrial mutations. The human
8-deoxyguanosine DNA glycosylase 1 (hOGG1) is an 8-OHdG-specific BER enzyme that
plays an integral part in reducing the rate of mutations. By being in the frontlines of
mitigating the effects of reactive oxygen species, OGG1 contributes to decreasing the
detrimental effects of oxidative DNA damage [2]. Therefore, identifying a subset of
potential miRNAs that control the post-transcriptional expression of OGG1 will provide
an assessment of the epigenetic regulation of the OGG1-mediated DNA repair mechanism
in response to ROS-induced oxidative damage.
A common feature of most validated targets is that their cognate miRNAs
preferentially bind to the 3′ untranslated regions (3’-UTR) sites that do not have complex
secondary structures and are located in the accessible regions of the RNA based on
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favorable thermodynamics [122]. Based on the small RNA sequencing and Comet assay
data, we hypothesize that some of the miRNA species that exhibited differential expression
following oxidative stress will bind within the 3’UTR region of the OGG1 transcript.
The expression levels of the miRNA candidates and their target mRNAs will be
initially verified using RT-qPCR. Since miRNA expression level is inversely related to the
expression level of its target mRNAs, it is expected to see a reciprocal mRNA and protein
expression pattern from the ensuing RT-qPCR and Western analyses. The interaction
between the putative miRNA/mRNA pairs will be further validated via miRNA
transfection (mimic or inhibitor) and/or immunoprecipitation assays (MirTrap System)
coupled with reverse transcription qPCR (RT-qPCR) technique [308]. The MirTrap
technology facilitates the discovery and detection of low abundance mRNA targets that
can be lost during traditional, less sensitive immunoprecipitation methods. We hypothesize
that if the transfected miRNA binds to the 3’UTR region of mRNA transcripts of interest,
the mRNA target will co-immunoprecipitate with the RISC complex.
4.2
4.2.1

Research Methodology

In Silico Prediction of OGG1-targeting MicroRNA Candidates
Multiple bioinformatics databases – mirWalk 2.0 [309], MiRDB [310], and

TargetScan [311] – were utilized to predict the probability of functional miRNA binding
sites within the 3’UTR of all eight splice variants of OGG1 mRNA (OGG1-1a, −1b, −1c,
−2a, −2b, −2c, −2d and −2e) that are registered in the NCBI gene and nucleotide database.
OGG1-1a is the only OGG1 present in the nucleus, the other seven isoforms excise 8OHdG from the mitochondrial genome [312]. The selection criterion was based on a
miRNA candidate getting a hit in at least two of the prediction algorithm tools which factor
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in seed-site pairing, site context, free-energy, and target conservation across multiple
vertebrates [313,314]. The computational analysis was focused on miRNA targets
conserved across mammals as these are more likely to be of functional significance [315].
4.2.2

Validation of miRNA-mRNA Interactions
Selected miRNA-mRNA target pairs were further analyzed to validate the predicted

regulatory network. Given the negative regulatory effect of miRNAs on their mRNA
targets, emphasis was placed on upregulated miRNAs and their impact on the expression
levels of OGG1, a canonical BER enzyme that is directly involved in base excision repair.
In addition to RT-qPCR, the pairwise binding between the selected miRNAs and the
3’UTR region of the OGG1 mRNA was confirmed via a combination of miRNA mimic or
inhibitor transfection and/or immunoprecipitation of tagged RNA-induced silencing
complex (RISC) that include miRNA/mRNA OGG1 pair.
Poly-(ADP-Ribose) polymerase 1 (PARP-1), an auxiliary DNA damage repair
protein [316] and miR-335, one of its cognate miRNAs identified earlier (Figure 3-10;
Table 3-2), were also analyzed via reverse-transcription qPCR (RT-qPCR). Interestingly,
OGG1 binding to PARP-1 stimulates its poly(ADP-ribosyl)ation activity which is essential
in the repair of oxidative DNA damage [317].
4.2.2.1

Reverse Transcription Quantitative PCR (RT-qPCR)
RT-qPCR was performed to validate the changes in the expression levels of the

selected, biologically relevant miRNAs and their mRNA targets before and after 10 µM
sodium dichromate treatment. The MicroRNAs, hsa-miR-335-5p (Sigma Aldrich, cat.
#MIRAP00323) and hsa-miR-1248 (Sigma Aldrich, cat. # MIRAP00761), were validated
using the MystiCq® MicroRNA Quantitation System (Sigma-Aldrich, St. Louis, MO).
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Briefly, cDNA was synthesized from treated and control small RNA samples using
MystiCq™ microRNA cDNA Synthesis Mix Kit according to the manufacturer’s
instructions. The cDNA concentration was measured using a Qubit 4 Fluorometer (Thermo
Fisher Scientific, cat. #Q32854). Equal amounts of each cDNA (2ng), mixed with 10 µM
of each MystiCq microRNA qPCR Assay Primer and 10 µM of MystiCq Universal PCR
Primer plus MystiCq microRNA SYBR Green qPCR Ready-mix, were amplified as
recommended by the manufacturer on a LightScanner 32 real-time PCR instrument.
Relative quantification of miRNA expression was determined by using the Livak-Schmidt
(2-ΔΔCT) method and normalized against SNORD 44 provided with the MicroRNA
Quantitation System [318,319]. The results are represented as mean ± standard error
calculated from three biological replicates.
The mRNA targets OGG1 and PARP1 were reverse-transcribed separately using
the TaqMan™ RNA-to-CT™ 1-Step Kit (ThermoFisher Scientific, cat. # 4392653) and
LUNA One-step RT-qPCR kit (New England BioLabs Inc., cat. #E3005S) respectively, on
a QuantStudioTM 3 Real-time PCR system (Applied Biosystems, Cat. # A28567). Total
RNA was harvested individually from treated and control cells with an RNA Miniprep Kit
(Zymo Research, cat. #R1054), while the quantity and quality of the extracted RNA were
determined by the Nanodrop 2000 system (Thermo Fisher Scientific, Waltham, MA).
Equal amounts of RNA (6 ng) were mixed with 10 µM forward and reverse primers (PARP
1 and GAPDH) to 0.5 µM final concentration, and reverse-transcribed for 10 min at 55°C,
followed by inactivation of reverse transcriptase and cDNA denaturation at 95°C for 1 min.
The subsequent amplification followed the vendor-recommended 40-cycle program of 10
seconds at 95°C, 30 s at 60°C, and 10 s at 95°C per cycle at a ramp heating/cooling rate of

87
20°C sec-1. The GAPDH and PARP1 gene primer sequences (Integrated DNA
Technologies, Coralville, ID) are shown in Appendix D.1. OGG1 mRNA expression level
was analyzed using OGG1 and GAPDH TaqMan™ Gene Expression Assay (FAM)
(ThermoFisher Scientific cat. # 4453320, 4448892), with an initial reverse transcription of
6 ng RNA at 480C for 15 min, followed by AmpliTaq Gold® DNA polymerase activation
at 950C for 10 min, and a final 40-cyle amplification of 950C for 15 s and 600C for 1 min.
Data were normalized to the CT values of the internal control gene GAPDH, and analyzed
using the 2-∆∆CT method [320].
To further probe sensitivity to exposure, changes in OGG1 mRNA expression at
higher concentrations of sodium dichromate (10 mM and 100 mM) were assessed via RTqPCR, using the same parameters as above.
4.2.2.2

Capillary Western Analyses
Automated Western blotting was performed for quantification of the relative

amount of OGG1 to the housekeeping protein, GAPDH using the ProteinSimple Wes®
System. Human astrocytes were grown till they reached 80% confluence and treated with
10 µM Na2Cr2O7 for 16 h. Both control and treated cells were trypsinized, washed with
PBS, and lysed with M-PER™ Mammalian Protein Extraction Reagent (ThermoFisher,
cat. #78501) and protease inhibitor to extract total protein. The protein concentration was
determined using Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, cat. # 23227)
and 1µg of protein was loaded per lane. The capillary western blot analysis was performed
according to the vendor's instructions. The protein lysates were mixed with a 5 × Master
Mix. The samples and the protein ladder (12 kDa, 40 kDa, 66 kDa, 116 kDa, 180 kDa, and
230 kDa) that provided the molecular markers for the assay were added to the wells in the
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plate. Both the control and treated samples were probed with anti-GAPDH and anti-OGG1
polyclonal antibody (ABclonal Science Inc., cat. #A1384) diluted 1:50 with antibody
diluent. HRP-conjugated anti-rabbit secondary antibodies and chemiluminescent substrate
were used for the detection step. The separation electrophoresis and the detection step were
performed with the Wes Protein Simple capillary system. The areas under the peak
correlate with the intensity of the bands and were calculated by the Compass Software
(ProteinSimple). The ratio between the area under the peak of OGG1 and GAPDH was
used as an assessment of the relative signal intensity of the immuno-detected protein.
4.2.2.3

Exogenous miR-103a Expression: Co-immunoprecipitation with OGG1
mRNA
The pairwise binding between miR-103a (identified as differentially downregulated

in 10 mM sodium dichromate-treated samples) and OGG1 mRNA target (verified by RTqPCR to be upregulated in 10 mM sodium dichromate-treated samples), was validated via
immunoprecipitation of RISC using the cutting-edge miRNA discovery technology
developed by Clontech (Mountain View, CA) – the MirTrap System (Cat. # 632017).
4.2.2.3.1

MirTrap System: Working Principle

The MirTrap System entails transfection of double-stranded miRNA mimics,
followed by immunoprecipitation of tagged RNA-induced silencing complex (RISC) that
includes miRNA/mRNA OGG1 pair. The guide strand of the mimic is designed to have
the same sequence as the endogenous miRNA, while the passenger stand has a
complementary sequence. Both oligonucleotides contain 3’ overhangs and are
phosphorylated at 5’ends. Since transfected miRNA “mimics” the endogenous miRNA of
interest and recognizes the mRNA target, the RISC becomes flooded with microRNA
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mimic/target RNA complexes which outcompete the endogenous microRNA/target RNA.
The MirTrap Vector introduces the expression of a dominant-negative subunit of RISC
protein that traps the miRNA/mRNA pair into the RISC and limits further processing. The
protein subunit is integrated into the endogenous Argonaut (Ago)/RISC complex and
tagged with a FLAG-epitope that has a DYKDDDDK sequence motif, thereby allowing
the immunocapture and isolation of the entire Ago/RISC/miRNA/mRNA complex, and
thus, selective purification of the target mRNA that undergoes direct regulation by the
transfected miRNA of interest. The presence or absence of the precipitated target mRNA
sequence is subsequently validated via sequencing or reverse-transcription qPCR (RTqPCR) analysis.
4.2.2.3.2

MirTrap System Protocol

According to the vendor’s protocol (Figure 4-1), the miR-103a mimic
(DharmaconTM miRIDIAN Mimic, Cat. # C-300522-03-0002 ) was co-transfected with the
pMirTrap vector that encodes the FLAG-tagged dominant-negative GW182 protein
subunit of the Ago/RISC complex (Appendix D.2.1) in the human astrocyte cell line.
Control miRNA (miR-132) together with the pMirTrap Control Vector and pMirTrap
vector were transfected in parallel with the main pMirTrap vector and miRNA mimic to
evaluate the transfection efficiency. The control vector encodes the gene for green
fluorescent protein (AcGFP1) which is a target for the control miR-132, as well as the
DsRed Express protein that is unaffected by miR-132 (Appendix D.2.2). Thus, a good
expression of DsRed Express (assessed via fluorescence microscopy) indicates successful
transfection of the pMirTrap Control plasmid, and if it is accompanied by a low AcGFP1
expression, it is indicative of successful miR-132 transfection.
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Figure 4-1 The MirTrap System: Protocol Overview
Following transfection, the astrocytes were lysed, and a portion of the lysate was
used to isolate total RNA (Before Immunoprecipitation, BIP). The RISC complex was
immunoprecipitated from the remaining lysate using anti-DYKDDDDK (FLAG-tag)
beads, and the bead-bound target mRNA was isolated (After Immunoprecipitation, AIP).
Both “BIP” and “AIP” RNA isolates were analyzed via RT-qPCR (One-Step SYBR®
PrimeScriptTM RT-PCR Kit II, Takara Bio, Cat. # RR086A), using the 3 sets of primers
included in the MirTrap Control Kit (positive control AcGFP1; negative control hPlod3;
internal control hGAPDH) to assess the efficiency of the transfection, and using primers
specific for the experimental miRNA target, OGG1 to calculate its fold enrichment in the
“AIP” samples relative to the “BIP” samples. A minimum of 2.5-fold enrichment of
triplicate experiments was considered a threshold for a miRNA:mRNA binding.
4.2.2.4

miR-1248 and miR-103a Inhibition: Assessment of miRNA:OGG1

Functional Relationship
4.2.2.4.1

miRNA Inhibitor Transfection Protocol

Human astrocytes were seeded at a uniform density of 3 x 105 cells per well in 6well plates and incubated for 72 h. At 80% confluency, the cells were transfected separately
in triplicates with mirVana® hsa-miR-1248 and hsa-miR-103a inhibitors (ThermoFisher
Scientific, Cat. # 4464084), and with mirVana® negative control #1 (ThermoFisher
Scientific, Cat. # 4464076), according to manufacturer's protocol. Briefly, the miR-1248
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inhibitor and the negative control #1 were reconstituted to 10 µM stock concentrations with
nuclease-free water, and then 3 µL of each was diluted in 150 µL Opti-MEMTM I Reduced
Serum Medium (ThermoFisher Scientific, Cat. # 31985062) to obtain 30 pmol per well. 9
µL LipofectamineTM RNAiMAX Transfection Reagent (ThermoFisher Scientific, Cat. #
13778100) was diluted in 150 µL Opti-MEMTM I Reduced Serum Medium. Both diluted
reagents were mixed at a 1:1 ratio and the resulting miRNA-lipid complex was incubated
for 5 min at room temperature. The transfection reagent mix was added to cells at 250 µL
per well, so that the final amount of miRNA inhibitor or negative control used per well is
25 pmol, while the final amount of LipofectamineTM RNAiMAX Transfection Reagent per
well was 7.5 µL. The transfected cells were incubated at 370C for 48 h. Control experiments
of non-transfected cells were also maintained in triplicate.
The efficacy of the transfection protocol was confirmed by assessing the expression
levels of miR-1248 post-inhibition, using an hsa-miR-1248 primer (Sigma Aldrich, cat. #
MIRAP00761) and the MystiCq® MicroRNA Quantitation System (Sigma-Aldrich, St.
Louis, MO) on a QuantStudioTM 3 Real-time PCR system (Applied Biosystems, Cat. #
A28567), as earlier described (See section 3.2.2.1: Reverse Transcription Quantitative PCR
(RT-qPCR)).
4.2.2.4.2

Relative Quantification of OGG1 mRNA via RT-qPCR

To assess the expression levels of the OGG1 mRNA after inhibitions of miR-1248
and miR-103a, total RNA was extracted from the transfected and non-transfected cells
using the Quick-RNATM Miniprep Kit (Zymo Research, Cat. # R1054), and quantified with
the QuibitTM RNA HS Assay Kit (ThermoFisher Scientific, Cat. # Q32852), used with the
QuibitTM 4 Fluorometer (ThermoFisher Scientific, Cat. # Q33238). RT-qPCR was
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performed with a TaqMan™ RNA-to-CT™ 1-Step Kit (ThermoFisher Scientific, cat. #
4392653) to analyze the gene expression level of OGG1 using GAPDH as an internal
control (ThermoFisher Scientific cat. # 4453320, 4448892).
4.3

Statistical Analysis

Statistical analyses were performed using GraphPad 6.0.1 software (GraphPad
Software Inc., San Diego, CA, USA). A p-value less than 0.05 was considered significant
and the results are expressed as mean ± SEM.
4.4
4.4.1

Experimental Outcomes

Computationally Predicted miRNA/OGG1 mRNA Interactions
Bioinformatics analysis for differentially expressed (DE) miRNA species that

selectively hybridize to the 3’ UTR of OGG1 mRNA predicted two miRNAs that satisfied
the criterion of a hit in at least two of the used miRNA-mRNA interaction databases. The
search on miRDB (Appendix D.3.1), filtered by a target prediction score of ≥75 and
excluding miRNAs with more than 2000 predicted targets in the human genome, returned
32 positive results which included two of the differentially expressed miRNAs in our data
set: miR-1248 (ranked 10th with a score of 88) and miR-103a (ranked 11th and 12th with a
score of 87). miR-1248 got a second positive call on miRWalk (Appendix D.3.2), while
miR-103a was corroborated on TargetScan (Appendix D.3.3). As obtained from the RNASeq data analysis, miR-103a was significantly downregulated in both 10 µM (~ 3 fold; p <
0.05) and 10 mM (~ 2.5 fold; p < 0.05) samples (Appendices C.1 and C.2). Because of its
very high significance in the 10 mM sample (p=1.13141E-77) and the upregulation of
OGG1 following 10 mM treatment (Figure 4-7), miR-103a was selected as a likely
candidate of OGG1 targeting for further validation. On the other hand, miR-1248 was
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upregulated (~ 2.8 fold; p < 0.05) in the 10 µM samples only, and so was selected for its
possible negative regulation of OGG1.
4.4.2

RT-qPCR Confirms miR-335 and PARP-1 Interaction
PARP-1 was significantly upregulated and miR-335 downregulated in 10 µM-

treated astrocytes compared to the non-treated samples. Hence, PARP-1 is a target of miR335 (Figure 3-10, Table 3-2) and the PCR results (Figure 4-2) validate the trend obtained
from the small RNA-seq analysis. Moreover, the relationship between miR-335 and PARP1 has been previously experimentally validated [321].

Figure 4-2 RT-qPCR confirmed (A) downregulation of miR-335, and (B) upregulation of
its target mRNA, PARP-1 (p<<0.001), n=3
4.4.3

Validation of Novel miRNA-Target mRNA Interactions
Assessment of the expression levels of the selected miRNAs (miR-1248 and miR-

103a) and the OGG1 target corroborate the opposite expression pattern that is consistent
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with the negative regulatory effect of miRNAs on their mRNA targets, as shown in the
following sections.
4.4.3.1

OGG1 is a Validated Target of miR-1248
PCR analysis indicates that miR-1248 is upregulated while its computationally

predicted target mRNA, OGG1 is downregulated (Figure 4-3). These findings are in
agreement with the established inverse expression relationship between miRNAs and their
target mRNAs. Furthermore, OGG1 protein expression was reduced after sodium
dichromate treatment (Figure 4-3C). In the treated sample, the OGG1 band was less intense
when compared to the control sample, indicating a decreased expression.

Figure 4-3 Effect of sodium dichromate treatment (10µM, 16 hours) on (A) miR-1248,
P<0.05, (B) OGG1 mRNA expression level (C) OGG1 protein expression estimated
using Protein Simple Wes® system Capillary western blot results were shown as gel-like
images of OGG1 (37kDa) and GAPDH (37kDa) for control and treated samples. The
relative area under the curve, error bars represent standard deviation, 1µg of protein
lysate was loaded per lane, (n=3)
The knockdown experiment showed that the inhibition of miR-1248 via
transfection of human astrocytes is associated with an upregulation of OGG1 mRNA
expression relative to the negative control-transfected and non-transfected controls (Figure
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4-4A). Experiments were performed to assess the expression level of miR-1248 after the
transfection to validate the successful inhibition of the targeted miRNA. As shown in
Figure 4-4B, the expression of miR-1248 was downregulated after transfection with the
inhibitor.

Figure 4-4 OGG1 and miR-1248 expression analysis after inhibition experiments.
(A) OGG1 upregulation (p<0.01), and (B) miR-1248 downregulation (p<0.05), after
inhibition of miR-1248 in human astrocytes (n = 3)
4.4.3.2

miR-103a is a Possible Regulator of OGG1
The transfection was considered effective based on the fluorescent imaging results

(Appendix D.4.1). The MirTrap control transfection experiments showed high expression
of DsRed Express (red fluorescence) with almost undetectable AcGFP1 expression (green
fluorescence). The RT-qPCR analysis to assess the fold enrichment of both positive
(AcGFP1) and negative (hPlod3) controls (Appendix D.4.2) corroborated the imaging
results. An 8-fold enrichment was observed for AcGFP1 (which contains miR-132
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recognition

elements

in

its

3’-UTR

and

so

is

expectedly

enriched

after

immunoprecipitation). Conversely, hPlod3 (which is not a miR-132 target and serves as a
negative control) had no significant enrichment (1.77 fold) (Figure 4-5).

Figure 4-5 RT-qPCR analysis showing fold enrichment of positive control (AcGFP1)
and negative control (hPlod3) genes after co-transfection of MirTrap Control vector and
miR-132
The co-transfection of astrocytes with miR-103a mimic and the pMirTrap vector
(containing tagged RISC) resulted in co-immunoprecipitation of the miR-103a-OGG1
complex which was validated by RT-qPCR, with an average OGG1 mRNA fold
enrichment of up to 7 (Table 4-1).
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Table 4-1 Average fold enrichment for miR-103a/OGG1 mRNA target via
immunoprecipitation analysis

Ct OGG1
Ct GAPDH ΔCt
2-ΔCt
Fold Enrichment
Before IP Sample 1
27.35
19.29 8.06 0.003747125
After IP Sample 1
32.06
25.79 6.27 0.012958118
3.458148925
Before IP Sample 2
28.06
20.01 8.05 0.003773189
After IP Sample 2
34.9
29.06 5.84 0.017457612
4.626752736
Before IP Sample 3
28.84
19.12 9.72 0.001185737
After IP Sample 3
34.79
28.92 5.87 0.017098339
14.4200074
Average enrichment
7.501636354
Inhibition of miR-103a via transfection experiments resulted in the upregulation of
OGG1 when compared to the negative control-transfected cells and the non-transfected
cells (Figure 4-6), adding another layer of confidence to the validated miR-103a:OGG1
interaction.

Figure 4-6 OGG1 upregulation (p<0.01) after inhibition of miR-103a in human
astrocytes (n = 3)
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4.4.4

Sodium Dichromate Exerts Dose-dependent Effect on OGG1 Expression
Having confirmed the downregulatory impact of 10 µM sodium dichromate on

human OGG1, the study sought to investigate the outcomes of exposure to higher doses
(10 mM and 100 mM). The RT-qPCR analysis confirmed a proportional dose-dependent
increase in OGG1 mRNA expression with increasing Na2Cr2O7 concentrations (Figure 47).

Figure 4-7 Dose-dependent increase in OGG1 expression with increasing Na2Cr2O7
concentrations
4.5

Discussion

Most degenerative diseases have underlying genetic etiologies linked to oxidative
stress and resultant chronic inflammation. Both are closely related pathophysiological
processes, one of which can be easily induced by the other [322–325]. Oxidative stress is
associated with mitochondrial dysfunction [326], progressive neurodegeneration, and
neuronal death [327]. Emerging evidence continue to support a strong relationship between
microRNAs and oxidative stress – and the associated DNA damage response pathways
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[91,270,328,329]. Base excision repair (BER) is the major pathway for the repair of
oxidative DNA damage. It acts by the removal and replacement of nucleotides modified
by methylation, alkylation, deamination, or oxidation [96].
The small RNA sequencing results indicate that a significant number of miRNAs
are downregulated (231) following sodium dichromate treatment (Appendices C.1 and
C.2). miR-1248 and miR-4284 expressions were upregulated (> 2.0-fold) due to cellular
stress. Complementary sequence matching predicted that miR-1248 binds to the 3’-UTR
of OGG1, a DNA glycosylase that is involved directly in the BER pathway (Table 3-2).
The fact that all the miRNAs participating in the BER network (Figure 3-10) are
downregulated suggests that their target DNA repair enzymes are upregulated. However,
the mRNA expression level of OGG1 is decreased (Figure 4-3), because its predicted
regulator, miR-1248 is appropriately upregulated.
OGG1 as an experimentally validated target of miR-1248 has no backing in
literature, and that prompted us to follow that lead to successfully establish a novel miR1248:OGG1 interaction via miR-1248 inhibitor transfection experiments (Figure 4-4).
Based on our experimental results, miR-1248 was upregulated after sodium dichromateinduced oxidative stress that leads to reduced expression of OGG1 and increased
accumulation of 8-OHdG in the DNA (Figure 3-2). Normally, the glycosylase would excise
the oxidized adduct to reduce cellular damage. Interestingly, OGG1 deficiency has also
been associated with a protective role against inflammatory lesions and mutagenic effects
associated with Helicobacter pylori infection in a mouse model [330]. Since ageassociated cellular inflammation contributes to neurodegeneration, understanding the
epigenetic mechanisms by which oxidative stress triggers chronic inflammation can lead
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to the development of therapeutics for dementia and associated diseases. The scores of
protein-protein interactions (Appendix C.5) that involve the amyloid precursor protein
(APP), a synaptic protein driving sporadic and familial Alzheimer’s disease [331,332],
lends credence to that possibility.
The induced expression of a relatively large number of pro-inflammatory proteins
in our PPI data set (Appendix C.5) may reflect a requirement for the activation of astrocytes
by cytokines produced from other immune cells during oxidative stress, possibly brain
microglia. miR-1248 is pro-inflammatory, regulating the expression of mRNAs involved
in chronic inflammatory reactions in an age-dependent fashion [333]. The inverse
relationship between miR-1248 and OGG1 (Figure 4-3) and the upregulation of the mRNA
target (OGG1) after miR-1248 inhibition (Figure 4-4) validates the computationally
predicted regulatory relationship between the miRNA/mRNA pair. miR-1248 was
previously reported to be involved in post-transcriptional regulation of IL-5 inflammatory
response [334], activation of IFN production with modulation of calcium signaling [335],
and TRIM24-mediated proliferation, and invasion of non-small cell lung cancer cells [336].
Our results (Figure 4-2) support a previous finding [321] that oxidative stress
caused the downregulation of miR-335, leading to increased expression of PARP-1. PARP1 modulates transcriptional responses by remodeling chromatin structure [337].
Interestingly, OGG1 binding to PARP-1 has been shown to play a functional role in the
recognition and repair of oxidative DNA damage by stimulating its poly(ADPribosyl)ation activity [317]. Our results suggest that the astrocytes may sense DNA damage
via PARP-1, but there may not be sufficient OGG1 levels to repair the damage. Conversely,
and very importantly, activated PARP-1 has been reported to exert inhibitory effects on the
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activity of OGG1 [338]. This negative feedback loop could well contribute to the impaired
8-OHdG excision capacity of OGG1 in the cells undergoing oxidative stress, as observed
in the Comet assay. The PARP-1-DNA trapping ability of certain PARP-1 inhibitors has
been employed successfully in cancer therapy. There is an ongoing debate on their
appropriateness and safety in neurodegenerative disorders due to the cytotoxic effects on
astrocytes [339]. In addition to blocking enzymatic activity, some of these inhibitors alter
the way PARP-1 interacts mechanistically with DNA – and this could be deleterious if this
interaction involves OGG1. Therefore, the selective use of PARP inhibitors to treat
neurodegenerative disorders should be investigated further, keeping in mind the
polypharmacological properties of PARP-1 inhibitors and the proposed reciprocal
interaction with OGG1.
Immunoprecipitation experiments that involve actual physical binding of
miRNA/mRNA pairs confirmed that OGG1 mRNA is also a target of miR-103a (Figure 45). To the best of our knowledge, this is the first documented evidence of miR-103a-OGG1
interaction, apart from bioinformatics prediction on miRDB and TargetScan. Other
established targets of miR-103a are PARP-1, CDK5R1, and RUNX2. Poly-(ADP-Ribose)
polymerase 1 (PARP-1) is a DNA damage sensor protein involved in DNA repair as well
as tumor transformation. miR-103a modulates oxidative stress in hypertension through
PARP-1 regulation [75]. It was also reported to play a role in the regulation of osteoblast
differentiation by directly targeting the 3’-UTR of RUNX2 mRNA to inhibit matrix
mineralization and bone formation [340,341]. CDK5R1 encodes p35, a specific activator
of the serine/threonine kinase CDK5, which plays a crucial role in central nervous system
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development and maintenance. So miR-103a affects neuronal migration by modulating
CDK5R1 expression [342].
The corresponding dose-dependent increase in OGG1 mRNA expression with
increasing Na2Cr2O7 concentrations negates the inverse relationship earlier established
with 10 µM treatment, and therefore points to the activation of an alternative stress
response mechanism that does not involve, or perhaps overrides, the miRNA-mediated
regulatory pathway. Other biological mechanisms can play a role in the restoration of
cellular homeostasis after increased potency of a stressor, including senescence [343] and
impaired mitochondrial dysfunction [11,271]. Also, histone deacetylase class I (HDACI)
has been reported to epigenetically interact with and enhance the cleavage activity of
OGG1 [269]. These alternative response mechanisms deserve further investigation.

CHAPTER 5
EXOPRIME TECHNOLOGY: ‘SMART’ MICROPROBE IMBUED
WITH BIOSENSING ELEMENTS FOR SOLID-PHASE
IMMUNOISOLATION AND OMICS ANALYSIS OF
SURFACE-MARKER-SPECIFIC EXOSOMAL
SUBPOPULATIONS

5.1

Rationale

The need for technology that can isolate pure exosomes rapidly, reproducibly, and
efficiently, has been recognized in the scientific community [249]. Multiple technologies
that improve exosomal isolation have been developed by exploiting the biochemical
properties of exosomes, and the process has rapidly evolved in recent years. While these
techniques have advantages and disadvantages, the most important drawback is that they
purify a heterogeneous population of exosomes that express different surface markers,
which is clinically disadvantageous.
Despite the efforts to develop systems for exosomes purification, little has been
reported on the development of solid-phase platforms for selective capture of extracellular
vesicles that express the same surface marker. A rapid, antigen-selective technology that
provides high-purity exosomal preparations will accelerate extracellular vesicles research
and the development of exosome-based products and applications.
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5.2

Aim and Hypothesis

Selective isolation of surface-protein marker-specific exosomal subpopulations for
subsequent genetic analysis is critical in studies to evaluate their clinical relevance because
they carry unique cargo that accurately represents the state of the cell [33]. A study has
shown the enrichment of CD63-positive exosomes in prostate cancer cells relative to
normal prostate cells [230]. The overexpression of the Epithelial Cell Adhesion Molecule
(EpCAM) in multiple types of cancers is linked to increased proliferation of epithelial cells,
as is seen in the development of tumors [344,345]. Given that EpCAM expression is
confined to epithelial tissues, its detection in mesenchyme-derived organs like the blood or
lymph nodes has been attributed to tumor-derived exosomes, making it a useful diagnostic
biomarker in circulating tumor cells (CTCs) in the blood of carcinoma patients. The
prognostic potential of EpCAM-1 for the early diagnosis of ovarian cancer has been
reported [346].
This study aims to develop a direct, one-step exosome sampling technology –
ExoPRIME – for selective capture of CD63+ exosome populations using an immuneaffinity protocol. Therefore, we hypothesize that the designed microprobe will specifically
capture and enrich exosome subpopulations expressing the CD63 antigen.
5.3

Experimental Workflow

5.3.1

Functionalization of ExoPRIME Microprobe

5.3.1.1

Preparation of Polyelectrolyte Solutions
Three polyelectrolyte solutions were used for this study: PEI, PSS, and PAA.

Positively charged poly[ethyleneimine], 3% w/v was prepared from 50% w/v PEI (MP
Biomedicals, cat. # 195444) by adding 6 mL PEI to 94 mL deionized water to obtain a
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3mg/mL PEI solution, with pH adjusted to 5 using HCl and NaOH. The negatively charged
poly[sodium 4-styrenesulfonate], 3 mg/mL PSS solution was prepared by dissolving 300
mg PSS (Sigma-Aldrich, cat. # 243051) in 100 mL deionized water and adjusted to pH 8.
Polyacrylic acid, another negatively charged polyelectrolyte, was prepared from a 35% w/v
stock by diluting 8.6 mL PAA (Sigma-Aldrich, cat. # 523925) in 91.4 mL deionized water
and adjusted to pH 8. To compact the resulting thin film and reduce its thickness, 25 µL
0.5 M NaCl prepared from a 5 M stock (Sigma-Aldrich, cat. # 7647-14-5) was added to all
polyelectrolyte adsorption solutions to increase their ionic strength [347].
5.3.1.2

Thin Film Deposition via Layer-by-Layer (LbL) Assembly
Deposition of multilayered polyelectrolyte coating over the Serin™ stainless steel

microneedle (300 µm × 30 mm) was performed using LbL thin-film deposition technique
[348]. The surface of the microneedle was polished with sandpaper to increase its
roughness and surface area. The needles were cleaned, to remove organic contaminants,
by a successive ultrasonic wash in acetone (Sigma-Aldrich, cat. # 270725) (5 min),
ultrapure water (5 min), hexane (Alfa Aesar, cat. # L13233) (15 min), and with ultrapure
water again (15 min, 50℃). The needles were further cleaned ultrasonically in acetone for
5 min and then dipped in warm acetone (50℃) for another 15 min, before chemically
etching them with sulfochromic acid (prepared by dissolving 6 g Na2Cr2O7 (Ward’s
science, cat. # 470302-532) in 100 mL H2SO4 (Ward’s science, cat. # 470302-858)) at 60℃
for 10 min. The etching of the microneedles provides a uniform negative (OH–) substrate
for the subsequent adsorption of the first cationic layer. The pre-treated needles were
washed with ultrapure water, dried with air, and stored in a desiccator under vacuum until
further use (no longer than 2 days).
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Oppositely charged polyelectrolytes were deposited via layer-by-layer assembly
with intermediate washing in deionized water and air-drying between each deposition
(Figure 5-1). An initial trilayer formed of PSS sandwiched in between two PEI layers
[PEI/PSS/PEI] was followed by additional 4½ polyanion/polycation bilayers, consisting of
PAA and PEI [(PAA/PEI)4+PAA] Thus, the film profile consisted of a total of six bilayers
providing carboxyl group at the last layer for the subsequent attachment of the aminomodified biotin. The incubation for each layer was as follows: PEI (3 h), PSS (30 min),
PEI (16 h), PAA (15 min), PEI (15 min), PAA (15 min), PEI (15 min), PAA (15 min), PEI
(15 min), PAA (3 h), PEI (15 min), PAA (15 min). All steps were performed at room
temperature with mild agitation on a shaking platform. The LBL layers serve as a substrate
for immobilization of biotin and the streptavidin-conjugated antibody
5.3.1.3

Anti-CD63 Antibody Immobilization
EZ-LinkTM Amine-PEG2-biotin (ThermoFisher, cat. # 21346) was covalently

linked to the carboxyl group of the last polyacrylic acid layer, via cross-linker chemistry
mediated

by

1-Ethyl-3-(3-dimethylaminopropyl)

carbodiimide

(EDC)

[349]

(ThermoFisher, cat. # 22980). Equimolar concentrations (50 mM) of amine-PEG2-biotin
and freshly prepared EDC were mixed in 1:1 volume to obtain a 25 mM biotin-EDC
complex mixture, which was further diluted to 5mM concentration with PBS. The needles
were submerged in the 5 mM biotin-EDC linker complex solution, on a rocking platform,
for 1 h at room temperature, and rinsed in 0.1% BSA in PBS. The biotinylated needles
were incubated in 1 µg mL-1 streptavidin-conjugated anti-CD63 antibody (Abcore, cat. #
AC12-0278-22) for 1 h at room temperature, with mild continuous shaking. To reduce nonspecific binding, blocking was performed by incubation-shaking in 0.1% BSA for 20 min
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at room temperature. The resulting CD63 antibody-coated microneedle is the ExoPRIME
microprobe used for the remainder of the study and was used on the same day it was
prepared (Figure 5-1) 4.

Figure 5-1 ExoPRIME probe functionalization workflow [36]
5.3.2

Evaluation of Probe Efficiency

5.3.2.1

Preparation of Conditioned Astrocyte Medium and Exosome Suspension
The biofluids used for these experiments were derived from human primary

astrocytes (Sciencell, Carlsbad, CA). Countess II FL Automated Cell Counter
(ThermoFisher Scientific) was used to count the cells that were seeded at a density of
2.1×106 cells in a T-75 flask containing 10 mL Astrocyte Medium (Sciencell, #1801),
supplemented with 1% penicillin/streptomycin solution (Sciencell, #0503), 2% Fetal
Bovine Serum (Sciencell), and 1% astrocyte growth supplement (Sciencell #1852). The

4

C.D. Nwokwu, S.M. Ishraq Bari, K.H. Hutson, C. Brausell, G.G. Nestorova. ExoPRIME:
Solid-phase immunoisolation and OMICS analysis of surface-marker-specific exosomal
subpopulations, Talanta 236(2022):122870. https://doi.org/10.1016/j.talanta.2021.122870.

108
cells were grown at 37°C, 95% humidity, and 5% CO2/air until they reached 80%
confluence. All cells used for these experiments were used within a maximum of 5
passages. When the cell reached 80% confluence, the conditioned culture medium was
collected and centrifuged at 2000 x g for 30 min at 40C to remove cellular debris. The
resulting conditioned astrocyte medium (CAM) was aliquoted and stored at – 20 0C until
needed. The enriched exosomal suspension (EXO) was obtained by mixing 0.5 volumes of
exosome precipitation reagent (Invitrogen Total Exosome Isolation, Cat. # 4478359) and
the clarified CAM, mixed well by vortexing and incubated for 16 h at 40C. The mixture
was centrifuged at 10,000 x g for 1 h at 40C and the residual exosomal pellet was resuspended in 0.2 volumes of 0.1% BSA in PBS, relative to the starting culture volume.
5.3.2.2

Exosome Immunoisolation and Quantification
The ExoPRIME microprobes were incubated in the corresponding biofluid at a

1:200 µL proportion, under a matrix of experimental conditions: biofluid type, incubation
temperature, and incubation time (Table 5-1).
Table 5-1 Incubation Conditions (Biofluid Type, Incubation Temperature and
Incubation Time)
16-h Incubation
Exosuspension at 40C
Exosuspension at 220C
Conditioned Medium at 40C
Conditioned Medium at 220C

2-h Incubation
Exosuspension at 40C
Exosuspension at 220C
Conditioned Medium at 40C
Conditioned Medium at 220C

After incubation, unadhered exosomes are washed off and steric crevices blocked
using 0.1% BSA in PBS (for the exosome suspension, the diluent is the same as the
blocking solution). A highly sensitive fluorescence-based enzymatic assay kit, FluoroCet
(System Biosciences, FCET96A-1) was used to quantify the number of captured exosomes
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according to the vendor’s guideline with minor modifications to accommodate the solidphase approach. Briefly, 5 microprobes were immersed in 60 µL PBS-diluted FluoroCet
lysis in a glass microcapillary tube (Roche, cat. #04929292001). The lysis setup was placed
on ice for 30 min to release exosomes captured on the surface of the microprobes. 50 µL
standard or exosomal lysate, 50 µL working stock of buffer A, and 50 µL working stock
of buffer B (making a 150 µL reaction volume) were mixed in each well of an opaque 96well plate and incubated, protected from light for 20 min at room temperature. The
fluorescence intensity (relative fluorescence units, RFU) was read using an Excitation:
530-570 nm and Emission: 590- 600 nm. in a Cytation 5 Cell Imaging Multi-Mode Reader.
The blank for assay samples consisted of 1:2 PBS-diluted FluoroCet lysis buffer, while the
blank for standard reactions was 1:2 PBS-diluted FluoroCet reaction buffer.
5.3.3

OMICS Analysis of Exosomal Cargoes

5.3.3.1

Extraction of RNA and Protein from ExoPRIME-captured Exosomes
The Total Exosome RNA and Protein Isolation Kit (cat #4478545) was used for

exosomal RNA extraction. RIPA Lysis and Extraction Buffer (Biosciences, cat #786-489),
mixed 7:1 with 7X protease inhibitors (Roche, Cat. # 04693124001) dissolved in deionized
water, was used directly for total protein extraction. Five microprobes were submerged in
60 µL lysis/resuspension buffer in a glass microcapillary tube (Roche, Ref. 04929292001)
and incubated on ice for 30 min to complete the lysis. The RNA isolation proceeded via
the organic extraction technique, according to the product’s guidelines, but with slight
modifications. Briefly, the exosomal lysates for RNA analysis were pooled into RNasefree tubes so that each tube contained ~ 200 µL, while the number of probes per tube was
recorded for eventual computation of protein concentration per probe. 1 volume of Acid-
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Phenol: Chloroform was added to each sample, vortexed for 30 seconds, before
centrifugation for 5 min at maximum speed (16,000 x g) at room temperature. The upper
(aqueous) phase was carefully removed without disturbing the underlying organic phase
and transferred to a fresh tube. 1.25 volumes 100% ethanol was added to the recovered
aqueous phase and mixed thoroughly. The remaining purification steps were followed as
prescribed, with multiple centrifugation and washing steps. Finally, the RNA was eluted in
100 µL pre-heated (95oC) elution buffer. The concentration and quality of the RNA
samples were assessed using an Agilent 2100 Bioanalyzer System with RNA Pico Chips
(Lot # YH19BK30), while the protein concentration was determined using a Pierce™ BCA
Protein Assay Kit (Thermo Fisher Scientific, Cat. # 23225) according to the vendor’s
guidelines.
5.3.3.2

MicroRNA Amplification of Enriched Exosomal RNA
The viability and integrity of probe-derived exosomal RNA were further evaluated

by RT-qPCR. Hsa-miR-21-5p (Sigma Aldrich, cat. #MIRAP00047) and hsa-let-7b-5p
(Sigma Aldrich, cat. #MIRAP00004) were amplified using the protocol stipulated for the
MystiCq® MicroRNA® Quantitation System (Sigma-Aldrich, St. Louis, MO). Briefly,
microRNA cDNA synthesis was carried out in two steps: (1) poly (A) tailing, using 3 µL
of each microRNA sample in the specified 10 µL reaction volume; and (2) first-strand
cDNA synthesis with the whole polyadenylated miRNA to generate a 20 µL cDNA
product. The cDNA concentration was measured using Qubit 4 Fluorometer (Thermo
Fisher Scientific, cat. #Q32854), and refrigerated until time for PCR amplification. Equal
amounts of each cDNA template (2ng) in 1 µL suspension, was mixed with 0.4 µL 10 µM
of respective MystiCq microRNA qPCR Assay Primer and 0.4 µL 10 µM MystiCq
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Universal PCR Primer, and 10 µL MystiCq microRNA SYBR Green qPCR Ready-mix,
and the total reaction volume made up to 20 µL with nuclease-free water. The miRNA
amplification followed the vendor-recommended 2-step PCR program (in 45 cycles) on a
LightScanner 32 real-time PCR instrument. The absolute threshold cycle (Ct) values were
noted, and the results were represented as mean ± standard error calculated from three
biological replicates (p < 0.05 is considered significant).
5.4
5.4.1

Results

Design and Fabrication of the ExoPRIME Microprobe
We employed a multidisciplinary approach that includes nanoscience, polymer

chemistry, and immunobiology, to design, fabricate, and characterize the “smart
microprobe” for the purification of antigen-specific exosomes. The ExoPRIME widget
consists of an inert Serin™ stainless steel microneedle (300 μm × 30 mm) functionalized
with an antibody (anti-CD63) that selectively binds to the corresponding tetraspanin
embedded in the lipid bilayer of the exosomes. Layer-by-layer (LbL) assembly was applied
to create the precursor layer of six alternating polyethyleneimine/polyacrylic acid bilayers
[PEI/PAA]6 for the immobilization of biotin to the stainless steel surface of the probe. 1Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) mediated chemical linkage of
amine-modified biotin to the carboxyl group of the PAA and was followed by the biotinstreptavidin covalent linkage of the CD63 antibody (Figure 5-1).
5.4.2

Evaluation of ExoPRIME’s Capture Efficiency
The feasibility of the ExoPRIME to capture exosomes was assessed using

conditioned astrocyte medium (CAM) and enriched exosome suspension (EXO). The
impact of temperature and incubation time on the ability of the tool to capture exosomes
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was evaluated as well. After incubation in a biofluid, the exosome capture efficiency was
quantified using a highly sensitive fluorescence-based enzymatic assay, FluoroCet
Exosome Quantification Assay, which measures the activity of exosomal cargo,
acetylcholinesterase. The ExoPRIME probe was blocked with 0.1% BSA in PBS to reduce
non-specific binding. Low levels of non-specific binding between the EVs and the biotin
were measured and subtracted from the signal obtained using the fully functionalized
probes. The fact that the ExoPRIME microprobe captured much more exosomes than a
non-functionalized microneedle is indicative of enrichment of CD63-expressing exosomes.
The ExoPRIME’s exosome loading capacity per microprobe was assessed under
different incubation conditions, as shown in Table 5-1. The capture efficiency ranged from
3 – 24 x 106 exosomes per probe depending on the experimental condition. The loading
capacity of the probe increased after incubation for 16 h at 40C in EXO suspension (24×106
exosomes per probe) and the efficiency decreased ~ 10 folds after 2 h at 40C (24×105
exosomes per probe). The incubation temperature has an impact on the capture capacity
leading to a 2-fold efficiency reduction after incubation for 16 h at 220C (12×106 exosomes
per probe). In summary, the reduced temperature with extended incubation times
constitutes the most optimal parameters that ensure high probe loading capacity (Figure 52A). This can be easily explained by the fact that lower temperatures maintain exosome
viability longer. The increased duration of the incubation increases the chances for
exosomes to make contact with the immobilized antibodies. However, the 2-hour roomtemperature incubation (2 h at 220C) of the ExoPRIME probe yielded an increased capture
efficiency (12×106 exosomes per probe) when compared to the 4°C incubation (24×105
exosomes per probe). A possible reason for this phenomenon is increased collision based
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on temperature-dependent molecular kinetics. At room temperature, the exosomes would
move at relatively higher speeds than at refrigeration temperatures, and so, would be
expected to experience more effective ‘collisions’ and interactions with the immobilized
antibodies. These outcomes raise the question as to which of the two parameters is a more
important determinant of efficiency. The varied interplay of time, temperature and biofluid
type, thus presents exosome researchers with the flexibility to choose the combined
parameters that best suit their purpose.

Figure 5-2 Exosome concentration obtained using ExoPRIME probe from enriched
exosome suspension and astrocyte medium (n=3). The numbers of exosomes shown as
isolated per microprobe are differential figures obtained from subtracting exosomes
captured by negative (non-anti-CD63-functionalized, NAF) microprobes from exosomes
captured by positive (biotin+anti-CD63-functionalized, BAF) microprobes [36]
At 16 h incubation, CAM-40C probes (4×106 exosomes per probe) bind more
exosomes than CAM-220C probes (3×106 exosomes per probe). The CAM results are
consistent with the trend obtained for EXO incubations, except for the zero-differential
number of exosomes after 2 h incubation under both temperature conditions (Figure 5-2B).
The CAM-2 h incubations did not generate a large enough signal to be quantified
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accurately. One key factor that could account for the generally lower exosome loading
capacity of the CAM probes relative to the EXO probes could be the presence of various
extracellular proteins and cellular debris, which could mask antibodies and compete
physically with exosomes for binding. Follow-up experiments that compared the protein
concentrations of EXO versus CAM probes (Table 5-2) further support this claim of
antibody sequestering by non-exosome components in the culture medium
5.4.3

Downstream Analysis of ExoPRIME-isolated Exosomes

5.4.3.1

MicroRNA and Protein Yields
Downstream analysis of the genomic and proteomic cargoes of ExoPRIME-

purified exosomes was performed to further assess the feasibility of the platform for direct
OMICS analysis. The antibody-functionalized probes yielded exosomal proteins from both
enriched exosome suspension and conditioned medium that is sufficient for downstream
analysis (Table 5-2).
Table 5-2 RNA and Protein Concentrations per ExoPRIME probe [36]
Sample
EXO (16 h, 40C)
CAM (16 h, 40C)
5.4.3.2

RNA (ng per probe)
0.54
0.30

Protein (ng per probe)
940
728

High Enrichment of Small RNAs (25 – 200 bp)
The RNA profile of the captured exosomes from the two different biofluids was

assessed via capillary-based electrophoresis using Bioanalyzer 2100 RNA Pico assay. The
electropherograms of the EXO and CAM samples confirm the enrichment of RNA that
have fewer than 200 nucleotides, with the highest abundance observed in the range of 25
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– 200 bp (small RNA) as expected for exosomal RNA samples (Figure 5-3) 5. Total human
RNA was analyzed as a positive control, alongside an RNA ladder. The narrow size
distribution and particularly high enrichment of small RNAs highlight the potential use of
the ExoPRIME probe in epigenetic studies involving non-coding RNAs for biomedical
research and diagnostics. Herein lies the nexus between the development of this
microprobe and the first prong of this project work that studied the differential expression
of short regulatory RNAs (microRNA) under conditions of oxidative stress.

Figure 5-3 Agilent 2100 Bioanalyzer RNA analysis of (A) RNA ladder; (B) Total
human RNA (3ng); (C) ExoPRIME-purified exosomal RNA from polymerprecipitated exosomes derived from human astrocytes; (D) ExoPRIME-purified
exosomal RNA from exosomes directly captured from conditioned human astrocytes
media. The electropherograms show the fluorescence intensity (FU) and size
distribution of the RNA nucleotides (nt) [36]

5

C.D. Nwokwu, S.M. Ishraq Bari, K.H. Hutson, C. Brausell, G.G. Nestorova. ExoPRIME:
Solid-phase immunoisolation and OMICS analysis of surface-marker-specific exosomal
subpopulations, Talanta 236(2022):122870. https://doi.org/10.1016/j.talanta.2021.122870.
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Assessment of ExoPRIME’s Diagnostic Utility

5.4.3.3

The diagnostics feasibility of the ExoPRIME technology for direct genetic analysis
was evaluated using reverse transcription-quantitative PCR (RT-qPCR) of the exosomal
RNA purified. The expression levels of the oxidative stress- and tumor-suppressingassociated microRNAs, miR-21 and let-7b, respectively, were measured in ExoPRIMEpurified exosomes from enriched exosomal suspension and directly from conditioned
astrocyte media (Figure 5-4). MiR-21 is highly expressed in astrocytes [350] and its
expression is dysregulated in astrogliosis, traumatic brain injury [283], and oxidative stress
[351]. MiR-let-7b has been identified as a biomarker for the early detection of cervical
lesions [352]. While the mRNA targets were successfully amplified, no significant
differences were detected between the EXO and CAM expression levels of both miRNAs.
These results further validate the feasibility of the technology to isolate structurally intact
exosomes and its application for direct genetic analysis from both enriched exosomes and
cell media.

Figure 5-4 RT-qPCR amplification cycles (n=3) of (A) An oxidative stress marker, miR21 (CAM 36.2;EXO 38.7); (B) A tumor suppressor gene, miR-let-7b (CAM 34.4; EXO
33.0), an array of 20 ExoPRIME microprobes [36]
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5.5

Discussion

Circulating exosomes encapsulate genomic and proteomic cargoes that are
potentially useful as cell-type-specific biomarkers for precise and non-invasive liquid
biopsy [21,34,35] and targeted therapeutics delivery [353–355]. However, despite efforts
to develop clinically advantageous systems for exosome purification, little has been
reported on the development of solid-phase platforms for selective capture of exosomes
that express the same surface marker. It has been emphasized that developing technology
for the isolation of homogenous populations of exosomes will facilitate the studies of their
biological function and lead to the accurate identification of biomarkers for early disease
diagnostics [33].
We report a non-invasive, one-step, solid-phase, microprobe-based technology –
ExoPRIME – for the direct isolation of pure exosome populations from both enriched
exosome suspension and conditioned cell culture medium. The novel ExoPRIME
microprobe provides direct, in situ enrichment of intact exosomes based on
immunoaffinity, without compromising their structure by avoiding the shear strain and
specimen destruction that may result from centrifugation [234]. Before deploying the
ExoPRIME microprobe for exosome enrichment, structural (SEM) and fluorescence
characterizations were conducted which indicated that polyelectrolyte assembly and biotin
attachment were successful and serve as a good substrate for antibody immobilization.
Also, EDX analysis further confirmed traces of organic materials (from the
polyelectrolytes) which are not found on the plain needles (Appendix E.1).
The developed ExoPRIME microprobe technology was tested with different
biofluids under various experimental conditions, and it demonstrated potential for high
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capture efficiency, as well as sufficient yield of exosomal RNA and protein for downstream
transcriptomic and proteomic analyses. A combination of immunofluorescence and
proteomic analysis was employed to assess the specificity of the ExoPRIME’s CD63+
exosome enrichment capability (Appendix E.2). Fluorescent imaging indicated distinct
differences between the control and exosome-specific groups, indicating enrichment for
the CD63-specific exosomal population. The proteomic profile generated by SDS-PAGE
showed fewer bands with a cleaner background for the microprobe-derived exosomal
protein sample compared to the traditional polymer-precipitated exosome proteins.
These results suggest that the ExoPRIME probe enriches for a homogenous
exosome population in comparison with the conventional purification method. The
traditional immuno-isolation system for exosome purification usually includes an
enrichment step to increase the concentration and purity of collected exosomes, adding
extra time and cost implications [243]. However, our novel system, with an antibodyfunctionalized microneedle at its core, captures antigen-specific subpopulation of
exosomes directly from biofluids, eliminating the requirements for additional filtration and
pre-concentration steps, and thereby cutting down costs and handling time without
compromising purity and viability of exosomal cargoes. Downstream characterization of
exosomal RNA lysates obtained from probe-derived exosomes indicates that the captured
exosomes remain intact, with viable nucleic acid cargo (Figure 5-4).
A major advantage provided by the designed probe over other platforms is its broad
dynamic range of temperature and incubation parameters that can be adjusted by the user
to provide optimal results, depending on the experimental workflow. This flexibility is a
desired factor for clinical and laboratory applications. Furthermore, this technology permits

119
the use of minimal sample volumes (≤ 200 µL). The biological sample can be reused, with
an average yield recovery rate of 2×107 exosomes per probe from an input volume of 200
µL. The fact that the sample is not consumed in the process is especially very important
for precious samples, such as cerebrospinal fluid. By bypassing the usual pre-concentration
and filtration, the technology minimizes the specimen volume requirement, simplifies the
workflow, providing faster sample analysis and cost savings.
Given the scalability afforded by the user-defined array of probes, the ExoPRIME
Microprobe Technology also offers prospects of diagnostic profiling of multiple EV
biomarkers via multiplexed analysis from the same sample. ExoPRIME has the potential
for integration into an automated microfluidics workstation for exosomal RNA isolation
for isothermal picomolar-range PCR detection [356], therefore, providing a potential
clinical diagnostic tool at the point of care (Figure 1-3). This could enable the development
of a versatile platform with a variety of biomedical applications in exosome-based disease
diagnostics and assessment of therapeutic interventions. Furthermore, the ExoPRIME
technology could have applications in plant exosomes research. Researchers have just
begun to unravel the physiological function of plant exosomes [357,358]. The minimal
invasiveness of the ExoPRIME probe could be easily exploited for plant exosomes analysis
and provide useful tools in agriculture, plant-based medicine, and nutraceuticals.

CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

6.1
6.1.1

Conclusions

Chapter 2 Conclusion
The present study indicates that proton and photon radiation exposure are

associated with impairment of the mitochondrial populations and suppression of the baseexcision repair capabilities of human astrocytes. Mitochondrial mass increased after
irradiation, indicating compensatory mitochondrial activity, which further exacerbates
oxidative damage (Figure 1-1). The increase in mitochondrial mass may simply serve to
accelerate the increase in the frequency of DNA damages and deficient mitochondria in the
overall mitochondrial population. The data reveals that photon radiation induces greater
mitochondrial alteration and has a more detrimental effect on the rate of repair of oxidized
adducts relative to a similar dosage of proton radiation. The findings of this study
contribute to the current knowledge of the DNA repair response and mitochondrial activity
in glial cells in response to radiation exposure.
Further studies should focus on the cellular mechanisms which regulate OGG1
expression to demonstrate the relationship between the enzymatic activity of the baseexcision repair pathway and radiation-induced mutation.
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6.1.2

Chapter 3 Conclusion
The exponential rise in chromium-related industrial products and activities

exacerbates the risk of poisoning among the general population, particularly because of its
ubiquity and persistence in the environment. The current research investigated the
epigenetic regulation of base excision repair following exposure to sodium dichromate and
oxidative stress. The intrinsic ROS vulnerability of the brain, particularly astrocytes that
have a central role in CNS activity and homeostasis, informed its use as our experimental
model.
The findings from this study indicate that micromolar concentrations of sodium
dichromate are associated with reduced growth and distinct morphological changes, and
induces accumulation of 8-OHdG adducts, as evaluated by Comet assay. Small RNA
sequencing was used to identify miRNAs that are differentially expressed in human
astrocytes. We report significant downregulation of multiple miRNAs (with only a small
subset upregulated) in treated cells, suggesting an underlying upregulation in the
transcription of their target genes. This phenomenon is attributable to the serially reported
interplay between ROS signaling and the microRNA biosynthetic pathways. Functional
enrichment analysis of the differentially expressed miRNAs linked many of them to
molecular pathways associated with bio-signaling, cell cycle control, and DNA damage
repair, especially the base excision repair mechanisms.
In conclusion, the study indicates a non-coding RNA-mediated DNA damage
response (DDR) loop activation. This supports our hypothesis that oxidative stress alters
the miRNA expression profile in such a way that coherent, functionally related pathways
are turned on/off either singly or as an assembly complex. The miRNA candidates
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identified by this study could serve as potential miRNA therapeutic targets for patients with
cancer and neurodegenerative disorders.
6.1.3

Chapter 4 Conclusion
The human 8-deoxyguanosine DNA glycosylase 1 (hOGG1) is an 8-OHdG-

specific base excision repair enzyme that plays an integral part in reducing the rate of
mutations. Given the sodium dichromate-induced 8-OHdG accumulation and the
preponderance of deregulated microRNAs that target DNA repair enzymes, as were
observed in the preceding experiments, this phase of the study focused on predicting and
validating specific miRNAs from our list of differentially expressed miRNAs that bind to
the 3’-UTR region of the OGG1 transcript.
Based on our results, the increased genomic 8-OHdG accumulation due to ROS’
oxidative burden correlates with reduced transcription and translation of hOGG1 and
impairs DNA repair capabilities of the cells – a forerunner of cancer and other
neurodegenerative disorders. Computational prediction analysis identified two miRNAs
that selectively target hOGG1 at its 3’-UTR – miR-1248 and miR-103a – and these were
validated as regulators of the hOGG1 protein via a combination of RT-qPCR, microRNA
mimic or inhibitor transfection, and/or immunoprecipitation assays. As far as we know,
this is the first experimentally validated assertion of these novel miRNA-mRNA pair
interactions in the public domain. Inhibition of miR-1248 and miR-103a via the
transfection of their inhibitors restored the increased expression levels of hOGG1 (Figure
1-2). Therefore, targeting the identified microRNAs could provide a therapeutic avenue for
reducing the nuclear DNA damage in the brain caused by exposure to mutagens.
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Collectively, the results from this work provide evidence that oxidative stress
affects DNA repair pathways in astroglial cells through non-coding RNA-controlled
mechanisms. We believe that this work has the potential for a high impact on the fields of
neurotoxicity and DNA repair biology. This study provides comprehensive information
regarding microRNA mediation of the genotoxic effects of sodium dichromate on the DNA
repair capabilities of human astrocytes that leads to a better understanding of the epigenetic
mechanisms that modulate this essential process.
6.1.4

Chapter 5 Conclusion
In this research project, we demonstrated the feasibility of a microprobe-based

technology for CD63-specific exosome purification that enables solid-phase CD63specific exosome immunopurification, and enables direct assessment of exosomal small
RNA expression. The ExoPRIME tool provides a Precise Rapid Inexpensive Mild (noninvasive) and Efficient (i.e. PRIME, from where the coinage is derived) alternative for
exosome isolation and analysis, with an exosome capturing efficiency of 3 – 24 x 106
exosomes per probe depending on the experimental condition.
Overall, results from this study collectively validate the specificity and efficiency
of the novel ExoPRIME microprobe technology, and thus, make a significant contribution
in advancing exosomes and microvesicles research. While this novel technology is still in
its developmental stages, its simplicity, scalability, tunability, affordability, portability,
non-invasiveness, low sample input volume (≤ 200 µL/probe) requirement, and very
importantly, its selective capture of exosomes from biological specimens, make it a
promising tool for potential use in the clinical setting. The current prototype: (1) is a
portable and affordable platform that does not require high amounts of antibody and large,
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expensive equipment, (2) operates in situ and eliminates the time-consuming, multistep
protocol for additional pre-concentration and filtration steps of the biological specimen, (3)
enables selective isolation of exosomes with a high spatial resolution, (4) provides flexible
options for scalability in terms of yield and speed, as desired by the user, (5) prevents
consumption or destruction of specimens, thus permitting reusability multiple times, and
(6) allows integration with microfluidics-based standard systems for genomic and
proteomic analysis of exosomal cargoes (Figure 1-3). Thus, this direct, single-step
ExoPRIME Microprobe Technology holds promise for real-time exosome sample
collection which can be applied for exosome enrichment and analysis of clinical specimens.
6.2

Future Directions

The first prong of this project established two novel miRNA-mRNA pairwise
interactions. Future efforts will be geared towards the validation of other putative
miRNAs/mRNA target pairs within the context of DNA damage response and repair.
Furthermore, preliminary data obtained show that lower doses of sodium dichromate lead
to hOGG1 downregulation while increasing the concentration leads to an upregulation.
This calls for more investigations into the threshold and limits of sensitivity of microRNA
involvement in cellular stress response.
The future outlook of the ExoPRIME microprobe technology will focus on tests
using other biofluids, and its integration with a lab-on-a-chip platform as a step towards
process automation. Successful implementation of this next phase aims to provide a simple,
bench-top bioanalytical system for automated high-throughput isolation and analysis of
exosomes and their cargoes, with lowered technical expertise barrier for the end-user.
Ultimately, the ExoPRIME microprobe technology would be useful in low-resource
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clinical and laboratory settings. This important utility cannot be over-emphasized in the
face of a pandemic, an epidemic outbreak, or other national health emergency scenarios,
for rapid-response testing and surveillance.

APPENDIX C

SMALL RNA-Seq DATA ANALYSES [SEE COMPACT DISC]
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C.1

Partek_Differentially Expressed Genes (10 µM Sodium Dichromate-Treated)

C.2

Partek_Differentially Expressed Genes (10 mM Sodium Dichromate-Treated)

C.3

miRNet_Gene Ontology and Pathway Analysis (10 µM Sodium DichromateTreated)

C.4

miRNet_miRNA-Disease Associations (10 µM Sodium Dichromate-Treated)

C.5

miRNet_miRNA-Protein-Protein Interactions (10 µM Sodium DichromateTreated)
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C.6

Partek_ PCA Plot for hsa-miR-21-5p (10 µM Sodium Dichromate-Treated vs NonTreated)

Figure C.1 PCA Plot for hsa-miR-21-5p (10 µM NaCr2O7-Treated vs Non-Treated)
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C.7

Partek_PCA Plot for hsa-miR-335-5p (10 µM Sodium Dichromate-Treated vs NonTreated)

Figure C.2 PCA Plot for hsa-miR-335-5p (10 µM NaCr2O7-Treated vs Non-Treated)

APPENDIX D

VALIDATION OF PREDICTED MICRORNA TARGETS
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D.1

Forward and reverse primer sequences for GAPDH and PARP-1

Table D.1 Forward and reverse primer sequences for GAPDH and PARP-1
Primer
GAPDH
PARP-1

Oligonucleotide sequences
F 5’– ACA TCG CTC AGA CAC CAT G – 3’
R 5’– TGT AGT TGA GGT CAA TGA AGG G – 3’
F 5’-CGC ATA CTC CAT CCT CAG TG- 3’
R 5’–GGA TCA GGG TGT AAA AGC GAT – 3’
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D.2

MirTrap Vector Information

D.2.1 pMirTrap Vecor Map

Figure D.1 pMirTrap Vector Map
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D.2.2 pMirTrap Control Vector Map

Figure D.2 pMirTrap Control Vector Map
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D.3

MicroRNA Target Mining Data

D.3.1 Predicted hOGG1-targeting MicroRNAs (miRDB) – See Compact Disc

D.3.2 Predicted hOGG1-targeting MicroRNAs (miRWalk) – See Compact Disc

D.3.3 Predicted hOGG1-targeting MicroRNAs (TargetScan) – See Compact Disc
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D.4

Evaluation of MirTrap Vectors Transfection Efficiency

D.4.1 Fluoresent Images of MirTrap Control Vector-Transfected Astrocytes

Figure D.3 Fluorescent Images at 100 ms Exposure Depicting Efficient Transfection
Consistent with High Expression of DsRed Express (Red Fluorescence) with very
negligible AcGFP1 Co-expression (Green Fluorescence)
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D.4.2 RT-qPCR Analysis of MirTrap Control Vector-Transfected Astrocytes

Table D.2 RT-qPCR Analysis Showing Fold Enrichment of Positive (AcGFP1) and
Negative (hPlod3) Controls, Relative to the GAPDH Internal Control

Before IP Sample 1
After IP Sample 1

Ct of
AcGFP1
20.71
24.91

Ct of
hGAPDH ΔCt
20.27
0.44
26.54
-1.63

Before IP Sample 2
After IP Sample 2

Ct of
AcGFP1
20.27
25.04

Ct of
hGAPDH ΔCt
18.79
1.48
26.44
-1.4

Before IP Sample 3
After IP Sample 3

2-ΔCt
0.74
3.10

2-ΔCt

4.20

Fold
Enrichment

0.36
2.64

Ct of
Ct of
AcGFP1
hGAPDH ΔCt
2-ΔCt
20.81
19.65
1.16
0.45
23.51
26.02
-2.51
5.70
AcGFP1 Average Fold Enrichment = 8.10

Before IP Sample 1
After IP Sample 1

Ct of
hPlod3
23.68
30.61

Ct of
hGAPDH ΔCt
20.27
3.41
26.54
4.07

2-ΔCt
0.09
0.06

Before IP Sample 2
After IP Sample 2

Ct of
hPlod3
24.03
30.07

Ct of
hGAPDH ΔCt
18.79
5.24
26.44
3.63

2-ΔCt
0.03
0.08

Before IP Sample 3
After IP Sample 3

Fold
Enrichment

Ct of
Ct of
hPlod3
hGAPDH ΔCt
2-ΔCt
24.75
19.65
5.1
0.03
30.41
26.02
4.39
0.05
hPlod3 Average Fold Enrichment = 1.77

7.36

Fold
Enrichment
12.73

Fold
Enrichment
0.63

Fold
Enrichment
3.05

Fold
Enrichment
1.64

APPENDIX E

CHARACTERIZATION OF THE EXOPRIME MICROPROBE

137

138

E.1

Structural Characterization of the LbL Precursor on the Microneedles
[Excerpts from Doctoral Dissertation of S. M. Ishraq Bari]6

E.1.1 Scanning Electron Microscopy (SEM) coupled with Energy-Dispersive X-ray
Spectroscopy (EDX)

Figure E.1 SEM micrographs of the tips (left panels) and stem (middle panels) of
polished plain needles (A, B) and LBL-coated microneedles (D, E), showing successful
and efficient deposition polyelectrolyte bilayers. The right panels show the corresponding
EDX spectra of plain (C) and LBL-coated (F) microneedles [36]

6

C.D. Nwokwu, S.M. Ishraq Bari, K.H. Hutson, C. Brausell, G.G. Nestorova. ExoPRIME:
Solid-phase immunoisolation and OMICS analysis of surface-marker-specific exosomal
subpopulations, Talanta 236(2022):122870. https://doi.org/10.1016/j.talanta.2021.122870.
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E.1.2 Validation of Biotin and Anti-CD63 Antibody Immobilization on the Microneedles

Figure E.2 Fluorescent images confirming successful LBL assembly and Biotin
immobilization on microneedles: (A) LbL+Biotin-EDC+Streptavidin+BiotinFITC; (B) LbL+Biotin-FITC; (C) Biotin-FITC. (D) ImageJ analysis of the of the
CTPF of A, B, C [36]
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E.2

Assessment of ExoPRIME’s Specificity
[Culled from the Master’s Thesis Hope K. Hutson]7

E.2.1 Immunofluorescence Imaging of the ExoPRIME Microprobe

Figure E.3 Schematic of exosome immunofluorescence imaging. Exosomes are
selectively captured to the surface of the ExoPRIME microprobes through antibodyspecific interactions of anti-CD63 and CD63 exosomes receptors. CD9 and CD81
antibodies are used for labeling of the captured exosomes followed by detection with
IgG secondary antibody conjugated to NL557 fluorophore [36]

7

C.D. Nwokwu, S.M. Ishraq Bari, K.H. Hutson, C. Brausell, G.G. Nestorova. ExoPRIME:
Solid-phase immunoisolation and OMICS analysis of surface-marker-specific exosomal
subpopulations, Talanta 236(2022):122870. https://doi.org/10.1016/j.talanta.2021.122870.
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E.2.2 Image J Analysis of Immunofluorescence Signal showing ExoPRIME Specificity

Figure E.4 CTFP Image J analysis of fluorescence signal obtained for different
experimental groups (n=4) [36]
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E.2.3 SDS-PAGE Gel Image confirming ExoPRIME’s Enrichment Capability

Figure E.5 Comparison of protein profile via SDS-PAGE analysis.
The gel legends indicate BioRad Kalediscope™ protein standard (Std);
ExoPRIME exosome (probe); polymer-percipitated exosomes
(Polymer reagent); and total protein lysate (total protein) at a
concentration of 20 µg per well [36]
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